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The  main  subject  of  the  work presented  in  this  thesis  is  the  further  development  of 
magnetic  resonance  imaging  (MRI)  as  a  non-invasive  method  of  investigating  tumour 
microcirculation.  Two  different MR techniques  were  used:  dynamic  contrast  enhanced 
(DCE)-MRI  and Blood  Oxygen Level Dependent  (BOLD)-MRI.  Intravital  microscopy 
was  used to  help  interpret  BOLD-MRI  results.  The  ultimate  aims  were  to  determine 
whether MRI methods could be relied upon to define a drug as having vascular disrupting 
activity and to develop techniques to predict the effectiveness of vascular disruptive agents 
(VDA).
In DCE-MRI, tissue  enhancement is  continuously monitored over several minutes  after 
intravenous  injection of contrast medium.  Modelling of contrast agent kinetics generates 
quantitative  parameters  related  to  tissue  blood  flow  rate  and  permeability,  e.g.  Ktrans 
(transfer constant).  In a clinical study, patients had DCE-MRI examinations before and 24 
hours  after cytotoxic  chemotherapy to  establish  whether any acute  anti-vascular effects 
could  be  detected.  No  acute  reductions  in  Ktran s  were  seen.  In this  project,  the  acute 
effects of the VDA, combretastatin A-4-phosphate, were investigated using DCE-MRI in 
SW1222 tumours in mice.  Responses were seen both at a clinically relevant dose and at 
higher doses, and a dose-response relationship established.
BOLD-MRI  can  detect  changes  in  oxygenation  and  blood  flow  within  tumours  using 
deoxygenated  haemoglobin  as  an  intrinsic  contrast  agent.  Tumours  contain  a  variable 
proportion of immature vessels, which may explain differential sensitivity to VDAs.  In this 
project,  BOLD-MRI  was  used  to  assess  tumour  vessel  maturity  using  consequent 
vasoreactivity to angiotensin II  and carbon dioxide  (as  air-5%C02   or as  carbogen)  in an 
animal model.  Intravital microscopy was used to directly observe response to these agents 
in mouse window chambers.  Results suggest that response to vasoactive agents is useful 
for assessing vascular maturity in tumours  but that  more  sensitive  non-invasive  imaging 
methods than BOLD-MRI are required for clinical use.
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Chapter 1  Introduction
This chapter describes the development of tumour vasculature, its functional and structural 
abnormalities  and the  consequences  of these  abnormalities  for anti-cancer therapy.  The 
identification  of  tumour  microcirculation  as  a  potential  therapeutic  target  and  the 
subsequent  development  of  vascular  disruptive  agents  are  discussed.  Tumour  vessel 
maturation  status,  its  implications  for  vascular-targeted  therapies  and  methods  for 
evaluating tumour vessel maturity are introduced.  Methods for measuring tumour blood 
flow in the laboratory and the clinic are described and compared.  The basic principles of 
magnetic resonance imaging and the specific techniques used for the work presented in this 
thesis are outlined.  Finally the aims of the thesis are given.
1.1  Tumour micro circulation
1.1.1  Angiogenesis
Angiogenesis,  defined  as  the  growth  of new capillaries  from  an  existing  vascular bed, 
involves  the  migration,  proliferation  and  differentiation  of  endothelial  cells  (Carmeliet,
2003).  Angiogenesis  is  crucial  for  normal  development  and  persists  in  the  adult  in 
physiological processes such as wound healing and the female reproductive system, and in 
pathological processes such as neoplasia and diabetic retinopathy.  The development of a 
blood supply is an essential requirement for a tumour to grow larger than 1-2 mm3  in size 
(Folkman,  1971)  and,  apart  from  a  few  exceptions  (see  below)  this  is  achieved  via 
angiogenesis.
Tumour cells promote angiogenesis by the upregulation of pro-angiogenic factors such as 
vascular endothelial growth factor (VEGF) and its receptors (Brown et al., 1995; Hatva et 
al.,  1995;  Plate  et  al.,  1993;  Takahashi et  al.,  1994;  Warren  et al.,  1995)  and the  down- 
regulation of anti-angiogenic factors such as thrombospondin-1  (Watnick et al., 2003).  In 
addition, the nature of the tumour microenvironment is conducive towards angiogenesis as 
the  presence  of  hypoxia  can  upregulate  many  pro-angiogenic  genes  including  VEGF 
(Forsythe et al., 1996; Hlatkyet al., 1994; Maxwell et al., 1997; Plate et al., 1993; Shweiki et 
al.,  1992),  Angiopoietin-2  (Ang-2)  (Mandriota  et  al.,  2000),  nitric  oxide  synthase  (NOS) 
(Melillo et al.,  1995), platelet-derived growth factor (PDGF)  (Kuwabara et al.,  1995) and 
basic and acidic fibroblastic growth factors (bFGF and aFGF) (Kuwabara et al., 1995).
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VEGF increases vessel permeability (Bates & Curry, 1996; Senger et al., 1986; Yuan et al., 
1996)  and induces endothelial cell migration and proliferation in conjunction with Ang-2 
(Maisonpierre et al.,  1997).  Endothelial sprouts are then formed that develop into blind- 
ending tubes and anastomose to form vascular loops (Jain, 2003).
In normal development, the nascent vascular network is then pruned and remodelled to 
match  the  metabolic  requirements  of the  tissue:  hyperoxia  decreases  VEGF  levels  and 
induces  vessel  regression  whereas  hypoxia  increases  VEGF  levels  and  induces  vessel 
growth  (Alon  et  al.,  1995;  Benjamin  et  al.,  1999;  Benjamin  et  al.,  1998).  Vascular 
remodelling may also occur by the insertion of tissue pillars that then become septa and 
divide the vessel -  ‘intussusceptive micro  vascular growth’ (Djonov et al., 2001; Djonov et 
al., 2000; Patan et al., 1996).  Vessels then undergo a process of maturation and stabilisation 
in which they acquire mural cells (smooth muscle cells in the case of arteries and veins and 
pericytes  in  the  case  of  capillaries),  a  basement  membrane  and  extracellular  matrix 
(Carmeliet, 2000; Jain, 2003) -  see Figure  1.1.  Studies using knockout mice have shown 
that Angiopoietin-1  (Ang-1), its tyrosine kinase receptor Tie-2, PDGF-B and its  receptor 
PDGFR-P  are important factors for vessel maturation (Flellstrom et al., 2001; Lindahl et 
al., 1997; Patan, 1998; Suri et al., 1996).  (Ang-1 and Ang-2 are counteracting ligands for the 
Tie-2 receptor (Hawighorst et al., 2002)).  Transforming growth factor-betal (TGF-pj) also 
has a role in vessel maturation as it can promote the expression of genes associated with 
matrix formation and smooth muscle cell differentiation (Chambers et al., 2003).
It is this association of new vessels with mural cells that appears to mark the end of growth 
factor dependence  (Benjamin et al.,  1998)  and cessation of vessel growth (Crocker et al., 
1970), thus ‘stabilising’ the vessel.  In utro studies have shown that pericytes in contact with 
endothelial  cells  can  inhibit their proliferation  (Orlidge  & D'Amore,  1987), probably by 
local activation of TGF-P (Wakui et al., 1997).
Apart from the examples of physiological angiogenesis discussed above, the mature adult 
vasculature  is  stable  and  quiescent.  In  contrast,  the  presence  of  high  levels  of  pro- 
angiogenic factors in tumours (Grunstein et al., 1999; Hawighorst et al., 2002; Holash et al., 
1999; Plate et al.,  1992)  results in on-going angiogenesis and the persistence of immature 
vessels.
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Figure 1.1: Process of vessel maturation, from (Carmeliet, 2003).  EC: endothelial cell; ECM: 
extracellular matrix; SMC: smooth muscle cell; M < |> : macrophage; PIGF: placental growth factor (a 
YEGF-related protein); TSP: thrombospondin; IFN: interferon; other abbreviations as in text.
1.1.1.1  Other mechanisms involved in tumour vasculature developm ent
There are other processes besides angiogenesis that may contribute to the development of
tumour vasculature.
Circulating endothelial precursor cells may be recruited to sites of neovascularisation where 
thev  differentiate  in-situ  into  mature  endothelial  cells,  a  process  termed  ‘vasculogenesis’ 
(Asahara et al., 1999).
The co-option of normal host vessels has been observed in tumours growing in lung and 
liver, both of which are very well-vascularised organs.  In a subset of non-small cell lung 
carcinoma (NSCLC)  specimens, an ‘alveolar’ pattern was observed, characterised by a lack 
of parenchymal destruction  and  the  absence  of both  tumour-associated  stroma  and  new 
vessels.  Instead, neoplastic cells filled up the alveoli and the only vessels present appeared 
to  belong  to  the  trapped  alveolar  septa  (Offersen  et  al.,  2001;  Passalidou  et  al.,  2002; 
Pezzella et al.,  1997).  Similarly, a ‘replacement growth’ pattern has been observed in liver 
metastases of colorectal and breast origin in which tumour cells replaced hepatocytes and 
co-opted the sinusoidal blood vessels between liver plates  (Stessels et al., 2004; Vermeulen 
et al., 2001).
Experiments in a rat glioma model suggest that even angiogenic tumours may initially co­
opt  normal  host blood vessels  (Holash  et  al.,  1999; Yancopoulos  et  al.,  2000).  The  co­
opted  host  vessels  were  observed  to  regress,  causing  tumour  necrosis,  but  successful
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tumours were able to initiate angiogenesis and so survive (Holash et al, 1999; Yancopoulos 
et al., 2000).
‘Vasculogenic mimicry5  is a term used to describe the presence within tumours of vascular 
channels  that  are  not  lined  by endothelial  cells.  These  have  been  described  in  both 
melanoma (Maniotis et al., 1999) and breast carcinoma (Shirakawa et al., 2002).  However, 
the existence of vasculogenic mimicry is controversial and McDonald et al. (McDonald et 
al.,  2000)  comment  that  extravasated  erythrocytes  in  the  extracellular  matrix  could  be 
misinterpreted as vascular channels.
If a tumour can develop a blood supply using mechanisms that do not involve endothelial 
cell  proliferation,  then  specific  anti-angiogenic  therapies  may  be  ineffective.  How 
significant a problem this maybe is not known.
1.1.2  Morphology of tumour vaseulature
Once  established,  tumour  vasculature  is  both  structurally  and  functionally  abnormal. 
Common features seen in solid tumours  include plexuses of wide venules and sinusoidal 
capillaries  of  varying  diameter  with  numerous  blind  endings  (Konerding  et  al.,  1995). 
Avascular and poorly vascularised regions are prevalent throughout tumours (Konerding et 
al.,  1999; Less  et al.,  1991)  and up to 20-fold more tumour cells  are  dependent on each 
vessel for nutritive support than are cells in normal tissue  (gut)  (Konerding et al.,  1999). 
The  pattern  of tumour vasculature  that  develops  is  dependent  on  tumour  location,  its 
biological features and the pre-existing vascular bed (Konerding et al., 1995).
Ultrastructural  studies  have  observed  the  presence  of  wide  interendothelial  junctions, 
fenestrae, transendothelial channels formed by vesicles, and discontinuous or absent basal 
lamina  in a significant fraction of tumour vessels  (Hashizume  et al.,  2000; Jain,  1987a). 
Tumour vascular permeability is significantly higher than that of skin or muscle (Dvorak et 
al., 1988; Jain, 1987a; Sevick & Jain, 1991) and the degree of tumour vessel permeability is 
dependent on tumour type and host organ (Fukumura et al., 1997; Hobbs et al., 1998) and 
on VEGF (Yuan et al., 1996).
It is not clear whether tumours contain lymphatic vessels as they are difficult to identify 
definitively  and  specific  markers  are  lacking  (Jain  &  Fenton,  2002).  However,  most
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evidence  suggests that functional lymphatics  are  absent from tumours  (Leu et al., 2000; 
Padera et al., 2002).
Tumour  vessels  may lack protective  mechanisms  such  as  mural  cells  and  a  basement 
membrane.  Even if mural cells are present, they may not be functionally normal: Morikawa 
et al. observed abnormalities in pericyte shape and abnormal separations between aSMA1  
and  CD31-positive  cells  on  tumour vessels,  indicating  that  pericytes  were  only loosely 
associated with endothelium (Morikawa et al., 2002).
Tumour vessels may not always have an intact endothelial cell lining. ‘Mosaic’ vessels have 
been observed that have focal regions where tumour cells appeared to be in contact with 
the vessel lumen (Chang et al., 2000; Hammersen et al., 1985).  However, endothelial cells 
can be very thin, so might not be apparent in thin histological sections.
1.1.3  Consequences of the structural and functional abnormalities of tumour 
vasculature
As  a consequence  of the  structural and functional abnormalities  of tumour vasculature, 
tumour blood flow is both spatially and temporally heterogeneous  (Endrich et al.,  1979; 
Leunig et al.,  1992; Tozer et al.,  1990; Vaupel et al.,  1989).  Many solid tumours contain 
hypoxic regions and tumours are also more hypoxic than typical normal tissues (Adam et 
al.,  1999;  Cemiglia  et  al.,  1997;  Chaplin  et  al.,  1998a;  Martin  et  al.,  1993;  Moulder  & 
Rockwell,  1984;  Vaupel  & Hockel,  1998).  The  degree  of  hypoxia  depends  on  oxygen 
consumption  rate  as  well  as  oxygen  supply (blood  flow)  and  will  be  dictated  by flow 
through individual vessels as well as the distance  between vessels.  Interruption in blood 
supply due to transient vessel shutdown leads to ‘acute’ hypoxia (Brown, 1979; Chaplin et 
al.,  1987)  whereas  ‘chronic’  hypoxia  is  dependent  on  a tumour cell’s  distance  from the 
nearest blood vessel (Thomlinson & Gray, 1955).
Tumours  have  a  lower extracellular pH than normal tissues  (Wike-Hooley et al.,  1984). 
The  mechanism  is  thought  to  be  increased  lactic  acid  production  due  to  aerobic  and 
anaerobic  glycolysis  in  tumour  cells  (Wike-Hooley et  al,  1984).  However,  glycolysis- 
deficient tumours still have a low pH, so production of other acids such as carbon dioxide 
may also contribute to a shift to acidic pH (Newell et al., 1993).
1  aSMA: alpha smooth muscle actin, used to stain smooth muscle cells and pericytes.  CD31 antigen: pan- 
endothelial marker.  See Section 1.3.
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Tumours  are  characterised  by an  elevated  interstitial  fluid pressure  (IFP),  compared to 
normal tissues Qain, 1987b; Leunig et al., 1992; Netti et al., 1996; Znati et al., 1996).  IFP is 
higher in the centre of a tumour and approaches normal physiological pressure towards the 
periphery (Boucher et al., 1990; Boucher et al.,  1996).  Tumour interstitial hypertension is 
presumably due to the proliferation of tumour cells within a confined area, high vascular 
permeability and the possible  absence  of functional lymphatics  (see  above)  Qain,  1987a) 
and is a cause of reduced tumour blood flow (Milosevic et al., 1999).
1.1.4  Implications for anti-cancer treatment
Drug  delivery to tumours  will be  compromised by an  inadequate,  heterogeneous  blood 
supply.  In addition, the presence  of high IFP inhibits  extravasation of macromolecules 
into the extravascular space Qain, 1988; Jain,  1989).
Tumour  response  to  treatment  with  both  chemotherapy and  radiotherapy will also  be
compromised.  Hypoxic  cells  are  more  radioresistant than  oxic  cells  (Gray et  al.,  1953). 
They  are  also  non-proliferating  and  so  protected  against  DNA-damaging  treatments 
(Chaplin  et  al.,  1998a).  It  has  also  been  shown that  hypoxia  can  select  for a  more
aggressive, pro-angiogenic  phenotype  (Brizel et al., 1996; Hockel et al.,  1999; Rofstad &
Danielsen,  1999), probably by selecting for resistance to  apoptosis  and by inducing pro- 
angiogenic growth factors (Graeber et al., 1996; Zhang &Hill, 2004).
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1.2  Tumour micro circulation as a therapeutic target
The dependency of solid tumours on a functional blood supply makes targeting the tumour 
microcirculation an attractive proposition.  The theoretical advantages of this strategy are:
1.  tumour vasculature is accessible to blood-bome agents;
2.  treatment-resistant  mutations  are  unlikely to  emerge  as  tumour endothelial  cells  are 
non-transformed;
3.  angiogenesis  occurs  in  very  limited  circumstances  in  adults  so  targeting  specific 
receptors on proliferating tumour endothelium is potentially safe;
4.  each capillary supplies hundreds of tumour cells, potentiating the anti-tumour effect.
In reality, treatment-resistant mutations may emerge (Kerbel et al., 2001) and clinical trials 
have shown that vascular-targeted therapies are not without toxicity (see below).
Differences between tumour and normal vessels that could be exploited include: increased 
endothelial cell proliferation rate,  — 20-35  times  that seen  in normal vessels  (Denekamp, 
1982; Denekamp & Hobson,  1982; Eberhard et al, 2000; Hobson & Denekamp,  1984); 
increased permeability (Dvorak et al., 1988); the presence of immature vessels (Eberhard et 
al., 2000); and abnormal vessel structure Qain,  1988; Konerding et al.,  1999).  Also, gene 
transcripts have been identified that are expressed predominantly by tumour endothelium 
that  could  be  potential  targets  for antibody or  gene-directed  therapies  (St  Croix  et  al., 
2000).
Tumour  microcirculation  may  be  targeted  either  by  inhibition  of  the  developing 
neovasculature (anti-angiogenic strategies) (Folkman, 1971) or by damaging the established 
vasculature  causing  blood  vessel  shutdown  (vascular  disruptive  strategies)  (Denekamp, 
1982).  There  is  potential  overlap  between the  effects  of  individual agents,  but for the 
purpose of description it is easier to divide them into these two categories, depending on 
the aims of the treatment.
Anti-angiogenic strategies include the development of inhibitors of growth factors such as 
VEGF  and  its  receptors,  matrix  metalloproteinase  inhibitors  and  agents  that  inhibit
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endothelial cells directly such as thalidomide and endostatin (Fox et al., 2001; Los & Voest, 
2001).
The  aim of vascular disruptive  strategies  is  to cause  a rapid and extensive  shutdown of 
tumour blood flow in the established tumour vasculature, leading to secondary tumour cell 
death (Tozer et al., 2002).  Denekamp et al. (Denekamp et al.,  1983) found that vascular 
occlusion, induced by clamping the base of subcutaneous tumours for 15-24 hours, caused 
early and extensive  tumour necrosis  in an  animal model.  This  pattern of cell death  is 
indicative of vascular-mediated tumour cell kill (Tozer et al., 2002).
There are several different types of vascular disruptive therapies:
1.  Small molecule vascular disruptive  agents.  These  are  not specifically targeted to 
tumour endothelium but can exploit the differences between tumour and normal 
tissue endothelium, producing selective vascular damage in tumour tissue.
2.  Ligand-directed  approaches  that  involve  the  selective  targeting  of  tumour 
endothelial cells using specific antibodies or peptides.
3.  Physical  methods.  These  include  hyperthermia,  tumour  embolisation  and 
photodynamic therapy.
4.  Gene-based  approaches.  In  theory,  gene-directed  vascular-targeted  therapies 
should be effective, but as yet there are no promising candidates.
1.2.1  Small molecule vascular disruptive agents
Low molecular weight dmgs with vascular disruptive activity can be divided into two main 
groups: tubulin-depolymerising agents  (e.g.  combretastatin A4-phosphate  -  CA-4-P)  and 
cytokine  inducers  (e.g. 3,4-dimethylxanthenone-acetic  acid  -  DMXAA) -   see Table  1.1. 
Figure 1.2 shows the chemical structures of some of these compounds.
1.2.1.1  Tubulin-depolymerising agents: background
Tubulin is  an essential component of the  eukaryotic cell cytoskeleton.  The cytoskeleton 
provides  physical  support  for  maintenance  of  cell  shape,  cell  motility  and  also  the 
infrastructure for the  movement of organelles within the cell and for signal transduction 
pathways.  It  comprises  three  principal  types  of  protein  filaments:  actin  filaments,
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microtubules  made  of tubulin  and  intermediate  filaments  made  of vimentin  and  other 
proteins (Alberts et al., 1989).
Actin filaments form cross-linked networks and small bundles in the peripheral cytoplasm 
and give mechanical strength to the  cell surface, allowing shape  change and movement. 
Microtubules are formed from tubulin heterodimers consisting of a and (3  tubulin, which 
polymerise  into  long  filaments  that  radiate  from  near  the  nucleus  throughout  the 
cytoplasm,  forming  a system of fibres  along which  organelles  can travel  (Alberts  et al., 
1989).  Microtubules,  and  their  associated  proteins,  are  required  for  mitotic  spindle 
formation and so are essential components of mitosis (Jordan et al., 1998).
Small molecule vascular disruptive agents 
Tubulin Binding agents
CA-4-P (Qxi 2021)
CA-l-P (Oxi 4503)
ZD 6126 -  phosphate prodrug of N-acetylcolchinol 
AVE8062 -  CA-4-P analogue, formerly AG7700 
Auristatin-PE (TZT-1027) -  synthetic derivative of dolastatin 10 
NPI-2358 
MN-029 
Cytokines or cytokine inducers 
TNFa 
FAA
DMXAA_________________________________________________
Ligand-directed approaches 
Agents causing direct vascular damage 
Exherin 
Agents inducing coagulation 
Alphastatin
Tissue factor fusion proteins 
Fusion proteins including toxins, anti-cytotoxics or radioisotopes
VEGF linked to diphtheria toxin 
VEGF linked to gelonin 
TES-23
niIndium-anti-PSMA antibody 
Agents directed against extracellular matrix
  TNFa linked to fibronectin-isoform antibody___________________
Table 1.1: Small molecule and ligand-based vascular disruptive agents in clinical or pre-clinical
development (see text).
The vinca alkaloids are tubulin-depolymerising agents that are used clinically for cytotoxic 
chemotherapy (Jordan  et  al.,  1998;  Wang  et  al.,  2000).  Their cytotoxic  activity is  due 
primarily to their anti-mitotic action: they inhibit spindle formation, causing mitotic arrest
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and subsequent cell death.  The taxanes arc another group of cytotoxic agents that inhibit 
spindle formation by binding to tubulin but they act by stabilising tubulin rather than by 
inducing depolymerisation (Jordan et al., 1998; Wang et al., 2000).
Tubulin-depolymerising agents also have vascular disruptive activity.  However, the early 
agents  studied  (colchicine  and  the  vinca  alkaloids)  were  only  found  to  have  vascular 
disruptive  effects  at close  to the  maximum tolerated dose  (MTD)  (Baguley et al.,  1991; 
Boyland & Boyland,  1937; Hill et al., 1993; Hill et al.,  1995).  Combretastatin A-4 (CA-4) 
was the first small molecule agent to be developed that had significant vascular disruptive 
effects at a tolerable dose in animal models (Dark et al., 1997).
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Figure 1.2: Chemical structure of A: colchicine; B: CA-4-P; C: ZD6126; D: DMXAA
1.2.1.2  Combretastatin A-4-Phosphate (CA-4-P)
The combretastatins were isolated from the African bush willow, Conbretum aiffrum, in the
1980s  (Pettit  et  al.,  1982).  They are  tubulin-depolymerising  agents  and  are  structurally
related to colchicine, binding to the same site on tubulin (McGown & Fox, 1989). CA-4-P
is the water-soluble pro-drug of CA-4 and has vascular disruptive activity at 1/ 10th of the
MTD in mice  (Dark et al.,  1997).  The plasma half-life of CA-4 is  0.86  hours  in the rat
(after 30 mg.kg1  CA-4-P given intraperitoneally  (Prise et al., 2002) and 1.01 hours in the
mouse  (after  100  mg.kg  1   CA-4-P  given  intraperitoneally)  (Dr M.RJL  Stratford, written
communication, October 1998).  Plasma CA-4 half-life is longer in humans (— 2-4 hours),
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measured  following  intravenous  administration  of  6-90  mg.m2   CA-4-P  (Dowlati  et  al., 
2002; Rustin et al., 2003b; Stevenson et al., 2003).
CA-4-P  (and  CA-4)  cause  a  rapid  vascular  shutdown  in  animal  and  human  xenograft 
tumour  models,  with  maximal  effect  at  3-6  hours  -  as  shown  by reduction  in  either 
perfused vascular volume, measured using Hoechst 33342 (Chaplin et al., 1999; Dark et al., 
1997; Grosios et al., 1999), or tumour blood flow (1 2 5 iodoantipyrine (1 2 5 IAP) method) (Prise 
et al., 2002; Tozer et al., 1999) or fraction of cardiac output f 6RbQ method) (Chaplin et al., 
1999; Murata et al, 2001a; Murata et al., 2001c)  (see Section 1.4).  Reduction in tumour 
blood flow is associated with an increase in vascular resistance (Tozer et al., 1999) and an 
increase  in vascular permeability (Tozer et al., 2001).  The  consequence  of blood vessel 
shutdown is tumour cell death, and extensive central haemorrhagic necrosis is seen at 24 
hours following administration of CA-4-P at 100 mg.kg1  in the mouse (Bohle et al., 2000; 
Darket al., 1997; Grosios et al., 1999).
In  comparison,  CA-4-P  has  little  or  no  effect  on  blood  flow  in  most  normal  tissues 
(Chaplin et al.,  1999; Murata et al., 2001a; Tozer et al.,  1999).  For example, a  — 100-fold 
reduction  in tumour blood flow was  observed at 6  hours  following treatment with  100 
mg.kg'1  CA-4-P in the P22 rat carcinosarcoma, whereas there was only a 7-fold reduction in 
blood  flow in the  spleen,  the  most  responsive  normal tissue  (Tozer et  al.,  1999).  No 
histological  changes  were  found  in  normal  tissues  at  24  hours  following  CA-4-P 
administration (Prise et al., 2002).
The use of MR techniques to assess the acute vascular disruptive effects of CA-4-P (and 
other small molecule vascular disruptive agents) is discussed in Section 1.5.5.
In utro, CA-4-P leads to rapid reorganisation of the cytoskeleton of endothelial cells and 
changes in their morphology and function.  Incubation of human umbilical endothelial cells 
(HUVECs)  with  CA-4-P  results  in  complete  depolymerisation  and  disruption  of 
microtubules within 30 minutes  and, in parallel, reorganisation of the  actin cytoskeleton 
into stress fibres associated with focal adhesions  (Grosios et al., 1999; Kanthou & Tozer, 
2002).  The cells contract and inter-cellular gaps appear if cells are grown in monolayers. 
In addition, a proportion of cells  round up and form numerous  surface blebs  lined with 
actin (Kanthou & Tozer, 2002).  CA-4-P causes the rapid phosphorylation of myosin light 
chains  (Kanthou  &  Tozer,  2002),  which  is  required  for  activation  of  actin-myosin
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interactions  and  leads  to  increased  contractility  and  stress  fibre  formation  (van  Nieuw 
Amerongen  &  van  Hinsbergh,  2001).  The  small  GTPase,  Rho,  and  the  associated  Rho 
kinase, are responsible for actin reorganisation into stress fibres and actin-myosin mediated 
contraction in a variety of non-smooth muscle cell systems, including endothelial cells (van 
Nieuw  Amerongen  &  van  Hinsbergh,  2001).  The  changes  in  actin  reorganisation  in 
response to CA-4-P in endothelial cells were found to be mediated via the activation of this 
Rho pathway since they could be blocked with inhibitors of Rho and Rho kinase (Kanthou 
& Tozer, 2002).
These  effects  on  the  cytoskeleton  and  cell  morphology  are  paralleled  by  changes  in 
endothelial  cell  function  (Galbraith  et  al.,  2001;  Kanthou  &  Tozer,  2002).  CA-4-P 
increases the permeability of endothelial monolayers to macromolecules, which can also be 
blocked  by  inhibitors  of  Rho/Rho  kinase,  suggesting  that  morphological  changes  are 
associated with important functional changes, in intro (Kanthou & Tozer, 2002).  If similar 
changes  occurred  in  vivo,  then  this  could  explain  the  increases  seen  in  tumour  vascular 
resistance  (due  to  rounding  up  and  blebbing  of endothelial  cells),  vascular  permeability 
(causing oedema and an increase in interstitial  fluid pressure), coagulation and rheological 
changes  at  slightly  later  times  and  the  resultant  vascular  collapse  (Chaplin  &  Hill,  2002; 
Prise et al., 2002; Tozer et al., 2002) -  see Figure 1.3.
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Figure 1.3:  Summary of the proposed mechanism of action of CA-4-P, (Tozer et al., 2002).
CA-4-P  also  has  direct  cytotoxic  effects  on  endothelial  cells  in  vitro  and  is  selective  for 
proliferating  cells  (Dark  et  al.,  1997).  Tumour  cell  lines  are  also  sensitive  to  CA-4-P  to 
variable degrees (Ahmed et al., 2003) and C Kanthou, personal communication.  CA-4-P is 
thought to primarily kill proliferating cells in mitosis —  by causing spindle malformation and
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nuclear DNA damage leading to cell cycle arrest in the G2/M phase of the cell cycle.  It is 
thought  that  cell  death  then  occurs  via  mechanisms  that  share  characteristics  with 
apoptosis (Kanthou et aL, 2004).  In vim cytotoxic effects are only observed after lengthy 
drug exposures.  For example, apoptotic changes in endothelial cells start to appear after 2- 
4 hours drug exposure, reaching significance at 8 hours (Kanthou et aL, 2004).  Therefore, 
considering the plasma half-life of CA-4, it is not certain how relevant these changes are in 
ma
However, cytotoxic effects may be relevant with administration schedules using repeated 
doses of CA-4-P (Tozer et al., 2002), which are much more effective  (Hill et aL, 2002a). 
CA-4-P  also  has  anti-angiogenic  effects  as  it  can  inhibit  endothelial  cell  migration  and 
sprout formation at non-cytotoxic doses (Ahmed et al., 2003).
Single doses of CA-4-P can kill substantial numbers of tumours cells: 100 mg.kg1  CA-4-P 
induced  1.5  log cell kill and 500  mg-kg'1   CA-4-P  induced  >3  log  cell  kill in the  CaNT 
tumour grown in mice (Chaplin & Hill, 2002).  However, single doses of CA-4-P produce 
either no or only modest growth delays (Chaplin & Hill, 2002; Chaplin et al., 1999; Grosios 
et  al.,  1999;  Hill  et  al.,  2002a).  In  comparison,  the  cytotoxic  agents,  cisplatin  and  5- 
fluorouracil (given at half-MTD), and also radiation produce similar or less log cell kill in 
the CaNT tumour but do induce growth delay (Chaplin & Hill, 2002).  This discrepancy 
may be  due  to  the  pattern  of  tumour  necrosis  seen  with  CA-4-P:  central  necrosis  is 
observed  at  24  hours  but  a  viable  peripheral  rim  of  tumour  cells  persists  that  can 
repopulate the tumour centre over the ensuing days (Chaplin et al., 1999).
Improved tumour responses are seen if CA-4-P is administered in repeated doses (Hill et 
al., 2002a) or as a continuous infusion (Malcontenti-Wilson et al., 2001).  Improved tumour 
responses  are  also seen if CA-4-P is  administered in combination with other anti-cancer 
therapies: cytotoxic agents (Chaplin et al., 1999; Grosios et al., 2000; Siemann et al., 2002); 
radiotherapy (Chaplin et al., 1999; Horsman & Murata, 2002; Li et al., 1998; Murata et al., 
2001c); radioimmunotherapy (Pedley et al., 2001) and hyperthermia (Eikesdal et al., 2001; 
Horsman & Murata, 2002).  When used in combination with radioimmunotherapy, CA-4-P 
has the additional benefit of increasing antibody retention in tumour (Pedley et al., 2001) 
(see Chapter 3).
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Three phase I trials of CA-4-P have now been completed (Anderson et al., 2003; Dowlati 
et al., 2002; Galbraith et al., 2003; Rustin et al., 2003b;  Stevenson et al., 2003).  In the 
majority of patients, CA-4-P was well-tolerated with the most common side effects being 
cardiovascular in origin (tachycardia and hypertension -  mostly grade l2 ) and tumour pain. 
However, 2 patients  developed cardiac ischaemia.  Phase I/II trials  in combination with 
cytotoxic agents, radiotherapy and radioimmunotherapy are now underway, with exclusion 
of patients at risk of ischaemic heart disease.
1.2.1.3  Other tubulin-depolymeris ing agents with vas cular dis ruptive activity 
ZD6126,  is  a  water-soluble  phosphate  pro-drug  that  is  converted  in  vivo  into  N-
acetylcolchinol.  N-acetylcolchinol  binds  reversibly  to  the  colchicine-binding  site  on
tubulin and has vascular disruptive activity.  ZD6126 induces endothelial shape changes in
vitro in a similar manner to CA-4-P (Davis et al., 2002; Micheletti et al., 2003).  Acute blood
vessel shutdown and haemorrhagic necrosis are seen in vivo with doses of ZD6126 up to
30-fold  lower than  the  MID  (Davis  et  al.,  2002).  Tumour growth  delay is  seen  with
ZD6126 in combination with cytotoxic agents but not as on its own in single doses (Davis
et al., 2002; Siemann & Rojiani, 2002).  ZD6126 is now in early clinical trials (Evelhoch et
al., 2002; Evelhoch et al., 2004; Gadgeel et al., 2002).
Other tubulin-depolymeris ing agents that are undergoing evaluation include: CA-l-P (Qxi 
4503),  a  close  structural  analogue  of  CA-4-P  (Ml  et  al.,  2002b;  Holwell  et  al.,  2002); 
AVE8062  (formerly AG7700),  a  synthetic  combretastatin  analogue  (Nihei  et  al.,  1999); 
Auristatin-PE  (TZT-1027), a synthetic derivative of Dolastatin (Otani et al., 2000); NPI- 
2358 (Palladino et al., 2004) and MN-029 (McCreedy et al., 2004).
1.2.1.4  Small molecule cytokine inducers
DMXAA is a synthetic flavonoid with vascular disruptive activity.  How it causes vascular 
damage is not known but is thought to involve both direct effects on tumour endothelial 
cells (Ching et al., 2002; Giing et al., 2004) and indirect effects via the release of cytokines, 
such as tumour necrosis factor-alpha (TNFa) and interferon-alpha (IFNa), and vasoactive 
agents  such as  5HT (serotonin)  and nitric  oxide  (Baguley, 2003; Baguley & Ching, 2002; 
Baguley et al., 1997; Cao et al., 2001; Thomsen et al., 1991).
2  Radiation Therapy Oncology Group (RTOG) toxicity criteria: grade 1  is transient and asymptomatic, no 
treatment required.
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DMXAA  is  a  synthetic  analogue  of  flavone  acetic  acid  (FAA),  which  has  vascular 
disruptive activity in experimental tumours (Bibby et al., 1989) but not in humans (Kaye et 
al.,  1990; Kerr et al.,  1989).  The lack of clinical activity of FAA is thought to be due to 
species  difference  in  response.  Whereas  DMXAA up-regulates  TNFa  mRNA in both 
human and murine monocyte/macrophage lineage cells, FAA had activity in murine cells 
only (Ching et al.,  1994)  and increases TNFa  levels  in mouse but not in human plasma 
(Chabot et al., 1993).
DMXAA has completed phase I trials (Galbraith et al., 2002; Jameson et al., 2003; Rustin et 
al., 2003a)  and is now entering phase II trials,  in combination with other therapies.  As 
with CA-4-P, improved tumour responses have been seen in animal models in combination 
with other anti-cancer therapies (Horsman & Murata, 2002; Murata et al., 2001b; Pedley et 
al., 1996; Pedley et al., 1999; Siemann et al., 2002; Siim et al., 2003).
TNFa has also been investigated as an anti-cancer agent.  It induces tumour regression in 
animal  models,  which  is  at  least  partially  mediated  by  selective  damage  to  tumour 
vasculature (Kallinowski et al, 1989).  Systemic administration of TNFa is toxic clinically 
(Lejeune  et  al.,  1998)  but  regional  administration  (via  isolated  limb  perfusion)  can  be 
tolerated and produces  tumour responses  -  for example,  as  a  neoadjuvant treatment  in 
combination  with  interferon-y  and  melphalan  for  patients  with  extremity  sarcomas 
(Eggermont et al., 1996).
1.2.2  Ligand-based therapies
Ligand-based  therapies  can  be  designed  to  expressly  bind  to  targets  on  the  tumour 
vasculature: either to cause acute vascular damage directly or to deliver cytotoxic agents, 
toxins or radio-isotopes to the tumour (Thoipe, 2004) (Table 1.1).
Novel tumour endothelium-specific targets can be identified by screening endothelial and 
non-endothelial cell libraries using expressed sequence tags (Huminiecki & Bicknell, 2000) 
or by identifying mRNA transcripts from purified endothelial cells  (St Croix et al., 2000). 
Alternatively, specific monoclonal antibodies can be generated in mice by injecting tumour 
endothelial cells  (Huang et al.,  1997; Tsunoda et al.,  1999)  or in iiw screening of phage- 
display libraries can be used to identify specific markers that bind to tumour endothelium 
(Arap et al., 1998; Pasqualini & Ruoslahti, 1996).
24Chapter 1 Introduction  -  Tumour microcirculation as a therapeutic target
Burrows  &  Thorpe  created  an  animal  model  to  test  the  vascular  targeting  approach 
(Burrows  & Thorpe,  1993).  Firstly, a major histocompatibility complex (MHQ  class  II 
antigen was  induced on tumour endothelium by the  transfection of neuroblastoma cells 
with a retrovirus containing the interferon-y gene.  Then, a fusion protein comprising the 
toxin,  ricin,  and an  anti-MHC class  II  antigen  antibody was  administered.  The  fusion 
protein  localised  to  tumour  endothelial  cells  and  induced  haemorrhagic  necrosis  and 
tumour regression.
Since  then,  other ligand-based therapies  have  been  developed that  might potentially be 
translated into clinical practice.  The N-cadherin antagonist, Exherin, is an example of a 
ligand-based  approach  that  causes  direct  vascular damage  (Lepekhin  et  al.,  2003).  N- 
cadherin  is  a cell adhesion  molecule  that holds  together and  stabilises  endothelial  cells. 
Exherin mimics the N-cadherin active site, preventing N-cadherin binding.  Administration 
of Exherin caused tumour blood vessel rupture within 60 minutes of injection in a range of 
animal models  (Lepekhin et al.,  2003)  It  is  thought to  be  selective  for tumour vessels 
specifically as they lack the full support structures found in normal  blood vessels.
Another approach is to selectively initiate coagulation within tumour vessels, thus inducing 
thrombosis  and  subsequent  tumour  necrosis.  Fibrinogen  E  (FgnE)  is  a  proteolytic 
fragment of the blood clotting protein, fibrinogen, that causes selective vascular damage in 
tumours  (Brown  et  al.,  2002).  The  peptide,  alphastatin  (constructed  from the  first  24 
amino-acids of the alpha chain of human fibrinogen) produces similar results (Staton et al.,
2004),  although  it  is  not clear why either FgnE  or alphastatin  are  selective  for tumour 
vasculature.  Selective vascular damage can also be induced by the administration of fusion 
proteins  comprising tissue factor and a tumour endothelium-specific  element  (Hu et al., 
2003; Huang et al.,  1997).  Tissue factor is  a cell membrane  receptor protein that is  the 
initiator of the extrinsic pathway of the coagulation cascade (Hu et al., 2003).  A truncated 
version  of  tissue  factor  is  used  that  is  only activated  when  brought  into  contact  with 
tumour endothelium.
Examples of fusion proteins comprising a tumour-endothelium selective agent and a toxin 
or cytotoxic agent include: VEGF fused to a truncated form of diphtheria toxin (Olson et 
al., 1997); VEGF fused to the plant toxin, gelonin (Veenendaal et al., 2002); and TES-23 (a 
specific  anti-tumour  endothelium  antibody)  fused  to  neocarzinostatin,  an  anti-tumour 
antibiotic (Tsunoda et al., 1999).
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It  is  also  possible  to  target  radio-isotopes  to  tumour  endothelium.  Prostate  specific 
membrane  antigen  (PSMA),  normally  expressed  on  prostate  epithelial  cells,  is  also 
expressed on the endothelium of several non-prostatic solid tumours (Chang et al, 1999a; 
Chang et al.,  1999b).  An 1 1  indium-labelled anti-PSMA monoclonal antibody is now in a 
phase I trial (Nanus et al., 2003).
Tumour extracellular matrix components may be targeted instead of endothelium.  Borsi et 
al. (Borsi et al., 2003) constructed a fusion protein composed of TNFa and an antibody to 
a  particular  fibronectin  isoform  (containing  the  extradomain  B)  that  is  a  marker  for 
angiogenesis (Tarli et al., 1999).  The fusion protein accumulated in tumour neovasculature 
in tumour-bearing mice and induced haemoirhagic necrosis and tumour regression (Borsi 
et al., 2003).
1.2.3  Other vascular disruptive strategies
1.2.3.1  Pbys ical methods
Photodynamic therapy (PDT) uses a photosensitising drug that is activated by exposure to 
light of a specific wavelength (Hopper, 2000).  The photosensitiser is injected intravenously 
and the  tumour site  illuminated using a laser.  The  activated photosensitiser reacts with 
molecular oxygen to produce short-lived reactive oxygen species that are highly cytotoxic, 
causing cell kill within a narrow radius (<0.02 pm).
PDT  has  a  vascular  disruptive  effect  as  well  as  causing  direct  tumour cell  kill.  It  is 
cytotoxic  for tumour endothelial  and  vascular smooth  muscle  cells,  inducing  apoptosis 
(Engbrecht et al.,  1999; Wyld et al.,  1997; Wyld et al., 2001) and can induce blood vessel 
shutdown in experimental tumours (Dolmans et al., 2002; Engbrecht et al., 1999; Gross et 
al., 2003; van Geel et al., 1996).
The photosensitisers, photofrin, a porphyrin derivative, and aminolaevulinic acid, which is 
metabolised into protoporphyrin IX, are both licensed for clinical use (Hopper, 2000).  In 
practice, PDT is limited to superficial lesions, e.g. basal cell carcinoma (Wang et al., 2001) 
or  local  chest  wall  recurrences  of  breast  carcinoma  (Cuenca  et  al.,  2004)  or  to 
endoscopically accessible tumours, e.g. Barrett’s oesophagus3  (Ackroyd et al., 2000).
3  Barrett’s oesphagus is a premalignant condition in which normal squamous mucosa is replaced by 
metaplastic columnar epithelium.
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Hyperthermia, the  heating of tumours to high temperatures  (43-44 °Q, can cause  direct 
vascular damage (Song, 1998).  There is selectivity for tumour vessels as normal tissues are 
able  to  dissipate  heat  more  efficiently  (by  increased  blood  flow).  Clinical  trials  of 
hyperthermia in combination with radiotherapy have shown increased response rates and 
even a survival benefit in some tumours (Wust et al., 2002).  Tumours are typically heated 
to at least 43 °C for 60 minutes (Overgaard et al., 1995; Vemon et al., 1996).  As with PDT, 
its application is limited to accessible tumours.
Liver  tumours  (e.g.  primary  hepatocellular  carcinoma,  neuroendocrine  tumours  or 
colorectal  metastases)  can  be  treated  with  tumour  embolisation  (Stuart,  2003).  The 
technique involves insertion of a catheter via the femoral artery into whichever branch of 
the hepatic artery is supplying the liver segment containing tumour.  Gelatin foam or plastic 
particles are then injected to embolise the tumour.  Cytotoxic agents, such as doxorubicin, 
may be injected concomitantly.  The technique can provide good palliation (Stuart, 2003) 
and has even improved survival in carefully selected patients with hepatocellular carcinoma 
(Llovet et al., 2002).  However, it is an invasive technique with significant toxicity (there is a 
post-embolisation syndrome of pain, fever and malaise and damage to normal hepatocytes 
may cause liver dysfunction) that is only applicable to selected patients.
1.2.3.2  Gene therapy
In theory, tumour vasculature is an ideal target for gene therapy as it should be easier to 
transfect endothelial cells than tumour cells (as they are in direct contact with blood) and 
transfection of only a limited proportion of endothelial cells would be necessary for vessel 
damage (Chaplin & Dougherty, 1999).
The objective is usually to transfect target cells with a retroviral or adenoviral vector and 
then to administer an agent that will only have activity in the transfected cells, resulting in 
selective damage.  Mavria and Porter have developed an experimental model system that 
provides proof of principle for this strategy (Mavria & Porter, 2001).  Tumour vasculature 
was transfected with a retroviral vector containing herpes simplex virus-thymidine kinase 
(by co-injection of the vector with tumour cells as a subcutaneous xenograft).  The pro­
drug  ganciclovir  was  then  administered,  resulting  in  its  selective  phosphorylation  and 
subsequent incorporation into DNA in transfected cells, leading to extensive haemorrhagic 
necrosis and tumour growth delay.
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Another example is the in utro transduction of endothelial cells with an adenoviral vector 
containing a chimeric protein comprising the extra-cellular domain of the VEGF receptor, 
Flk-l/KDR,  and  the  cytoplasmic  domain  for Fas  (which  is  involved  in  the  apoptotic 
pathwa^.  Endothelial  cell  apoptosis  is  then  triggered  by administration  of  exogenous 
VEGF (Carpenito et al, 2002).
While direct injection with a viral vector might be feasible for superficial or endoscopically 
accessible tumours, in general safe systemic administration of gene therapy will be required 
for translation into clinical practice.  Currently vascular disruptive gene therapy strategies 
are still at the pre-clinical stage.
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13  Inves tigation of tumour vessel maturity
Tumours are characterised by the persistence of immature blood vessels due to on-going 
angiogenesis and high levels of growth factors (see Section 1.1).
One  indication of vascular maturity is  the presence  of a smooth muscle cell or pericyte 
coating, which can be typically identified by alpha-smooth muscle actin (aSMA) or desmin 
immunohistochemistry  (Morikawa  et  al.,  2002).  A  pan-endothelial  marker  (e.g.  von 
Willibrand  factor  (vWF)  or  CD31  antigen)  is  used  to  identify all  vessels  present  in  a 
histological section.  A vascular maturation index can then be defined as the percentage of 
vessels staining positive for aSMA or desmin.
Vascular maturation index = (number of positive staining vessels/total vessels) xlOO
In one study, the vascular maturation index (using aSMA)  for a panel of normal tissues 
(brain, gut, heart, kidney, liver, lung, skin) was 85-95% but only 60% for the corpus rubrum 
of the ovary (used as a model of active angiogenesis) (Goede et al., 1998).  In contrast, the 
same  index ranged from  <10%  to  >80%  in a range  of different human tumours  (again 
using aSMA) -  see Figure 1.4 (Eberhard et al., 2000).
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Figure 1.4: Vascular maturation index for different human tumour types from (Eberhard et 
al., 2000).  Vascular maturation index is here termed ‘pericyte coverage index’.
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localises to mature venules and capillaries but not to newly formed vessels  (Passalidou et 
al, 2002).
This index might be inaccurate if not all pericytes stain positively for aSMA (or desmin) or 
if partial pericyte coverage is missed in thin histological sections  (Morikawa et al., 2002). 
The former point may not be a problem as Morikawa et al. found that both aSMA and 
desmin identified pericytes consistently in tumours.  However, in normal tissues, capillaries 
expressed immunoreactivity to desmin but not aSMA (normal tissue arterioles and venules 
were identified by both markers) (Morikawa et al., 2002).
Evaluation of the proportion of immature vessels within a tumour is pertinent for several 
reasons.  The  molecular  control  of  the  maturation  phase  of  angiogenesis  is  only just 
beginning  to  be  understood  (see  Section  1.1)  and  has  the  potential  for providing  new 
targets  for anti-angiogenesis  based  cancer therapy.  Analysis  of  vessel  wall  maturity in 
tumours  is  a  step towards  identifying  likely targets  for disrupting  angiogenesis/vascular 
function in tumours  (Benjamin et al.,  1999).  Also,  knowledge  of the  extent of tumour 
vessel  immaturity might aid prediction of response  to  anti-angiogenic  agents  and might 
explain differential sensitivity to CA-4-P (and other vascular disruptive agents).
Using  neonatal  mouse  retinal vessels  as  a  model of  angiogenesis,  it can  be  shown that 
VEGF withdrawal leads to regression of capillaries that are not covered by pericytes  (i.e. 
immature  vessels)  and  an  increase  in vascular maturation  index  (Benjamin  et  al.,  1998; 
Goede et al., 1998).  An increase in vascular maturation index following VEGF withdrawal 
has  also  been  demonstrated  in  tumours:  in  a  mouse  glioma  model  (with  a  conditional 
VEGF expression system)  and in human prostate  cancers  (VEGF reduction induced by 
anti-androgen therapy (Benjamin et al., 1999).  These findings suggest that tumours with a 
high  proportion  of  mature  vessels  are  unlikely to  have  a  large  response  to  anti-VEGF 
inhibitors.
It is  not known why CA-4-P should be  selective for tumour vasculature  and why some 
tumour types  are  more  sensitive than others  (Beauregard et al.,  2001; Beauregard et al., 
2002).  However, the relative lack of smooth muscle cell/ pericyte investiture of the vessel 
walls in tumours is one potential predisposing factor influencing response.  For instance, 
smooth muscle cell/pericyte investiture could confer structural stability to the vessels.  In 
turn, the maturity of the vascular wall will affect its permeability to blood solutes.  It has
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been shown that sensitivity to CA-4-P, as measured by DCE-MRI, is proportional to the 
permeability of the  vascular wall to  macromolecules, across  a range  of different rodent 
tumour types (Beauregard et al., 2001).
Our preliminary data has shown that the human adenocarcinoma, HT29, stains well for 
aSMA, indicating a mature vascular wall, whereas the murine mammary carcinoma, CaNT, 
stains  poorly.  This  difference  may relate to the  differential sensitivity to  CA-4-P of the 
HT29  tumour  versus  CaNT  -  CaNT  being  more  sensitive  (Dr  SA  M l  -   personal 
communication).  The  relative  lack of sensitivity of the  HT29  to  CA-4-P has  also  been 
confirmed by other authors (Beauregard et al., 2001; Beauregard et al., 2002).  Preliminary 
data investigating fibrosarcomas expressing different single VEGF isoforms has shown that 
they  display  a  differential  sensitivity  to  CA-4-P  that  corresponds  to  their  vascular 
maturation index.  Histological vascular maturation index was  30%  and  100  %  for the 
VEGF1 2 0  and the VEGF1 8 8  expressing fibrosarcomas respectively (Ireson et al., 2004).  In a 
window chamber model, red cell velocity was reduced to  — 10-20% of baseline at 3 hours, 
persistent  at  24  hours  following  CA-4-P  administration  in  the  VEGF1 2 0   fibrosarcoma, 
whereas red cell velocity was reduced to only 60% of baseline, with recovery by 24 hours 
following  CA-4-P  administration  in  the  VEGF1 8 8   fibrosarcoma  (Dr SA Hill -   personal 
communication).
If the  maturity index  of tumour blood vessels  proves  to  be  important  for determining 
vascular  response  to  CA-4-P  and  similar drugs,  it  would  be  useful  to  develop  a  non- 
invasive functional measure of tumour vessel maturation status, with the ultimate aim of 
translation  into  the  clinic.  Whereas  a  histological  vascular  maturation  index  can  be 
obtained using human cancer specimens, it is invasive and its application is limited as an 
index based on a biopsy may be inaccurate due to tumour heterogeneity and it is often not 
practical,  or  indeed  possible,  to  obtain  repeat  biopsies  in  order  to  assess  treatment 
response.
Vessel  response  to  a  vasoactive  agent  is  a  functional  measure  that  might  discriminate 
between  mature  and  immature  tumour vessels.  That  is,  blood vessels  with  a  vascular 
smooth  muscle  cell/pericyte  coat should  be  able  to  vasoconstrict/vasodilate  effectively, 
whereas immature vessels should be less responsive.
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Vasoactive agents  act by changing blood vessel diameter, altering vascular resistance and 
hence tumour blood flow rate.  Resistance  is  inversely proportional to the vessel radius 
raised to the fourth power - so only a small change in vessel diameter is required to have a 
significant effect on blood flow (Pocock & Richards, 2004).
1.3.1  Use  of  BOLD-MRI  response  to  vasoactive  agents  to  investigate  vessel 
maturity
Blood Oxygen-Level Dependent magnetic resonance imaging (BOLD-MRI) is sensitive to 
changes in tumour oxygenation and blood flow and has been used as non-invasive method 
of monitoring tumour response to hyperoxic gases such as carbogen (95% oxygen (O2), 5% 
C02 ) and to vasoactive agents (see Section 1.5.4).
1.3.1.1  Carbo n dioxide (COJ
It has been proposed that BOLD-MRI can be used to non-invasively distinguish mature 
from immature tumour vessels by their differential response to breathing air-5% C02  and 
carbogen gas  (Abramovitch et al.,  1999; Neeman et al., 2001).  C02  is  a vasodilator (see 
below), so mature vessels should vasodilate  in response to air-5% C02   (because  of their 
well-developed vascular wall) resulting in an increase in tumour blood flow and a positive 
BOLD  response,  whereas  immature  vessels  will  not  respond.  The  hypothesis  is  that 
BOLD-MRI can selectively detect mature vessels by their response to air-5% C02, whereas 
the  entire  functional  vasculature  is  detected  by increased  signal  change  in  response  to 
hyperoxia (breathing carbogen) (Neeman et al., 2001).
‘Vascular  function’  and  ‘vascular  maturation’  maps  of  functional  and  mature  vessels 
respectively may be obtained by identifying voxels showing a significant change in signal 
intensity when breathing carbogen or air-5% C02  compared to air alone (Abramovitch et 
al.,  1999; Neeman et al., 2001).  Figure  1.5 (from Neeman et al., 2001) shows change in 
signal intensity in response to air-5% C02  and carbogen for regions of interest containing 
mature and immature vessels respectively in a C6 glioma model.  The difference in change 
in signal intensity in response to air-5% C02  between these two areas was significant.
Vascular maturation maps obtained by this method have been validated by spatial matching 
with histological staining with aSMA (Abramovitch et al., 1999; Gilead et al., 2004).  (See 
also the discussion in Chapter 4).
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Figure 1.5: Change in MRI signal intensity over time in a region of interest with immature 
(squares) and mature (circles) vessels, (Neeman et al., 2001).
The  rationale  for the  addition of 5%  C02  to  oxygen to form carbogen gas  for tumour 
radiosensitisation  is  that  C02   counteracts  the  vasoconstrictive  influence  of pure  oxygen 
(Bird & Telfer, 1965; Du Sault, 1963; Kruuv et al., 1967).  In addition, C02  is a respiratory 
stimulant and shifts  the  oxygen-haemoglobin curve to the  right,  reducing the  affinity of 
haemoglobin for oxygen and so increasing the amount of free oxygen in the blood (Kruuv 
et al., 1967).
Evidence  for  the  vasodilatoiy  effects  of  C02   comes  from  studies  of  normal  tissue 
vasculature.  Studies  using  an  isolated  preparation  of  rat  mesenteric  small  arteries  to 
investigate the vasoactive effects of C02  have shown that an increase in C02  (from 5% at 
baseline  to  10%)  induces  initial vasoconstriction then  prolonged  relaxation  (Carr et  al., 
1993; Nielsen et al., 1991).  Relaxation was dependent on an intact endothelium and on the 
presence of the vasodilator, nitric oxide  (Carr et al.,  1993).  Further confirmation of the 
importance  of  nitric  oxide  comes  from  Iadecola  (Iadecola,  1992)  who  found  that  a 
carbogen-induced increase in cerebral blood flow (as measured by laser Doppler flowmetry 
in a rat model) was virtually abolished by nitric oxide synthase inhibition.
Investigation  of  the  effect  of  carbogen  on  tumour  blood  flow  has  produced  variable 
results, with  some  authors  reporting  either no  change  or a  decrease  in  blood  flow  (or 
surrogate  marker)  (Table  1.2).  Although  variation  between  tumour types  may reflect 
different  levels  of  tumour vessel  maturity or a  lack of  sensitivity of  the  measurement 
technique,  there  is  evidence  that  C02   can  also  act  as  a  vasoconstrictor.  In  a  window 
chamber  model,  Dewhirst  et  al.  found  that  carbogen  induced  vasoconstriction  (non­
significant)  in  normal  skin  arterioles  but vasodilation  (again  non-significant)  in  tumour-
AIR AIR-5%C02  CARBOGEN
O
*  O ’ - Q ’ T X T r
o o o
33Chapter 1 Introduction  -   investigation of tumour vessel maturity
feeding arterioles (Dewhirst et al., 1996).  Again, using a window chamber model (without 
implanted tumour), Neeman et al. found that air-5% C02  resulted in a small but significant 
vasoconstriction in skin arterioles but did not affect venules or the neovasculature.  This 
suggests that the mechanism of action of C02  maybe organ and tumour-specific.  As both 
0 2   and  C02   can  modulate  the  production  of both  nitric  oxide  and endothelin-1,  local 
balance  between  these  factors  may be  responsible  for the  different  responses  seen  in 
tumours (Bell & Chaplin, 1998; Chaplin et al., 1998a; Chaplin et al., 1998b).  A study using 
a P22 tumour tissue-isolated preparation found that tumour vessels failed to vasodilate in 
response to acetylcholine (which acts primarily via receptor stimulation of endothelial cells 
to  release  nitric  oxide),  suggesting  that  some  tumours  are  incapable  of  nitric  oxide 
production (Tozer et al., 1996).
Animal studies
Method Tumour type Outcome
(Kruuv et al., 
1967).
Thermal 
circulation 
index method
O H  spontaneous 
tumour & S3HBA 
tumour in mice
Increase in TBF vs air 
breathing
(Grau et al., 1992) 8 6 RbQ O H  tumour in mice No difference in TBF vs 
air breathing
(Honess & 
Bleehen, 1995)
86RbCl RiF tumour in mice Increase in TBF vs air 
breathing
(Hill et al., 1998a) Laser Doppler 
flowmetry
SaF sarcoma in mice Decrease in red cell flux
(Lanzen et al., 
1998)
Laser Doppler 
flowmetry
R3230Ac in rat Variable response
(Hill et al., 1998b) Laser Doppler 
flowmetry
HT29 in mice Increase in red cell flux
(Dunn et al., 1999) Laser Doppler 
flowmetry
R3230Ac in rat 
window chamber
Decrease in red cell flux
(Thews et al., 
2002)
Laser Doppler 
flowmetry
DS sarcoma Increase in red cell flux
Clinical studies
(Powell et al., 
1996)
Laser Doppler 
flowmetry
Range of tumour 
types: 8 patients
No overall change
(Hulshof et al., 
1998)
"Tc-HMPAO 
SPECT 
(1st pass 
extraction)
Glioblastoma 
multiforme 
6 patients
No change in tumour to 
normal brain ratio for 
perfusion
Table 1.2: Effect of carbogen on tumour blood flow (TBF)
1.3.1.2  Angiotens in II
It  is  possible  that  other vasoactive  agents  might be  more  appropriate  for evaluation  in 
conjunction  with  BOLD-MRI.  It  has  been  observed  that  tumour  vessels  are  more
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responsive to vasoconstrictors than vasodilators, suggesting that tumour vessels are usually 
in  a  maximally-vasodilated  state  (Mattsson  et  al.,  1982),  possibly as  a  result  of  tissue 
acidosis and hypoxia (Vaupel et al., 1989).
An ideal agent for clinical use needs to be safe, have had extensive pre-clinical experience, 
an established mechanism of action in the peripheral vasculature, a quick onset of action 
(so would have to be in an intravenous formulation or a gas) and a short half-life (of a few 
minutes).
The vasoconstrictor, angiotensin II  (ATII), is  a potential candidate for use with BOLD- 
MRI  for  the  investigation  of  tumour  vessel  maturation  status.  It  is  an  endogenous 
peripheral vasoconstrictor that is formed by the activation of the renin-angiotensin system. 
It increases mean arterial blood pressure (MABP) by binding to ATII receptors on vascular 
smooth muscle cells resulting in vasoconstriction within a few minutes of the start of an 
intravenous infusion.  It has a short half-life, a rapid onset of action (Sato et al., 1995) and 
no cardiac inotropic or chronotropic effects.
ATII has been proposed as a means of increasing tumour blood flow relative to normal 
tissues  in order to improve the  delivery of cytotoxic  agents.  It is  assumed that tumour 
vessels  will either be  incapable  of response  to  ATII  or respond to  a lesser extent than 
normal tissues, depending on the degree of tumour vessel maturity.  ATII has already been 
tested in clinical trials with no adverse effects  (Burke et al., 2001; Goldberg et al,  1991; 
Hemingway et al., 1992; Noguchi et al., 1988; Sasaki et al., 1985).
The  majority of  studies  have  shown  that  ATII  infusion  increases  tumour  blood  flow 
relative  to  normal tissues  in  animal  models  (Burton  et  al.,  1985;  Dworkin  et  al.,  1997; 
Dworkin et al.,  1996; Jirtle  et al.,  1978; Suzuki et al.,  1981; Tanda et al.,  1991;  Tozer & 
Shaffi, 1993; Trotter et al., 1991) and in patients (Burke et al., 2001).  Changes in absolute 
tumour blood  flow in  response  to  ATII  will  be  dependent  on  the  capacity of tumour 
vessels  to  vasoconstrict  in  response,  which  explains  the  variable  results  found.  Some 
studies still report an increase in absolute tumour blood flow in response to ATII (Tanda et 
al., 1991,Sasaki, 1985 # 1316), but other studies report a decrease (Bell et al., 1996; Dworkin 
et al., 1997; Jirtle et al., 1978; Tozer & Shaffi, 1993).
The  evaluation  of  BOLD-MRI  response  to  vasoactive  agents  as  a  means  of  assessing 
tumour vessel maturity is part of the work presented in this thesis (see Section 1.6).
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1.4  Measurement of tumour btood flow in the laboratory and the clinic
1.4.1  Introduction4
Tracer kinetic studies use  freely diffusible  or intravascular tracers to obtain tissue blood 
flow from the measurement of tracer concentration in the tissue of interest and in arterial 
blood over time.  In addition, intravital microscopy and laser Doppler flowmetry can be 
used to obtain endpoints that are related to blood flow: red cell flux and velocity.  Some 
techniques can only be used in animal models whereas others can be used in both animal 
and clinical studies.  Table 1.3 summarises the main techniques used.
1.4.2  Tmcer and contrast agent kinetic techniques
In nuclear medicine studies, a trace  amount of an inert radioactive  substance, ‘tracer*, is 
injected into the blood and then monitored in the tissue of interest.  The tracer can also be 
injected directly into  a tissue  and then  its  clearance  measured.  Tissue  concentration  is 
measured from the specific activity of the tracer.  Tracer kinetic principles can be adapted 
for  computerised  tomography  (Cl)  and  magnetic  resonance  imaging  (MRI),  in  which 
pharmacological doses of contrast agent are injected intravenously and change in contrast 
agent concentration measured from the change in signal intensity in image voxels.
For tracer kinetic studies, it is assumed that the physiological system is in a steady state and 
that blood flow in a tissue of interest is constant.  There are three fundamental equations 
on which almost all tracer kinetic studies are based (Peters, 1998).
a =aL _a  (1)
dt  dt  dt
where Qt, Q, and Qv are the  amounts  of tracer in tissue, feeding arterioles  and draining 
veins respectively (in mg or MBq for tracer, mmol for radiological contrast agents).  This is 
Fields principle - that the amount of tracer in an organ or tissue at a given time is equal to 
the  difference  between the  amount  arriving and the  amount leaving  (or  =  input  rate  —  
output rate) (Kety, 1960a; Kety, 1960b; Peters, 1998).
4 For tracer studies, blood flow is usually expressed per unit tissue volume or mass (ml.min1.ml1  or ml.min ’.g-1 ).  The 
term ‘perfusion’ can also be defined as flow per unit tissue volume or mass.  However, in MRI experiments, perfusion is 
usually defined more generally, describing the process of delivery of arterial blood to a tissue capillary bed (Buxton, 2002) 
so, to avoid confusion, this latter definition of perfusion will be used.
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Method Technique What measured? Clinical
use?
Advantages/disadvantages
First pass 
extraction 
technique
8 6 RbQ
extraction
TBF as fraction 
of cardiac output 
or absolute 
TBF/ unit gram 
of tissue
No +: relatively simple; absolute TBF if
arterial sampling
-: single measurements only
Doppler
Ultrasound:
microbubbles
TBF as fraction 
of cardiac output
Yes +: serial measurements possible 
-: limited to accessible tumour s
SPECTwith
"m Tc-HMPAO
TBF as fraction 
of cardiac output 
or absolute 
TBF/  ml of 
tissue
Yes As for PET, but much better 
availability
Dynamic CT TBF/unit 
volume of tissue
Yes +: non-invasive, CT scanners widely 
available
-: complicated modelling/software, 
radiation dose to patient
Kety model for 
freely diffusible 
tracer
1 2 3 I or 1 4 G 
labelled IAP
TBF/unit gram 
of tissue
No -kConsidered gold standard 
-: single measurements only
lsO PET TBF/unit 
volume of tissue
Yes +: serial measurements possible, 
good time resolution 
-: poor spatial resolution; requires 
arterial cannulation; radiation dose to 
patient, limited availability
DCE-MRI with 
Gd-DTPA
Transfer 
constant, Ktr a n s is 
related to TBF 
and
permeability- 
surface area 
product
Yes +: widely available; non-invasive, 
good spatial resolution; serial 
measurements.
-:complicated modelling, cannot 
easily separate TBF from 
permeability-surface area product
1 3 3 Xenon
clearance
TBF/ unit gram 
of tissue
Yes +: quantitative
-: superficial tumours only, radiation 
dose to patient
Thermal
clearance
TBF/ unit gram 
of tissue
Yes -: large errors under conditions 
where thermal conduction is 
important -e.g. superficial tumours
Bolus tracking 
technique
DCE-MRI with 
Gd-DTPA
Relative TBF Yes +: non-invasive, serial measurements 
possible
-: complicated modelling, ?accuracy
Dynamic CT TBF/ unit gram 
of tissue
As above
Doppler effect Laser Doppler 
flowmetry
Red cell flux and 
velocity
Yes -: limited to accessible tumours, serial 
measurements not possible, invasive
High- frequency
Doppler
ultrasound
Red cell flux and 
velocity
Yes +: non-invasive, serial measurements 
possible
-: superficial tumours only
Direct
observation of 
fluorescently- 
labelled red 
cells
Intravital
microscopy
Red cell flux and 
velocity
No +: direct observation of tumour 
vessels, serial measurements 
-: only possible for very small 
tumours
Table 1.3: Summary of techniques to measure TBF
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C = —   (dilution equation)  ’   (2)
where C is concentration (mg.ml1 , MBq.ml'1  or mmoLml'1 ), Q is tracer amount (mg, MBq 
or mmol),  and VD  is the volume of distribution of the tracer (ml) - the fraction of the total 
tissue volume that the agent can enter.
V
t = -j-  (transit time equation)  (3)
were x is time (min1 ) and/is blood flow (ml.min1 ).  The transit time equation is based on 
the central volume principle (Stewart, 1894) and has been proved for tracer kinetic studies 
by Meier and Zierler (Meier & Zierler, 1954).  It is assumed that the distribution of transit 
times of tracer particles does not change with time; flow of tracer particles represents blood 
flow; there are no stagnant pools of blood; no recirculation occurs and the tracer is injected 
instantaneously (Meier & Zierler, 1954).
For tracer studies, parameters are usually expressed per unit gram of tissue.  However, for 
imaging  studies  they are  expressed  per unit  volume  of  tissue  with  units: /  (min1 ),  VD  
(dimensionless) and concentration, C (mmoLml'1 ).
A general expression for tissue tracer concentration can be constmcted by adding up the 
amount of agent delivered by a certain time, weighted by the probability that the agent is 
still present in the tissue at that time (Buxton, 2002).  If the probability that a particle of 
tracer that  entered the  tissue  at  time  t'  is  still present  at time  t  is  r(t-  t')  (the  ‘residue 
function’), then the number of tracer particles entering in between t' and t'  + dt is/^a(t')dt', 
where Ca is the arterial tracer concentration.  Tissue concentration at time t, Q is then:
t
C, (0 = J/c„ w y u  -  t')dt’  = fC. (t) ® [r(o]  (4)
0
where 0  denotes convolution (Buxton, 2002).
Equation (4) is usually written as:
C,(0 = C ,(0 ® [/x r(0 ]  (5)
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If the equation is thought of in terms of linear systems, then Q(t) is the input, Q(t) is the 
output and  fi(t) is the ‘impulse response’.
1.4.2.1  Tumour blood flow meas ured by firs t pass extraction techniques
One  method  of  measuring  blood  flow  is  to  use  radioactive  or  fluorescently  labelled
microspheres, made of glass, plastic or starch.  The microspheres are injected into a large
artery or the left ventricle, to make sure that they are fully mixed.  They are small enough to
pass  through arterioles  but become trapped in the  capillary beds  of tissues  on the  ‘first
pass’ through the circulation.  Therefore, they distribute to the tissues as a fraction of the
cardiac output (CO) received by the tissues  (see Figure  1.6A).  The tissue concentration
time curve will be sigmoidal in shape with a plateau, H such that:
H o c J -  
CCt
As none of the microspheres leave the tissue, r(t)  = 1 for all time so equation (5) becomes 
(Buxton, 2002):
Ct(t) = /Ca(t)  (7)
arterial
-  A
H tissue
time
Figure 1.6: (a) arterial and tissue concentration time curves following injection of microspheres, 
(b) the integral of the arterial concentration curve has the same shape as the tissue concentration
curve (see text).
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If the arterial input function is obtained from blood sampling, then absolute measurements 
of blood flow can be  made.  A clinically applicable  example  of this  technique  is  using 
microbubbles and intermittent Doppler ultrasound (Krix et al., 2003).
Certain chemical species, under certain circumstances, also distribute as a fraction of the 
cardiac  output  if  injected  intravenously (e.g.  rubidium  chloride)  and  may be  used  in  a 
similar way  (Sapirstein,  1958;  Zanelli  & Fowler,  1974).  In  the  laboratory,  8 6rubidium 
chloride (^RbCl) has been used to measure the relative change in tumour blood flow rate 
(as change in fractional cardiac output) following CA-4-P in rodent models (Chaplin et al., 
1999; Eikesdal et al., 2001; Murata et al., 2001c).  Measurement of cardiac output and hence 
absolute  tumour blood flow (per gram of tissue)  is  possible  in rats  but technically very 
difficult in mice.  Tumour and organs are excised for measurement of radioactivity so serial 
measurements are not possible.
This  method  may be  used  clinically using  SPECT  (single  photon  emission  computed 
tomography).  SPECT is  a nuclear medicine procedure  in which a radiotracer is  injected 
intravenously,  its  activity  detected  using  a  rotating  gamma  camera  and  then  a  cross- 
sectional  image  reconstructed.  The  procedure  has  similar advantages/disadvantages  to 
PET  (see  below).  Tracers  such  as  99m Tc-HMPAO,  a  non-toxic  lipophilic  agent that  is 
almost completely extracted during the  1st pass, are used (Hulshof et al., 1998; Langen et 
al., 1989; Rowell et al., 1990; Rowell et al., 1989).
Tissue blood flow can also be obtained from measurement of the maximum slope  of Q 
(Peters et al., 1987).  Integration of the arterial concentration curve generates a curve with 
the  same  shape  as  the  tissue  concentration  curve  (see  Figure  1.6B),  therefore,  the 
parameters of the two curves will be in proportion and
t = 1 l  (8) A  Sa
where A is the plateau of the integrated arterial curve, ga its maximum slope and gt is the 
maximum slope  of the  tissue  curve.  A is  also the  area under the  arterial concentration 
curve,  before  integration,  and  g,  the  same  as  its  peak  height  (Peters  et  al.,  1987). 
Substituting for H:
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(9)
The tissue-concentration curve of a tracer that is not completely extracted on its first pass 
will  not  reach  a plateau but  its  maximal  slope  will be  the  same  as  that  obtained  with 
microspheres  (Miles,  1991; Peters et al.,  1987).  Therefore, the principles  outlined above 
can be applied to recirculating tracers, provided that the shape of the tissue concentration 
time curve can be determined accurately.  This is one of the methods used with dynamic 
CT to  obtain  blood  flow  measurements  (Miles,  1991)  and  has  been  used  with  CT to 
measure tumour blood flow clinically (Hermans et al., 2003).
The  advantages  of  dynamic  CT  are  that  it  has  good  spatial  resolution  and  serial 
measurements  can be  made.  Also,  increase  in  signal density is  directly proportional to 
contrast agent concentration.  However, it involves a dose of radiation for the patient and 
complicated software modelling is required.
1.4.2.2  Techniques based on Kety model  for freely diffusible tracers
Another  way of  approaching  blood  flow  measurement  is  to  use  the  model  originally
described by Kety for tissue uptake of a freely diffusible, inert tracer (Kety,  1960a; Kety,
1960b).  This  model  assumes  that  the  tissue  can  be  treated  as  a  single,  well-mixed
compartment.
Equation (1) can be rewritten:
0- =  F(Ca-C v)  (10)
dt
Where F is blood flow in mintin'1  (not at this stage, per unit volume or mass) and Q  is the 
tracer concentration in venous  blood.  Q  is  difficult to  measure  but if the  exchange of 
tracer between tissue and venous blood is very rapid, such that the two compartments stay 
in equilibrium even as the overall concentration is changing, then Q   = Q A  - where X is 
the  partition  coefficient between tissue  and venous  blood.  For a tracer that  is  equally 
soluble in tissue and in blood, X can be thought of as the volume of distribution.  In solid 
tumours, however, there are non-peifused areas to which tracer cannot get access such that 
tracer VD   = aX, where a is the perfused fraction of tissue/tumour and so Q   = Q/VD. 
Substituting in equation (10):
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Q,  F
dt  VD< y D C'-c.)  ■   (ii)
If the tracer used is not freely diffusible then equation (11) has to be modified to include 
the extraction fraction, E (the fractional loss from blood to tissue in a single passage).
If equation (11) can be expressed per unit of tissue:
where /is blood flow per unit volume (or mass) of tissue.  If Q is variable, but zero at time 
0, then
/
C,(t) = E f\c y »  dt  (13)
0
Comparison with the general expression of tissue tracer concentration, equation (5), shows 
that the residue function for a freely diffusible tracer, r{t) = e~Ji'v,).
Equation (13), known as the Kety equation, applies for injection of an intravenous bolus of 
tracer and is used for measurement of tumour blood flow in animals using radiolabelled 
iodoantipyrine  (IAP)  (Tozer et al.,  1994).  In the clinic, radiotracers  suitable for positron 
emission tomography (PET)  (Anderson & Price, 2002) are used and the method has also 
been adapted for DCE-MRI (see Section 1.5) (Tofts, 1997; Tofts &Kermode, 1991).
In the laboratory, IAP, labelled with either 1 2 5 iodine (1 2 5 I) or 1 4 carbon (1 4 Q, can be used to 
obtain absolute  measurements  of blood flow (IAP  is  assumed to be  freely diffusible  so 
E =1) (Kety, 1960b; Tozer et al., 1994).  IAP has been used to investigate the acute effects 
of CA-4-P (Maxwell et al., 2002; Tozer et al., 1999).  Tumour levels of IAP are measured 
after  excision  by scintillation  counting  and  serial  arterial  blood  samples  are  taken  for 
estimation of the arterial input function.  It is also possible to investigate spatial distribution 
of blood flow (using autoradiograph)).  The  disadvantages  of this  method are  that it is 
labour  intensive  and  although  routine  in  rats,  is  technically  difficult  in  mice.  Also, 
sequential measurements in the same animal are not possible.
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PET can be used to measure blood flow both in the laboratory and clinically.  A radiotracer 
that emits positrons (such as 1 5 0  or 1 8 F) is injected as an intravenous bolus.  Each positron 
is  rapidly annihilated by collision with a nearby electron, producing 2 gamma rays.  The 
gamma rays  are  at  180 degrees to each other and are  detected by a band of coincident 
detectors.  The original position of the positron can then be calculated and a 3D image 
formed.  Blood  flow can  be  calculated using very similar modelling  to  IAP  with  lsO- 
labelled water as the tracer (Herscovitch et al., 1983; Raichle et al., 1983).  PET has been 
used  to  measure  tumour  blood  flow  (Anderson  &  Price,  2002)  and  also  to  monitor 
response to CA-4-P in a phase I trial (Anderson et al., 2003).  The advantages of using PET 
to measure blood flow are that it is a sensitive technique and quantitative measurements 
can be made relatively easily.  External imaging and a very short tracer half-life means that 
sequential  measurements  can  be  made.  The  disadvantages  of  this  method  are:  PET 
availability is currently limited; spatial resolution is poor and anatomical resolution requires 
co-registration  with  either  CT  or MRI;  arterial  cannulation  is  required  for quantitative 
measurement; the patient receives a dose of radiation (Anderson & Price, 2002; Anderson 
et al., 2001).  Also, this method is only practical with an on-site cyclotron to generate the 
short-lived radio-isotopes required (tV£ for lsO is about 2 minutes).
DCE-MRI  involves  the  intravenous  injection  of  contrast  agent,  e.g.  gadopentetate 
dimeglumine (Gd-DTPA), while a series of images are acquired.  As with dynamic CT, it is 
a relatively insensitive technique, requiring pharmacological doses of contrast agent (c.f. the 
trace  amounts  required  for  nuclear  medicine  studies).  The  advantages  of  using  this 
technique are that MRI is widely available, and does not involve a dose of radiation for the 
patient.  Images  have  good  spatial  resolution -   so  heterogeneity of  response  within  a 
tumour can be investigated.  As with PET, sequential imaging is possible.  Unfortunately, 
there is no readily diffusible tracer available and so contrast agent uptake depends on vessel 
permeability as well as blood flow rate.  Also, change in contrast agent concentration is not 
directly proportional to change  in signal intensity and cannot be measured directly.  The 
modelling  is  still  based  on  that  devised  by  Kety  (Kety,  1960a;  Kety,  1960b)  but  it 
incorporates  a term to  include vascular permeability for the contrast agent (Tofts,  1997; 
Tofts &Kermode, 1991) (see Section 1.5).
The Kety model can be adapted for interstitial injection of an inert tracer.  In this case Ca  
will be negligible and blood flow will be related to tracer clearance from the tissue.  This 
method has been used to calculate blood flow in tumours after local injection of 1 3 3 Xe or
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99m Tc04  in animal models (Giffe et al.,  1994; Lyng et al., 1992) and clinically (with 1 3 3 Xe) 
(Mantyla et al., 1988).  However, the technique is invasive, involves a dose of radiation for 
the patient and can only be  used for superficial tumours.  Similar modelling is used for 
thermal clearance (Samulski et al., 1987).
1.4.2.3  Bolus tracking of intravascular tracer
This technique (also known as indicator dilution analysis) was originally described for non- 
diffusible radioactive tracers (Meier & Zierler, 1954; Zierler, 1965) but has been adapted for 
imaging techniques such as DCE-MRI (Rosen et al.,  1990) and dynamic CT (Axel,  1980; 
Cenic et al., 2000).  It can be used to calculate mean transit time and blood volume and 
hence blood flow from the transit time equation - equation (3).
The  model is based on a simple  system with a single  inlet and outlet with flow f   The 
system can represent an entire organ or tissue or an individual MR or CT voxel.  If the 
tracer is injected as an instantaneous bolus then tracer concentration at the outlet will rise 
to a peak and then return to zero (assuming there has not been time for recirculation).
Tissue blood volume  can be obtained relatively easily.  All tracer that enters the  system 
must leave so
oo  oo
\fca (t)dt = \fc. (t)dt  (14)
0  0
where Ca and Q  are the tracer concentrations entering and leaving the system, respectively. 
Q  = Q/Vd (see above).  Rearranging and substituting in equation (14) gives:
oo
\c,(t)dt
V  =-2_______
V D  00
\Ca(t)dt
0
For  an  intravascular  tracer,  VD=blood  volume,  so  tissue  blood  volume  is  directly 
proportional to the  area under the tissue  concentration time curve  (Axel,  1980;  Buxton, 
2002).
(15)
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If the  arterial input function,  Q(t)  is  known, then blood flow, /  may be  obtained from
deconvolving equation (5).  Alternatively, if the mean transit time, x, is measured, then/can 
be obtained by substituting in equation (3).
moment’,  x can be expressed in terms of the tracer concentration at the outlet (the venous 
concentration) as
-  i.e. as the normalised first moment of the venous concentration-time curve (Axel,  1980; 
Meier & Zierler,  1954).  (Also,  see  Peters  (Peters,  1998)  for a  worked  example  of the 
calculation of x).
tissue concentration curve is used as an approximation for x (Axel,  1980; Weisskoff et al., 
1993).  However the tissue-concentration and venous-concentration time  curves  are  not 
directly comparable as Q(t) is modelled as the convolution of Ca(t) with h(t), whereas Q(t) 
is  modelled  as  the  convolution  of  Ca(t)  with fi{t),  (Buxton,  2002).  For  the  venous 
concentration, the  impulse response  is  h(t) which depends primarily on the mean transit 
time and so the ratio of VD //(transit time equation), whereas for the tissue concentration,
The fraction of tracer leaving per unit time is termed h(t).  This is related to the fraction of 
tracer remaining, the residue function r(t) as
(16)
O O
As all tracer must leave the system,  jh(t)dt = 1.  The mean transit time is then given by:
o
0 0
(17)
0
Equation (17) defines the centre of gravity or ‘centroid’ of h(t) and is also known its ‘first
oo
jtCAO-dt
(18)
0
For imaging studies, it is not possible to measure Q  and instead the first moment of the
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the  impulse  response  is fc{t)  which is  dependent on both/and VD, not just their ratio. 
Therefore, the influence of / on the tissue concentration curve cannot be cleanly separated 
from VD  and sensitivity to flow increases is reduced, particularly for a broad arterial input 
function (Buxton, 2002).
1.4.3  Measurement of red cell flux and velocity using intmvital microscopy
Intravital microscopy is a powerful imaging technique that allows continuous non-invasive
observation of living tissue (Jain et al., 2002).  It can be used to study tumour (or normal 
tissue)  vasculature using chronic transparent window preparations  or acute  (exteriorised) 
tissue preparations (Jain et al., 2002).
The  dorsal  skin  flap  window chamber model was  developed  for  intravital  microscopic 
investigation of transplanted rodent tumours (Dewhirst et al., 1987; Papenfuss et al., 1979) 
and has been adapted for use with human xenografts in SQD mice (Leunig et al., 1992).  It 
involves  surgical  implantation  of  a  metal  or  plastic  frame  containing  a  glass  chamber 
through which the growing tumour maybe observed.
The animal is placed in a jig on an adapted microscope stage so that blood vessels can be 
observed under magnification.  A fluorescent dye (e.g. the carbocyanine dye, Dil) is used to 
label  red-cell  membranes  (Unthank et  al.,  1993).  Dil  is  lipophilic  so  dissolves  in  and 
diffuses throughout the  lipids  of the cell plasma membrane.  Labelled red cells  are then 
injected  intravenously  prior  to  the  experiment.  Video  recordings  are  made  under 
transmitted and fluorescent illumination for off-line-analysis at a later stage.  Red cell flux 
(the number of red cells passing a point/min) and velocity can be measured for individual 
vessels within a region of interest (Tozer et al., 2001).  Blood flow in a particular vessel can 
be calculated from vessel diameter and velocity (=diameterz  x velocity x  7t/4).  Intravital 
microscopy has  been  used to  monitor  response  to  CA-4-P  in tumours  implanted  in  a 
window chamber in rats (Tozer et al., 2001).
The effect of vascular-targeted strategies on tumour vasculature can be observed using this 
model  e.g.  vascular  disruptive  agents  (Tozer  et  al.,  2001)  or  anti-angiogenic  agents 
(Vajkoczy et al., 2000; Yuan et al., 1996).  The model can also be used to directly visualise 
tumour vessel response to vasoactive agents, e.g. ATII (Hori et al., 1993) and hydralazine 
(Dewhirst  et  al.,  1994),  and to  hyperoxic  gases  including  carbogen  (Abramovitch  et al., 
1998; Dewhirst et al., 1996; Dunn et al., 1999).
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The window chamber model has also been used to investigate related parameters such as 
interstitial fluid pressure (Boucher et al, 1996; Leunig et al., 1992) and tumour oxygenation 
(Dewhirst et al., 1999; Dewhirst et al., 1992; Kimura et al., 1996; Torres Filho et al., 1994). 
Tumour vessel permeability can be  investigated using high molecular-weight fluorescent 
markers,  such  as  FlTGdextran  (Yuan  et  al.,  1993).  More  recently,  multi-photon 
fluorescent imaging has  been used to facilitate accurate quantification of fluorescence  in 
3D images (Tozer et al., 2005).
1.4.4  Measurement of red cell flux and velocity using the Doppler technique
Laser Doppler flowmetry is a clinically applicable method where the signal recorded relates
to red cell flux and velocity.  The underlying principle is that light scattered from moving 
objects (red blood cells) within the tissue will show a change in frequency that is related to 
their velocity (Stem,  1975).  Microprobes  are  inserted  into  the  tumour and  the  signal 
recorded  for  up  to  approximately two  hours  (Hill  et  al.,  1998a).  The  signal  is  then 
calculated relative to pre-treatment values.  Laser Doppler flowmetry can be used both in 
animal models (Hill et al., 1998a) and clinically (Goodchild et al., 2001; Powell et al, 1996). 
It has been used to monitor response to CA-4-P in an animal model (Malcontenti-Wilson 
et al., 2001).  The limitations of this technique are that only a representative sample of the 
tumour can be sampled and serial readings are not possible (as the microprobes cannot be 
positioned reproducibly).  Also, there is a complicated relationship between the signal and 
blood flow rate, hence absolute blood flow rate cannot be calculated and it is difficult to 
compare  measurements  on  different  occasions  and  between  different  institutions.  In 
humans,  studies  are  limited  to  accessible  tumours  e.g.  neck  nodes  or  skin  metastases 
(Powell et al., 1996).
High frequency Doppler ultrasound has also been used to monitor the effects of vascular 
disruptive therapy on superficial tumours (Goertz et al., 2002).  It is non-invasive and can 
be used for serial measurements, but is limited to superficial tumours of <5-10 mm depth.
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1.5  MRI methods for imaging tumour microcirculation5
1.5.1  Overview of MRI principles
Atoms  with an odd number of protons  or neutrons  possess  nuclear spin  (spin angular 
momentum).  The  nucleus  is  positively charged,  so  induces  a  magnetic  field  (as  it  is  a 
moving charged particle).  Each of these spinning nuclei can therefore be thought of as a 
tiny magnet spinning on  its  long  axis  -  see  Figure  1.7A.  Magnetic  resonance  imaging 
(MRI)  is  derived from the  interactions  of these  nuclear ‘spins’  with an external applied 
magnetic field.  Hydrogen nuclei (which possess a single proton) are usually used as they 
are  abundant  in tissue  and have  the  strongest  magnetic  dipole  ‘moment’  of  any stable 
nucleus  -  so  produce  the  strongest  signal.  However,  other isotopes  such  as  1 3 carbon, 
1 9 fluorine, 23sodium or 3 1 phosphorus have also been used.  All work presented in this thesis 
has been performed using !H (proton)-MRI.
The  nuclear spins  present  in  a defined volume  of tissue  can  each  be  represented  by a 
magnetic dipole  moment vector with a defined magnitude and axis  of rotation -  Figure
1.7.A  These vectors are orientated randomly in all directions, so when summed, the net 
magnetisation vector will be zero -  see Figure I.7.B.  If the tissue is placed in an external 
magnetic field, Bq  (units = tesla, T), there is an interaction between the nuclear spins and Bq  
such that individual spins rotate, or ‘precess’, gyroscopically around the axis of Bq  (Figure
1.8.A) and the magnetic dipole moment vector of each spin lines up either parallel or anti­
parallel  to  Bq   (Figure  1.8.B).  The  spins  precess  at  a  frequency proportional  to  the 
magnetic field strength of Bq , known as the Larmor frequency:
v.o=rBo  (19)
where co0  is the Larmor frequency (Hz), y is the gyromagnetic ratio (Hz.T1 ) of the nuclear 
spin and Bq  is the external magnetic field (T).  y is a constant which is an intrinsic property 
of a particular nuclear spin.
5  Bibliography for this section:
A Training Course in Magnetic Resonance Imaging and Spectroscopy, Oct 2001. Royal Marsden NHS Trust/Institute of
Cancer Research and The Institute of Physics and Engineering in Medicine.
J.P. Homak website http://www.cis.rit.edu/htbooks/mri/inside.htm
Buxton RB.  Introduction to Functional Magnetic Resonance Imaging.  Cambridge University Press, Cambridge, UK
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Figure 1.7 A: a nuclear spin, rotating about its longitudinal axis, B: volume of tissue 
containing randomly orientated spins, arrows indicate axes of rotation.
net spin 
orientation
Spinning
nucleus
(b)
li
Figure 1.8 The application of an external magnetic field, Bo causes the nuclear spin to precess 
gyroscopically around Bo (A ) and to line up with their net orientations either parallel or anti-parallel
to Bo (B).
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Hydrogen  nuclei can  exist at two  energy levels.  Nuclei at the  lower energy level have 
magnetic vectors  aligned parallel with Bq  (spin-up)  as this  requires  less energy than anti­
parallel (spin-down) alignment.  A tiny excess number of hydrogen nuclei (7 per 10 million) 
have magnetic vectors in parallel alignment, creating a net magnetisation vector, M o> in the 
same  direction  as  Bq   (Figure  1.9.A).  These  vectors  can  be  described using  Cartesian 
coordinates:  Bq   and Mg are  conventionally said to be  in the  Z-axis  and the  longitudinal 
magnetisation vector is termed Mz.  At equilibrium, Mz = Mo and there is no magnetisation 
vector in the tranverse plane (M^y).
Mq  is the source of the MRI signal, but cannot be detected when it is in parallel with B0. 
The application of a radio-frequency (RF) pulse, B,, at the Larmor (resonance) frequency, 
in the transverse (XY) plane (i.e. perpendicular to Bq),  causes the nuclear spins to precess 
around Bj instead so the net magnetisation vector rotates out of alignment with Bq  (Figure
1.9.B).  The flip angle, a, is the angle of rotation produced by Bj.  For example, a flip angle 
of 90° will rotate Mo into the transverse  (XY) plane, where it is now termed Mi  (Figure
1.9.B).
There is now a moving magnetic field in the transverse plane that can induce a voltage in a 
receiver coil.  This electric voltage is the nuclear magnetic resonance (NMR) signal.  Once 
the RF pulse is  switched off, the net magnetisation vector will realign with Bq , along the 
longitudinal (Z) axis (as the nuclear spins will rotate back to precess around Bq).  As only 
magnetisation in the transverse plane (XY) can induce voltage in the receiver coil, the MR 
signal will decay as Mi rotates back to Mo -  a process known as ‘free induction decay5 .  An 
MR image could then be constructed from this signal, though it is usually too fast to allow 
spatial encoding and so other RF pulses are generally used, in sequence with magnetic field 
gradients,  to  form encoded  echoes.  These  can then  be  Fourier transformed  into  final 
images.
The RF pulse provides the energy required to excite nuclear spins from the lower energy 
level to the higher energy level -  this is ‘resonance’.  The moment the RF pulse ceases, the 
excited spins will revert to the lower energy level in a process called ‘relaxation’, which is a 
re-establishment of thermal equilibrium.  There are two relaxation processes: the recovery 
of  longitudinal  magnetisation  (Mz)  and  the  decay  of  tranverse  magnetisation  (M^)  -  
governed by relaxation time constants, Tj and T2  respectively.
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(A) (B)
Figure 1.9: A:  The net magnetisation, Mi at equilibrium, B: Application of a RF pulse causes Mo to 
rotate through a flip angle of O C  to give a net magnetisation of Mi.
(a) (b)
time
- -  M
time
Figure 1.10 A:  Ti relaxation time-curve B. Ta relaxation time-curve
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Tj  (‘spin-lattice’  relaxation)  depends  on how quickly nuclear spins  give up energy to the 
surrounding tissue or ‘lattice’ and is defined as the time taken for Mz to return to 63% of 
its original value (ML i.e. to increase Mz by a factor of e (Figure 1.10.A).
T2  (‘spin-spin’ relaxation) depends on the interaction with adjacent spins.  At the end of the 
RF pulse, all spins are processing in the transverse (XY) plane (assuming a 90° flip angle has 
been applied) at the same frequency and are ‘in phase’ with each other.  Once the RF pulse 
is switched off, the precessional frequency of a particular spin is altered by interactions with 
adjacent nuclear spins, resulting in a gradual loss of phase coherence and hence transverse 
magnetisation.  T2  is defined as the time taken for Mxy to decay to 37% of its maximum 
value, i.e. to decrease Mxy by a factor of e (Figure 1.10.B).
B0   is  not  uniform,  as  there  are  local  field  distortions  due  to  magnetic  susceptibility
differences between different tissues.  ‘Magnetic susceptibility’ is a measure of the degree to 
which a material becomes magnetised when placed in a magnetic field.  Air, bone and other 
tissues all have different magnetic susceptibilities, resulting in distortions in Bq  at interfaces 
between different structures.  Local inhomogeneities in Bq  will influence the rate of decay 
of transverse magnetisation.  The effective transverse relaxation under  these circumstances
is faster than T2  and the term T2* is used to describe it and:
T2   *  T2  t 2
where T2' is the extra relaxation component due to Bq  inhomogeneities.  (Equation 20 may 
also be written as R2* = R2+R2', where R2  is the relaxation rate and = 1/T2 ).
1.5.2  Image Contrast
Tissues have characteristic Tj and T2  values.  Tj values in the body vary between about 0.2 
and 4 seconds and are 8-10 times longer than T2  values.  To create an image, a particular 
sequence  of  RF  pulses  and  magnetic  field  gradients  is  applied  -   called  a  MR  pulse 
sequence.  The size, direction, timing and frequency of these pulses and gradients can be 
manipulated  such  that  tissues  with  different  relaxation  times  will  have  different  signal 
intensities and there is contrast between them in the resultant image.  The repetition time, 
TR,  is  the  time  between  one  RF  pulse  and the  next.  The  echo  time,  TE,  is  the  time 
between  centre  of the  initial  pulse  and the  time  when the  MR signal  is  measured  (see
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Figure  1.11).  On  a  ‘Tr weighted image’  (short TR,  short  TE),  tissues  with  a short  Tt 
appear bright  and  those  with  a  long  Tt  appear dark.  The  opposite  occurs  with  a  T2  
weighted image  (long TR, long TE): tissues with a long T2   appear bright whereas those 
with a short T2  appear dark.
R F -|------------------------------------- h}----------------
S  -------------------------------------------------
TR
■TE
Figure 1.11: Diagram to show relationship between RF pulse, resultant signal (S), TR and TE
MRI visible protons are those within soft tissues and liquids.  Solid tissues  or structures 
such as bone have a fixed lattice and appear black on all image types.  Image contrast may 
also  be  produced  by using  pulse  sequences  sensitive  to  the  relative  number of  mobile 
protons available within a tissue.  This is termed ‘proton density5  (PD) image contrast.  For 
example, cerebrospinal fluid has  a high proton density whereas  brain tissue  has  a lower 
proton density.  The proton density is responsible for the magnitude of signal generated 
(signal amplitude).  Proton density contrast is regarded as ‘basic’ MR contrast as it is not 
dependent on tissue relaxation times.  (Measured PD images do have some residual Tj and 
T2  contrast by the nature of the sequence timings used in their measurement).
Image contrast may be enhanced by the use of intravenous contrast agents such as the low 
molecular weight agent, gadopentetate dimeglumine (Gd-DTPA, Magnevist®).  Gd-DTPA 
is paramagnetic6, as the gadolinium ion contains seven unpaired electrons and so has a large 
magnetic dipole moment.  The presence of Gd-DTPA in a tissue shortens the Tt and T2  
relaxation times, increasing the ‘relaxation rates’, 1/Tl and 1/T2, such that (for TJ
— = ——  + r,C  (2 1)
Tlobs  m   ^  }
6 A paramagnetic material will develop a weak attractive force if placed in an magnetic field.
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where  l/T lobs is the observed value  in the presence  of Gd-DTPA,  1/Tj(0)  is  the  innate 
value, C is the concentration of Gd-DTPA (mM) and q is the ‘relaxivity’ of Gd-DTPA in 
mMTs'1   (specific  water relaxation  rate  due  to  Gd-DTPA,  dependent  on  magnetic  field 
strength).  (Equation 21  may be written in a similar fashion substituting T2  for TJ.  The 
effect of Gd-DTPA is to increase signal intensity on a Tj-weighted image (as tissues with a 
short Tj are bright) and to decrease signal intensity on a T2  (or T2*) weighted image (as 
tissues with a short T2  are dark).  Gd-DTPA is used primarily as a Tj-agent as its effect on 
Tj is greater than on T2  for the same dose of contrast agent (as Tj >T2 ).  The effect of Gd- 
DTPA is often described in terms of relaxation ‘rate’ constants -  e.g. Rj = 1/Tj and so on.
Gd-DTPA has a low molecular weight (0.57 kD) and so diffuses out of blood vessels into 
the extracellular space (except in cerebral imaging when the blood-brain barrier is intact). 
Tumour  vessels  are  more  permeable  than  normal  vessels  (Jain,  1987a),  so  Gd-DTPA 
diffuses more rapidly into tumour extravascular extracellular space (EES) than into normal 
tissue  EES,  providing  contrast  by  increasing  tumour  signal  intensity  on  Tj-weighted 
images.
Gd-DTPA can also provide contrast by its  effect on tissue  magnetic susceptibility.  The 
presence  of Gd-DTPA within blood vessels  alters  the  magnetic  susceptibility of blood, 
inducing local distortions in Bq .  The consequence is shortening of the relaxation time, T2* 
(as nuclear spins dephase more rapidly and a decrease in signal intensity on a T2*-weighted 
image.  Protons in extravascular water adjacent to the vessel are also affected - resulting in a 
decrease in signal intensity over an area wider than the vessel diameter.  This significantly 
increases contrast agent sensitivity.  The effect only occurs  during the brief period when 
Gd-DTPA is  confined to  the  intravascular space,  as  Tj  effects  will  dominate  once  the 
contrast agent starts extravasating into the EES.
Blood Oxygen Level Dependent (BOLD)-MRI is a special technique that exploits the fact 
that deoxygenated haemoglobin (deoxyHb) is weakly paramagnetic and so can be used as 
an intrinsic  contrast agent via  its  effects  on  magnetic  susceptibility (Ogawa et al.,  1990; 
Ogawa et al., 1993) - see Section 1.5.4.
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1.5.3  Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI)
DCE-MRI involves the acquisition of a set of images as an intravenous bolus of a contrast
agent, such as  Gd-DTPA, is  injected.  The bolus  of Gd-DTPA will briefly be  confined 
within the vascular space before diffusing rapidly into tumour EES.
During the  initial ‘vascular’ phase, a T2*-weighted sequence can be used to detect signal 
change due to passage of the bolus of Gd-DTPA through the tissue capillary bed (Figure 
1.12).  Gd-DTPA can be treated as a non-diffusible, purely intravascular agent during this 
brief time.  Modelling of this phase (using the indicator dilution theory for non-diffusible 
tracers (Meier & Zierler, 1954; Rosen et al., 1990; Zierler, 1965)) can produce estimates of 
relative tumour blood flow and volume (see Sections 1.4.2.3 and 1.5.3.2).  Sequences with 
rapid image acquisition are used (e.g. images every 2 seconds for a total of 60 images).
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Figure 1.12: Graph of signal intensity versus time showing the transient dip in signal intensity due 
to T2* effects following bolus injection of Gd-DTPA (with thanks from Dr Nf Taylor).
The contrast agent then passes rapidly into tumour EES -  detected as an increase in signal 
intensity if a Tr weighted sequence is used.  The sequences used do not need such rapid 
image acquisition and typically have image time resolutions of 10-12 seconds.  During this 
phase, Gd-DTPA can be treated as a diffusible tracer and the model developed by Kety 
(Kety, 1960a; Kety,  1960b) applied to produce estimates of vessel permeability, perfusion 
and leakage space (see Section I.4.2.2. and below).  There will be some T2* effects during 
this  phase  that  cannot be  eliminated completely but the  sequence  can be  optimised by 
appropriate choice of TR and TE values.
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The  change  in signal intensity (ASI)  oyer time  following contrast agent injection can be 
analysed  to  obtain  semi-quantitative  parameters  such  as  maximum  gradient,  maximum 
amplitude  or  area  under  the  ASI-time  curve  (AUQ.  These  parameters  can  provide 
information  about the  tumour microcirculation  as  they are  indirectly related to  tumour 
perfusion,  vascular  permeability  and  vessel  surface  area  (Beauregard  et  al.,  1998; 
Hawighorst  et  al.,  1999;  Mayr et  al.,  1996).  Unlike  CT imaging,  the  change  in  signal 
intensity on the MR image does not reflect contrast agent concentration directly but rather 
is a map of the effect of Gd-DTPA on the relaxation times of hydrogen nuclei present in 
the  tissue.  Therefore  it  is  difficult  to  compare  non-quantitative  results  from  different 
institutions  as  different  sequences,  machines  and  injection  procedures  will  produce 
different changes  in signal intensity for the same  change in contrast agent concentration 
(Parker  et  al.,  1997).  For  quantitative  analysis  (to  obtain  comparable  results  between 
institutions)  and tracer kinetic  model application, estimation of the  tissue  contrast agent 
concentration is required.
1.5.3.1  Tf weighted DCE-MRI kinetic parameters
The Tr weighted quantitative parameters derived for the work presented in this thesis are 
IAUGC (the initial area under the Gd-DTPA concentration vs time curve) and the kinetic 
parameters  obtained  from  the  Tofts’  model  (Tofts  &  Kermode,  1991):  the  transfer 
constant for Gd-DTPA from plasma to tumour extracellular space, Ktrans and the volume of 
the EES or leakage space, ve.  How these parameters are derived is outlined below.
1.5.3.1.1  Quantitative  analysis:  conversion  of  signal  intensity  to  Gd-DTPA 
concentration
For quantitative analysis, signal intensity values have to be converted first into Tj relaxation 
times and then into Gd-DTPA concentration values.
In the  clinical  study (see  Chapter 2),  data  from a  calibration  experiment that  involved 
phantoms  with  known  Tj  relaxation time  values  were  available.  Signal  intensities  were 
converted into Tx   relaxation times using this  calibration data in conjunction with proton 
density images (Parker et al., 1997).
The concentration of Gd-DTPA present at time t, Q, can then be calculated from equation 
22 (a rearrangement of equation 21) (Donahue et al, 1994):
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(22)
r i
where T^t) is the post-contrast signal intensity at time t, Tj(0) is the pre-contrast relaxation 
time  and rx  is the longitudinal relaxivity of protons in mo due to Gd-DTPA respectively. 
For the clinical study, rx  was taken to be 4.5 mM'1 s'1  for a 1.5 Tesla system (Donahue et al., 
1994).
The  method used for Tj  calculation  for the  CA-4-P/SW1222  study (see  Chapter 3)  is 
given in the Appendix.  Relaxivity, q at 4.7 Tesla was also determined for this study -  the 
details of the method used are given in Chapter 3.
1.5.3.1.2  IAUGC
The IAUGC (units: mMmin or mM.s) is usually calculated for the first 60 or 90 seconds 
following  Gd-DTPA  injection  (Evelhoch,  1999;  Evelhoch  et  al.,  2004).  It  cannot  be 
related  simply  to  tumour  physiology,  but  has  the  advantage  of  being  a  quantitative 
parameter that is  obtained without mathematical modelling or knowledge  of the  arterial 
input  function  (see  below).  As  such,  changes  in  voxels  that  are  excluded  from  the 
modelling analysis are evaluated by the IAUGC parameter.  It is a measure of how much 
contrast agent is  taken up by the tumour in the  first  60  or 90  seconds  post-Gd-DTPA 
injection  and  is  influenced by tumour blood flow rate  and tumour vessel permeability. 
IAUGC values can be easily and robustly calculated for individual voxels  in the tumour 
region of interest, (quantification of baseline Tj is required).  An average IAUGC value for 
the whole tumour can then be determined.  Figure 1.13 shows the derivation of IAUGC
Signal
intensity
Change in tumour 
signal intensity vs time
Change in tumour 
Gd-DTPA concentration vs time
Gd-
DTPA
IAUGC
Time (s)
Gd-DTPA injected
Figure 1.13: Diagram to show derivation of IAUGC
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1.5.3.1.3  K ^andV e
The transfer constants for Gd-DTPA diffusion into the tumour extracellular extravascular 
space from blood plasma (Ktran s) and back again (k j can be calculated using a mathematical 
model (Tofts’ model - see Figure 1.14) (Tofts et al., 1999; Tofts &Kermode, 1991).
This  model  is  an  adaptation  of the  Kety model,  which was  developed to  describe  the 
uptake of a freely diffusible inert tracer from the plasma to tissue extracellular extravascular 
space (Kety, 1960a; Kety, 1960b) (see Section 1.4.2.2).  The main differences between the 
Tofts’  and Kety models  are  that  Gd-DTPA is  not a freely diffusible  tracer (which is  a 
requirement of the Kety model) and that the transfer constants elicited are expressed per 
unit volume rather than per unit gram of tissue.
Using the Tofts’ model, the time course of contrast agent concentration in tumour can be 
described by:
C, (<) = K ,mns x c„ (0 ®  e~kept  (23)
where Qt represents the contrast agent concentration in arterial blood plasma at time t, (the 
‘arterial input function’ or AIF), Ktrans (min1 ) represents the transfer constant for transport 
from plasma to the tumour extravascular extracellular space  (EES), k^ (min1 )  represents 
the rate constant for transport from the EES to plasma and ® denotes convolution.  This 
equation is in the same form as equation (5) -  see Section 1.4.2.  The volume of EES per 
unit volume of tissue in the tumour, ve (%), is equal to K1 1 5 ® 8 /^  .
Ktrans (and k j have both blood flow rate and permeability components as Gd-DTPA is not 
freely diffusible and their biological meaning is dependent on the balance between capillary 
permeability and blood flow in the tissue of interest (Tofts et al.,  1999; Tofts,  1997).  In 
high permeability situations, Ktran s  is  equal to the blood plasma flow per unit volume  of 
tissue.  In low permeability situations, such as in the brain, it is equal to the permeability 
surface area product between the blood plasma and the EES (Tofts, 1997).  Fit failures may 
occur with the derivation of Ktrans due to the presence of either non-perfused regions, or 
regions of very high blood flow (see also Section 1.5.5).
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Figure 1.14: Diagram to show Toft’s model for Gd-DTPA uptake kinetics.
There are a lot of assumptions when applying Tofts’ model to tumours so these parameters 
should  be  regarded  as  the  ‘apparent’  blood  flow  rate/permeability  and  leakage  space 
(Parker et al, 1997).  In principle, however, as the values of Ktrans and ve that are derived are 
based on Gd-DTPA concentration, comparisons  between different studies  and different 
MR centres can be made.
1.5.3.1.4  Calculation of arterial input function
The arterial input function, Ca, can be approximated to a bi-exponential function:
Ca =£>j?ie  m,t+a2e  m2‘\  (24)
where D is the dose of Gd-DTPA (mmoLkg1 ) and aly a^ m„ and m2  are free parameters. 
For the clinical study (see Chapter 2), a standard arterial input function was used based on 
measurements  on  a  group  of  healthy  volunteers  (Weinmann  et  al.,  1984).  For  the 
SW1222/CA-4-P  study,  the  arterial  input  function was  derived using  data from both  a 
blood-sampling method and in uw imaging (see Chapter 3 for details).  Wedeking et al. 
measured Q in rats and recommended fitting to a tri-exponential function (Wedeking et al., 
1990).  However measurements were  made out to 90  minutes  post-Gd-DTPA injection. 
For shorter time spans, a bi-exponential function is commonly used (Checkley et al., 2003; 
Furman-Haran et al., 1996; Lyng et al., 1998).  Although a multi-exponential decay function
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better describes  the  total  plasma  concentration  curve,  a  bi-exponential  function  seems 
sufficient to fit plasma concentration if the time range is short (Su et al., 1994).
1.5.3.2  T{^-weighted DCE-MRI (for calculation of rB Vand rBF)
The  bolus-tracking  technique  for measurement  of  blood  volume  and  flow requires  an
intravascular tracer (see Section 1.4.2.3) (Meier & Zierler, 1954; Zierler, 1965).  Gd-DTPA
fulfills  this  requirement in cerebral  imaging, providing the  blood brain barrier is  intact.
Therefore,  the  bolus  tracking technique  can be used to  measure  relative  cerebral blood
volume and flow (Rosen et al.,  1990).  In situations when vessels are permeable to  Gd-
DTPA (in visceral imaging or cerebral imaging with disruption of the blood brain barrier
e.g. by tumour), the contrast agent will have a brief intravascular phase before it starts to
leak out into extracellular extravascular space -  so the technique can still be applied.
The intravenous bolus of contrast agent produces  a transient decrease in signal intensity 
(and hence a transient increase in R2*) on a T2*-weighted image as  it passes through the 
cerebral vascular bed.  It is  assumed that there  is  a linear relationship between contrast 
agent concentration  and the  change  in transverse  relaxation  rate,  AR2*  (Belliveau et al., 
1990; Rosen et al., 1990; Villringer et al., 1988):
C(t)x AR2  *(/) = - “ In
TE S o ,
(25)
where S0  and S(t) are the signal intensities at the baseline and at time t respectively and TE 
is the echo time of the MR sequence used (Belliveau et al., 1990; Rosen et al., 1990).  It is 
also assumed that the amount of contrast agent that diffuses into the EES during the first 
pass is minimal and so does not affect the susceptibility gradient and hence AR2* (Barbier 
et al., 1999).
The shape of the AR2*-time curve will be affected by re-circulation of the Gd-DTPA bolus 
(see  Figure  1.15)  which  can  be  corrected  by fitting  to  a  gamma  (T)-variate  function 
(Benner et al., 1997; Thompson et al., 1964).  rBV is calculated from:
t-BV = |a/?2  *(t)dt  (26)
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(see  Section  I.4.2.3.)  Blood  volume  measurement  is  relative  as  the  constant  of 
proportionality relating  C(t)  and  AR2*  is  not  known.  Reproducibility is  improved  by 
normalising to  the  integral of the  arterial-concentration time  curve  and then to  grey or 
white  matter in the contralateral hemisphere  (in cerebral imaging).  The ratio of grey to 
white  matter  cerebral  blood  volumes  obtained  using  this  MR  technique  is  in  good 
agreement with that obtained with PET (Belliveau et al., 1990; Guckel et al., 1994).  Brain 
tumour rBV measurements have been obtained from this technique (Aronen et al., 1994; 
Guckel et al.,  1994; Jackson et al., 2002b; Maeda et al.,  1993; Rosen et al.,  1991a) -  and 
found to correlate with measurements made with PET (Rosen et al., 1991a).
If contrast is  able to  leak into tumour EES then ^-shortening will occur, producing an 
increase in signal intensity (Tj  ‘shine-through’)  and reducing the peak of the AR2* curve 
(Jackson  et  al.,  2002b).  The  T-variate  function will  help  to  correct  for any T}   effects 
(Boxerman et al., 1997; Rosen et al., 1991b), as will ‘pre-enhancing’ the tumour with a dose 
of contrast agent 5-10 mins prior to imaging (Jackson et al., 2002b) and choosing a small 
flip  angle  (Maeda  et  al.,  1993).  Using  a  double  dose  of  contrast  agent  also  improves 
sensitivity (Bruening et al., 2000).
AR *
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Figure 1.15: Diagram to show Y-variate fit to AR2* curve.
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x centroid
Figure 1.16: Schematic tissue concentration-time curve showing the approximations used 
for the mean transit time.  FWHM: full-width half-maximum.
The  measurement  of  relative  blood  flow  (rBF)  is  more  complex  mathematically than 
measurement of rBV and so is more prone to error (Buxton, 2002) (see Section 1.4.2.3). 
Using the general equation for tissue tracer concentration (see the introduction to Section 
1.4.2), rBF can be obtained by deconvolving the AR2*-time curve from the arterial input 
function (Axel, 1983; Ostergaard et al., 1996).  A more pragmatic approach, that does not 
require  knowledge  of  the  arterial  input  function,  is  to  use  either  the  normalised  first 
moment, or the ‘full-width half-maximum’ measurement, of the AR2* - time curve (Figure 
1.16) (Perthen et al., 2002) as an approximation for the mean transit time (t).  rBF may then 
be obtained by substituting in the mean transit time equation.
There  have  been  several  studies  comparing  this  MR technique  with  other  methods  of 
measuring cerebral blood flow in humans such as 1 3 3 Xe SPE CT (Wirestam et al., 2000) and 
1 5 0-H20-PET (Lin et al., 2001; Mukherjee et al, 2003; Ostergaard et al., 1998).  There is 
positive correlation between different methods, at least for relative measurements.
This MR technique has been used to obtain estimates of rBV and rBF in visceral tumours 
(Ah-See et al., 2004; Jackson et al., 2002a; Taylor et al., 2004) and this particular application 
is discussed further in Chapter 2.
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1.5.4  BOLD-MRI
The presence of deoxyHb in blood causes a decrease in signal intensity on a T2*-weighted 
image due to its magnetic susceptibility effects (Ogawa et al., 1990; Ogawa et al, 1993).  In 
contrast, oxyhaemoglobin does not affect magnetic susceptibility as the presence of oxygen 
suppresses the magnetic properties of the iron molecules, present in the heme group7.
The BOLD-MRI signal is related to the amount of deoxyHb present and the blood volume 
as:
R2* oc VfdHbf  (27)
Where V is blood volume, [dHb] is deoxyHb concentration and p is  — 1-1.5 depending on 
vessel size (Davis et al., 1998).
BOLD-MRI will be  sensitive  to  changes  in tissue  oxygenation and blood flow as  these 
factors will alter tissue deoxyHb levels.  This  is the basis  of functional brain imaging as 
neuronal  stimulation  increases  cerebral  blood  flow  and  oxygen  delivery  to  the 
corresponding  cortical  area.  The  consequence  is  a  decrease  in  deoxyHb  levels  and  a 
transient  increase  in  signal intensity on  a BOLD  image,  for example, visual stimulation 
‘lights up’ the visual cortex (Kwong et al., 1992; Ogawa et al., 1992).  Tissue oxygenation 
and/or blood flow can also be manipulated by extrinsic factors such as breathing hyperoxic 
gases or administration of vasoactive agents.  This has led to the development of BOLD- 
MRI as a non-invasive method of monitoring tumour response to hyperoxic gases such as 
carbogen (Abramovitch et al., 1999; Collingridge, 1997; Griffiths et al., 1997; Jordan et al., 
2000; Neeman et al., 2001; Rijpkema et al., 2002; Robinson et al., 1997; Taylor et al., 2001). 
There have also been studies using BOLD-MRI to monitor the effects of vasoactive agents 
such as hydralazine (Robinson et al., 2000); calcitonin gene-related peptide (CGRP) (Howe 
et al., 1996) and the nitric oxide donor, isosorbide dinitrate (Jordan et al., 2000).
Analysis  of the  BOLD  response  can  either be  semi-quantitative,  describing  changes  in 
signal intensity seen, or quantitative, in which absolute T2* or R2* measurements are made 
(a  change  in  T2* will be  in the  same  direction  as  change  in  signal intensity).  A multi­
gradient echo sequence can be used to sample the NMR signal during transverse relaxation.
7  DeoxyHb is paramagnetic and oxygenated haemoglobin is diamagnetic.
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Assuming TR >T2*  signal intensity can be approximated by:
S « A0e~TERl*   (28)
where Aq  is  signal intensity extrapolated to zero  echo time  (the  intercept on the y-axis) 
(Lebon et al.,  1998).  Sampling the transverse relaxation at several echo times allows the 
decay to be fitted, assuming monoexponential decay, providing R2* and Aq values.  Aq is 
sensitive to blood flow rate whereas R2 if is sensitive to oxygenation (Lebon et al., 1998). Aq 
is dependent on the system adjusts, so rises and falls with signal intensities.  AAq in a given 
experiment (e.g. breathing carbogen gas) will be proportional to flow.
An increase or decrease in tumour oxygenation will change deoxyHb levels and so have a 
direct effect on BOLD signal intensity.  A change in tumour blood flow can also affect 
BOLD signal intensity -  an increase  in flow would be  anticipated to  decrease  deoxyHb 
levels by flushing out deoxygenated blood with fresh, oxygenated blood.  Choice of MR 
sequence  parameters  will also  influence the  effect of TBF on BOLD  signal intensity as 
hydrogen spins  in blood flowing into an observed slice produce  a much stronger signal 
than stationary spins.  This is termed the ‘inflow effect’ and occurs because spins in static 
tissue are already partially saturated (have a reduced signal intensity) by previous RF pulses 
(Howe et al.,  1999).  Therefore, the BOLD signal intensity change is dependent on both 
oxygenation and blood flow, depending  on the  MR sequence  used  (Howe  et  al.,  1996; 
Howe et al., 1999).
As the BOLD signal is dependent on deoxyHb levels, an R2* map of a tumour ROI should 
be  indicative  of tumour hypoxia.  However, the  interpretation  of intrinsic  R2*  maps  is 
uncertain  as  the presence  of oedema,  haemorrhage  and necrosis  will all affect  magnetic 
susceptibility and hence the BOLD signal (Robinson et al., 2003a; Robinson et al., 2003b). 
Regions  of  high  signal  intensity  (slow  R2*)  are  thought  to  delineate  well- 
oxygenated/  perfused areas  of tumour whilst dark areas  (fast R2*)  are thought to indicate 
poorly perfused/necrotic  regions  (Robinson  et  al.,  2000).  A clinical study investigating 
prostate  cancer  hypoxia  compared  R2*  maps  with  pimonidazole  (a  hypoxic  marker) 
immuno-staining  of co-registered  histological sections.  Preliminary results  showed that 
regions with a fast R2* (defined as > 28 s'1 ) were positively correlated with hypoxia (with a 
sensitivity and specificity of 96% and 59% respectively) (Taylor et al., 2003).
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1.5.5  The use of MRI in the assessment of vascular disruptive agents
Tj-'weighted DCE-MRI has been used to investigate the acute effects of vascular disruptive
agents  in  animal  models:  CA-4-P  (Beauregard  et  al.,  2001;  Beauregard  et  al.,  2002; 
Beauregard et al., 1998; Galbraith et al., 2003; Maxwell et al., 2002); DMXAA (Beauregard 
et al., 2002); 2D6126 (Evelhoch et al., 2004; Robinson et al., 2003a).  Acute reductions in 
semi-quantitative and/or quantitative parameters are seen within 24 hours of treatment in a 
range  of tumour types.  Similar results  were  seen  in  phase  I  clinical  trials  of vascular 
disruptive agents which used change in DCE-MRI parameters as biomarkers for vascular 
disruptive  effect:  CA-4-P  (Dowlati et al.,  2002;  Galbraith et  al.,  2003;  Stevenson  et al., 
2003); DMXAA (Galbraith et al., 2002); ZD6126 (Evelhoch et al., 2004).
As Ktran s has both blood flow and permeability components (see above), reduction in Ktrans 
cannot be  directly equated to the  acute  blood flow shutdown  seen with  CA-4-P  using 
intravital  microscopy.  However,  the  use  of DCE-MRI  to  assess  response  to  vascular 
disruptive agents has been validated by Maxwell et al. (Maxwell et al., 2002).  Changes in 
Ktrans in response to CA-4-P in a rat carcinosarcoma model matched changes in blood flow 
rate measured using uptake of radiolabelled 1 2 5 iodoantipyrine (IAP).  Reductions in absolute 
tumour blood flow rate at 4 and 24 hours as measured by IAP correlated with reductions in 
Ktrans (and IAUGC) as measured by DCE-MRI.  Although the size of the decrease seen in 
Ktran s was  smaller than that seen in tumour blood flow rate, the  time  course  and dose- 
dependency patterns were very similar.  Reductions in ve were also seen, with no significant 
change  in k^.  Treatment with  CA-4-P  may alter Gd-DTPA kinetics  such that,  in this 
situation, blood flow rate is the dominant influence on Ktrans.
The  fall in ve seen in the  study by Maxwell et al.  (Maxwell et al, 2002)  seems  counter­
intuitive.  CA-4-P increases vascular permeability to macromolecules  (Kanthou & Tozer, 
2002)  which would lead to oedema and an increase  in extracellular space -  which is not 
consistent with a fall in ve.  However, as  CA-4-P results in the complete shutdown of a 
large proportion of tumour blood vessels (Dark et al., 1997) then some tumour areas will 
be cut off from flowing blood -  and this would explain the fall in ve seen (Maxwell et al., 
2002).  Therefore, ve represents the fraction of EES to which Gd-DTPA has access rather 
than the entire EES (Maxwell et al., 2002).
Lyng et al.  (Lyng et al.,  1998)  have  compared measurement of tumour blood flow rate 
using uptake of 8 6 rubidium chloride f 6 RbCl) or 1 4 carbon-labelled IAP (1 4 GIAP) with DCE-
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MRI parameters in two melanoma xenograft models.  They used the Kety model directly 
for Gd-DTPA kinetics  to  obtain separate values  for the  extraction fraction,  E, and for 
tumour blood flow (which they designate ‘PERFK ety’ and which is expressed in mintin'1  per 
unit gram of tissue)  (Lyng et al., 1998) -  see Section I.4.2.2.8   Extraction fractions were 
>70%  and  tumour  blood  flow  rates,  as  measured  by PERFK ety  (based  on  Gd-DTPA 
concentration data), were almost identical to values obtained using the 8 6 RbQ or 1 4 GIAP 
methods  for the  two  tumour types.  In  contrast,  DCE-MRI  parameters  derived  from 
signal-intensity  or  Gd-DTPA-concentration  time  curves  (initial  uptake  rate,  maximum 
uptake)  did not provide  reliable estimates  of relative blood flow rate  (Lyng et al.,  1998). 
Although this study did not measure Ktrans directly, it adds support to the proposition that 
Ktrans is flow-dominated, at least for extra-cranial tumours.  As Ktran s incorporates E, it will 
under-estimate tme tumour blood flow rate - by approximately 15-30% (based on Lyng et 
al.’s and Maxwell et al.’s data (Lyng et al., 1998; Maxwell et al., 2002).
The pattern and time course of changes in Ktrans seen in a clinical phase I trial of CA-4-P 
was  similar  to  that  seen  in  animal  models  (Galbraith  et  al.,  2003)  indicating  the 
appropriateness  of using Ktran s  as  a  surrogate  marker of vascular response  to treatment. 
This view has been endorsed by a specialist panel meeting under the auspices of Cancer 
Research UK - the Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee 
(PTAQ  -  who  considered the  measurement and analysis  methodology requirements  for 
robust application of DCE-MRI to vascular disruptive clinical trials (Leach et al., 2005).
BOLD-MRI has also been used to monitor the acute effects of vascular disruptive agents 
(Robinson et al., 2003a) -  see the discussion sections in Chapters 2 and 3.
8 In the Tofts’ model, Ktrans is expressed per unit volume of tissue.  Ktran s is related to PERFkety as Kmns  =
EPERFkety.p(l-Hct), where p is tissue density and Hct is haematocrit (Tofts et al, 1999).
66Chapter 1 Introduction -M R I methods
1.5.5  Further development of DCE-MRI to assess vascular disruptive response
The work presented in this thesis has attempted to explore further whether MRI methods
can be relied upon to define a drug as having vascular disruptive activity.  In particular, to 
investigate whether the acute DCE-MRI changes seen with CA.-4-P do not also occur with 
conventional cytotoxic agents.  It is assumed that the acute blood vessel shutdown seen in 
response to treatment with vascular disruptive agents is unique to this class of agent and so 
acute reductions in Tr DCE-MRI parameters, such as Ktrans, would not be seen in response 
to conventional cytotoxic agents.  It is important to confirm this supposition - firstly, to aid 
interpretation of any DCE-MRI examinations performed to assess response to the vascular 
disruptive agent, and secondly, to determine any overlapping toxicities.
DCE-MRI has also been used to investigate further the acute vascular disruptive response 
to CA-4-P in a pre-clinical study.  The combination of CA-4-P and radioimmunotherapy 
(using 1 3 1 I-A5B7, an anti-CEA antibody9, in the SW1222 colorectal cancer xenograft) has 
led to tumour cures (Pedley et al., 2001) and is now being tested in a phase I clinical trial. 
It is presumed that the combination is effective due to additive effects and also increased 
antibody retention in tumour.  However, the pre-clinical study used a relatively high dose 
of CA-4-P (200 mg.kg'1 ) and did not investigate the effectiveness of lower doses.  It would 
be helpful to investigate the effect of lower, more clinically relevant, doses of CA-4-P and 
compare  the  magnitude  of  vascular  disruptive  effect  (using  DCE-MRI)  to  effect  on 
antibody retention and therapeutic efficacy.
9 CEA: carcino-embryonic antigen
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1.6  Aims of thesis
The  main  objective  of the  work presented  in  this  thesis  is  the  application  and further 
development of MRI as a non-invasive method of investigating functional aspects of the 
tumour  microcirculation.  In  particular,  the  validity and  role  of  using  DCE-MRI  for 
assessment of acute tumour response to vascular disruptive agents and the development of 
BOLD-MRI  as  a  non-invasive  method  of  evaluating  tumour  vessel  maturity  were 
investigated.
The specific aims of this thesis were:
•  To  use  Tr weighted DCE-MRI  to  determine  whether conventional cytotoxic  agents 
cause any acute damage to the tumour vasculature in patients with pelvic or abdominal 
gynaecological  tumours.  In  particular,  to  determine  the  reproducibility  of  this 
technique in this patient group and then to assess the acute response  (<24 hours) to 
chemotherapy.  In addition, to determine the reproducibility of BOLD-MRI (R2*) and 
T2^-weighted DCE-MRI  (rBV and rBF)  measurements  in this  patient group  and to 
further  explore  the  use  of  these  parameters  for  the  assessment  of  the  tumour 
microcirculation (Chapter 2).
•  To use Tj-- weighted DCE-MRI to investigate the acute effects (at 4 and 24 hours) of 3 
different dose levels of CA-4-P (30,  100 and 200 mg.kg'1 )  on the SW1222 tumour in 
mice. (Chapter 3).
•  To further explore BOLD-MRI as a clinically applicable technique for the assessment 
of tumour vascular maturity.  In particular, to determine if Neeman et al’s technique 
using BOLD-MRI  response to  air then air-5%  C02 /carbogen can be  applied to the 
assessment of different tumour types with different degrees of vessel maturity (HT29, 
CaNT and T138).  Also, to determine whether using a vasoconstrictor, Angiotensin II, 
with BOLD-MRI can discriminate between mature and immature vessels.  In addition, 
to use intravital microscopy to directly observe tumour vessel response to these agents, 
in order to aid interpretation of BOLD-MRI results (Chapter 4).
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Chapter 2  DCE-MRI measurement of acute vascular disruptive 
effects of cytotoxic agents 
2.1  Introduction
The  hypothesis  of  the  study presented  in  this  chapter was  that  taxane  and  platinum 
cytotoxic agents would not have significant acute (within 24 hours) anti-vascular effects as 
determined by DCE-MRI.
2.1.1  Background
DCE-MRI has been used to evaluate vascular disruptive and anti-angiogenic agents in both 
xenograft studies  and human trials.  Significant reductions  in tumour DCE-MRI  kinetic 
parameters are seen within 4-24 hours of vascular disruptive therapy (Dowlati et al., 2002; 
Evelhoch et al., 2002; Galbraith et al., 2003; Galbraith et al, 2002b; Maxwell et al., 2002; 
Stevenson et al., 2003) and by 48 hours with anti-angiogenic agents (Checkley et al., 2003a; 
Checkley et al., 2003b; Gossmann et al., 2002; Jayson et al., 2002; Morgan et al., 2003) (see 
also Section 1.5.5).
As DCE-MRI is  used in early clinical trials to confirm that vascular disruptive and anti- 
angiogenic agents target vasculature, it is important to know whether cytotoxic agents also 
have acute effects on vasculature.  As well as classifying agents according to their method 
of  action,  such  information  would  also  help  in  planning  combination  therapy  and 
interpreting DCE-MRI results of such combination therapy.
The acute effects of cytotoxic agents on DCE-MRI kinetic parameters have not previously 
been reported, although measurements have been performed after 1-2 cycles of treatment 
(Ah-See et al., 2004; Barentsz et al., 1998; Reddick et al., 1999; Wolf et al., 2003).  However, 
at this time-point objective tumour shrinkage and pathological response are also seen, so 
changes in DCE-MRI parameters may be due to a reduction in blood flow secondary to 
tumour cell kill rather than a direct anti-vascular effect.  Animal studies suggest that apart 
from possibly the vinca alkaloids, significant acute vascular disruptive effects are unlikely 
(Chaplin & Hill, 2002)  but significant anti-angiogenic  effects  might be  more  of an issue 
(Miller et al., 2001).
All chemotherapy regimens tested in this study included a taxane and/or platinum agent, as 
these  are  likely candidates  for combination therapy in future  clinical trials.  The taxanes
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exert  their  cytotoxic  effects  by  inhibiting  spindle  formation  but  act  by  stabilising 
microtubules  rather than  inducing depolymerisation,  so  do  not have  vascular disruptive 
properties (Jordan et al., 1998; Wang et al., 2000).  The platinums are alkylating agents that 
bind to DNA, inducing cross-link formation (Cavalli et al., 2000).  Belotti et al. found that 
both cisplatin and paclitaxel have anti-angiogenic  effects  in u tw ,   but only paclitaxel had 
anti-angiogenic effects inuw (Belotti et al, 1996).
2.1.2  Study objective
The  objective was  to  investigate  the  acute DCE-MRI  effects  of conventional  cytotoxic 
agents measured 24 hours after the start of the first cycle of treatment.  Two pre-treatment 
scans were performed on consecutive days to estimate the  measurement error associated 
with  DCE-MRI.  A  third  scan  was  performed  20-24  hours  after  treatment  and  the 
significance of any changes were determined with reference to the ‘reproducibility’ of the 
technique.  Patients with gynaecological cancers (mostly ovarian) with pelvic or abdominal 
masses were selected, as this group reflects our practice and to avoid tumour movement 
with respiration during imaging.
The Tj  -weighted DCE-MRI kinetic parameters, Ktrans, ve, k^ and IAUGC, were measured. 
In  addition,  T2*-weighted DCE-MRI  imaging was  used  to  obtain  estimates  of tumour 
relative blood volume  and blood flow and BOLD-MRI was used to  obtain estimates  of 
tumour R2*.
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2.2  Methods
2.2.1  Patient Selection
Local ethics committee approval for the trial protocol and written informed consent from 
all participating patients were obtained.  Eligibility criteria for the study were: histologically 
confirmed cancer at an anatomical site suitable for imaging with MRI; tumour mass >3 cm 
in  diameter;  patient  due  to  start  first  cycle  of taxane  or platinum-based  chemotherapy 
regimen; calculated creatinine clearance1   >50 ml.min'1; WHO performance status <22; age 
>18 years; no history of allergic reaction to contrast agents.
2.2.2  MRI protocol
The MRI studies were performed on a 1.5 Tesla Magnetom Symphony scanner (Siemens 
Medical Systems, Erlangen, German)), using a body phased array coil.  In the first scanning 
session, initial Tj and T2  weighted anatomical images were obtained to select four suitable 
contiguous slices through the centre of a tumour mass.  Care was taken to place the patient 
in the same position on the follow-up sessions, in order to obtain the same anatomical slice 
location.  The following MR sequences were then acquired (slice thickness was 8 mm for 
all sequences, field of view (FOV) was 350 x 350 mm for sequences 1-3 and 128 x 128 mm 
for sequence 4):
Multiple  spoiled GRE  images were acquired on a single central slice with increasing TE 
times (5-75 ms and TR 100 ms, flip angle (a) 40°, in-plane resolution 1.37 x 2.19 mm) -  for 
calculation of R2* (BOLD).
A proton density (PD)-weighted spoiled gradient-recalled echo  (GRE)  sequence: TE  4.7 
ms; TR 350 ms; a 6°; in-plane resolution 1.37 x 2.19 mm; 4 slices -  for calculation of Tj 
relaxation rates, see below.
A dynamic series of 40 Tr weighted GRE  images: TE 4.7 ms, TR 11  ms, a 35°, in-plane 
resolution 1.37 x 2.19 mm, total imaging time of 8 min 5 s -  using the same slice positions
■ : Calculated creatinine clearance (mintin'1 )  = [(140-age in years) x 1.04 x weight in kg]/plasma creatinine in pmol.11  (the 
Cockcroft-Gault equation).
2 World Health Organisation performance status scale: 0=normal activities, 1 =light work, 2=resting <50% of day, 
3=resting >50% of day, 4=bed-bound.
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as  the  PD  sequence.  Gadopentetate  dimeglumine  (Gd-DTPA,  Magnevist(R ),  Schering 
Health Care Ltd., Burgess  Hill, UK)  was  the contrast agent used, injected intravenously 
using  a  power  injector  (dose  0.1  mmolkg1   bodyweight)  at  4  mis'1   during  the  fifth 
acquisition.
A dynamic series of 60 T2*-weighted spoiled GRE images were then acquired on a single 
central slice (TE 20 ms, TR 30 ms, a 40°, in-plane resolution 2.73 x 2.73 mm).  A second 
Gd-DTPA  injection  (dose  0.2  mmolkg \  at  4  mis'1 )  was  administered  after the  tenth 
acquisition.
System gain and scaling factors were maintained between acquisition of the proton density 
and Tr weighted dynamic series of images, to enable the calculation of tissue contrast agent 
concentration (Parker et al.,  1997).  Patient blood pressure  and pulse were  measured on 
each day before imaging.
2.2.3  Image Analysis
Images  were  transferred to  a  Sun  Ultra  60  workstation,  (Sun  Microsystems,  Mountain 
View,  CA,  USA)  and  analysed  using  specialist  software  (Magnetic  Resonance  Imaging 
Workbench  (MRIW),  Institute  of  Cancer Research,  London  UK)  (Parker et  al.,  1998). 
Using information from anatomical and post-contrast Tt images, regions of interest (ROIs) 
were  carefully drawn  around  the  tumour  edges  by a  trained  radiologist  who  carefully 
excluded areas of artefacts and blood vessels.  An elliptical ROI was also placed in an area 
of muscle (usually gluteus maximus as the majority of patients had pelvic tumours) on the 
central  imaging  slice.  Similar  ROIs  were  used  for  all  three  MR  examinations  in  an 
individual patient.
2.2.3.1  Calculation of Tpweightedparameters
MRIW software  was  used to convert MRI  signal intensities  into  Tt  relaxation rates  and 
then to Gd-DTPA concentrations for individual voxels, using the methods  described by 
Parker (Parker et al.,  1997).  The  relaxivity, r1 5  was taken to be  4.5  mM'V1   at  1.5  Tesla 
(Donahue et al., 1994)  (see Section 1.5).
The  following  Tr weighted parameters  were  calculated in the  MRIW software:  IAUGQ 
Ktrans, l^p and ve.  IAUGC was calculated over the first 60 seconds following injection of 
contrast agent, taking the onset time as the median value of the whole tumour ROI.  Then,Chapter 2 DCE-MRI measurement of acute vascular disruptive effects of cytotoxic agents: Methods
the.data were fitted to a standard compartmental model (Kety, 1960), to characterise the 
arterial influx of Gd-DTPA into the tumour extracellular extravascular space and its venous 
efflux to obtain Ktrans,  and ve.  An assumed arterial input function (AIF) was used for the 
modelling  procedure  (Tofts,  1997;  Weinmann  et  al,  1984)  as  described  previously 
(Galbraith et al., 2002a).
Voxels  with  negative  or zero  values  of IAUGC were  excluded from analysis.  For the 
modelled data, non-enhancing voxels, voxels containing enhancing modelling failures and 
voxels with Ktran s values  <0.001 or >5 min1  were excluded from analysis. The analysis was 
performed on concatenated data from all slices containing tumour, and the central slice for 
muscle, taking the median voxel value as representative of central tendency.  Median rather 
than  the  mean  voxel  values  were  used  as  histogram  distributions  of  some  kinetic 
parameters were skewed.
2.2.32  Calculation of T  weighted DCE-MRI parameters: rB V and rBF
AR2* values were calculated for each time point and fitted using a T-variate function using
MRIW software.  rBV is then the integral of the AR2*-time curve (using the T-variate fit) - 
see Section I.5.3.2.
The relative mean transit time  (MTI)3  was approximated by measuring the width of the 
AR2*-time  curve  at half its  maximum value  (‘full-width,  half-maximum’)  (Perthen et al., 
2002).  rBF was  then obtained by substituting in the transit time  equation  (see  Section 
1.4.2.3).
A single  global value  for the  entire  ROI  was  obtained by taking the  median of all the 
individual voxel values of the parameters.  Parameter values  >100,000 were excluded from 
analysis.
2.2.3.3  Calculation ofR/r  (BOLD)
R2* maps  were  calculated using IDL(R )  (Research Systems, Inc,  Boulder,  CO, USA).  A 
straight line was fitted to a plot of lnSt against TE for each voxel, of which the gradient is 
-R2* (re-arranging equation 28, Section 1.5.4).  Voxels with either negative or zero values 
were excluded from analysis.
3  For MRI, the abbreviation, MTT is usually used for mean transit time instead of t.
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2.2.4  Statistical Analysis
A reproducibility analysis  was  performed for each measured parameter.  This  has  been 
done  previously for  Tr weighted  parameters  (Galbraith  et  al.,  2002a)  but  not  for  T2*- 
weighted parameters.
The  statistical  analysis  used  to  determine  reproducibility has  been  described  previously 
(Bland & Altman,  1996a; Bland & Altman,  1996b; Galbraith et al., 2002a; Padhani et al.,
2002).  The key statistical parameters  are the 95%  confidence  intervals for change for a 
group of n patients and for an individual patient (the latter also known as the repeatability 
statistic).  The 95% confidence intervals can then be used to determine whether a change in 
a kinetic parameter following an intervention is statistically significant or not (see below). 
The within-patient coefficient of variation was also calculated, as  other MRI  researchers 
have quoted this parameter.
In  summary,  for  each  patient,  the  difference  d  between  the  two  pre-treatment 
measurements  of  a  parameter  was  calculated.  Data  were  transformed  using  natural 
logarithms if the variability of d was found to depend on its mean value (Bland & Altman, 
1996b).  The square root of the mean squared difference, dsd, (=V[(ZJ2 )/ri\ where n is the 
number of patients)  was then calculated.  The 95% confidence interval for change for a 
group of n patients is then equal to ±(1.96 x dsd)/^In).  For an individual patient, n=1 so the 
95% confidence interval for change is equal to ±(1.96 x dsd), which is also known as the 
repeatability statistic, r (Bland & Altman, 1996a).
The  within-patient  standard  deviation  uSD  =  dsd/'ll,  as  there  are  two  pre-treatment 
measurements.  This  is  a  measure  of  the  precision  of  the  measurement  error.  The 
difference between a patient’s parameter measurement and the true value is expected to be 
less than 1.96 x uSD for 95% of observations.  The within-patient coefficient of variation, 
isCV, is then obtained by dividing uSD by the group mean pre-treatment value for each 
parameter.  uCV quantifies measurement error relative to the size of the (positive) kinetic 
parameters.  If data had to be transformed, then zdCV was approximated by uCV = e^D -l 
(Bland & Altman, 1996b).
The results of the reproducibility analysis were then used to assess whether there had been 
a  statistically significant  change  in  kinetic  parameters  due  to  chemotherapy,  either  for 
individual patients or the group.  As there were two pre-treatment measurements  (days  1
90Chapter 2 DCE-MRI measurement of acute vascular disruptive effects of cytotoxic agents: Methods
and 2), the mean of the two pre-treatment examinations was taken as the pre-treatment 
value  for each parameter.  The  null hypothesis  was  that there  would be  no  difference 
between this combined pre-treatment value and the post-treatment value.
For individual patients, the repeatability statistic, ry  expressed as a percentage of the group 
mean pre-treatment value for each parameter, gives  a range within which the  difference 
between pre and post-treatment values would be expected to lie for 95% of observations, 
assuming that the null hypothesis  is true.  If the difference falls  outside this range for a 
particular  kinetic  parameter,  then  a  significant  change  was  deemed  to  have  occurred. 
Similarly, to assess mean response in the group, the 95% confidence interval for change, 
expressed as a percentage of the group mean pre-treatment value, gives the range required.
In  addition,  Spearman’s  p  was  used  to  determine  whether  there  was  a  significant 
correlation between any of the baseline  (day 1) parameter values  (JMP Statistics  (version 
3.2.6, SAS Institute, Inc, Gary, North Carolina, USA).
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2.3  Results
2.3.1  Patient characteristics
24 female patients were imaged in total.  The average age was 56 years old (range 29 to 74 
years).  Data  from  four  patients  were  excluded  from  analysis  (3  technical  failures,  1 
voluntary patient motion).  Data could not be obtained from all slices on day 3 for one 
patient  (no.19  in Table  2.1)  due to  internal organ motion.  One  patient was  unable to 
complete the post-treatment scan but data from the two pre-treatment scans were included 
in the reproducibility analysis (no.20 in Table 2.1).  Therefore, for ^-weighted DCE-MRI 
parameters,  there  were  20  complete  data  sets  for  the  reproducibility  analysis  and  18 
complete  data  sets  for the  response  analysis.  For T2^-weighted DCE-MRI  parameters 
(rBV, MIT, rBF) there were only 16 complete data sets for reproducibility and response 
analysis, as 4 patients did not complete this section on at least one  of the imaging days. 
There  were  20  complete  data  sets  for  the  R2*  (BOLD)  reproducibility and  response 
analysis.
The average time from the start of chemotherapy to the third scan was 21 hours (range 17 
to 23 hours).
Table  2.1  shows  patient  details  including  diagnosis,  chemotherapy  regimen  used  and 
response to treatment.  Response was assessed after three cycles of chemotherapy either on 
CT or MRI imaging or by CA125 measurements4  (based on REQST6 or CA125 criteria) 
(Rustin, 2003; Therasse et al., 2000).
Table 2.2 gives total voxel numbers and the percentage of voxels that were non-enhancing 
or were modelling failures.  Baseline (day 1) MR parameter values for each patient are given 
in Table 2.3.
Figure  2.1 shows a baseline  Tr weighted image and also Ktrans, rBV and R2* MR images 
from days 1, 2 and 3 (data from patient 4).
4 CA125 is a serum tumour marker that may be raised in ovarian cancer.
5 REGST: The ‘Response Evaluation Criteria in Solid Tumours’ group have issued guidelines for assessment of
radiographic and clinical response based on % change in tumour size (Therasse et al., 2000).
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N Age Tumour type Tumour
site
Chemotherapy
regimen"'
Previous
treat­
ments
Outcome:}:
1 55 Adenocarcinoma,
ovary
pelvis C: AUC 6f 1 Stable
disease
2 70 Mixed mullerian 
tumour/ carcinosarc 
oma
pelvis P 60 mg.nr2, A 60 mg.nr2 0 Not
evaluable#
3 59 Adeno carcinoma, 
ovary
pelvis C: AUC 6 0 Stable
disease
4 46 Adeno carcinoma, 
ovary
anterior
abdominal
wall
C: AUC 5, T 175 mg.m 2 0 Stable
disease
5 6 6 Adenocarcinoma -  
Povary or colon
para-aortic 
lymph 
nodes
C: AUC 5 0 Progressive
disease
6 73 Clear cell 
carcinoma, ovary
pelvis C: AUC 6 2 Stable
disease
7 42 Primary peritoneal 
carcinoma
pelvis P 25 mg.nr2, D 60 mg.m-2 
weekly
5 Stable
disease
8 65 Mixed mullerian 
tumour
pelvis P 70 mg.m-2, E 70 mg.nr2 0 Partial
response
9 62 Adenocarcinoma,
ovary
pelvis P 60 mg.m-2, £> 4 0 mg.m-2 
weekly
1 Partial
response
10 57 Adeno carcinoma, 
ovary
pelvis D 80 mg.m-2 day 1,
G 1250 mg.m-2days 1 & 8
2 Partial
response
11 49 Granulosa cell 
tumour, ovary
pelvis B 30mg days 2,8,15,
E  165 mg.m-2 days 1-3, 
P 50 mg.m-2 days 1 & 2.
0 Partial
response
12 45 Adeno carcinoma, 
ovary
pelvis C: AUC 6 0 Stable
disease
13 54 Adeno carcinoma, 
ovary
pelvis C: AUC 6 2 Partial
response
14 59 Primitive neuro­
ectodermal tumour
pelvis P 50 mg.m-2 
E  150 mg.m-2 days  y
0 Partial
response
15 46 Adeno carcinoma, 
ovary
pelvis C: AUC 6 1 Stable
disease
16 6 6 Adenocarcinoma
ovary
pelvis P 60 mg.m-2 weekly, 
Etop 50mg PO od
4 Not
evaluable
17 67 primary peritoneal 
carcinoma
pelvis C: AUC 6 , T 175 mg.m-2 1 Partial
response
18 52 Adenocarcinoma,
endometrium
pelvis P 60 mg.m-2, a  60 mg.m 2 0 Partial
response
19 29 Squamous cell 
carcinoma, cervix
cervix P 60 mg.m 2, 
M 300 mg.m-2, 
B 30 mg.m-2
0 Not
evaluable
2 0 74 Poorly 
differentiated 
carcinoma Povary
anterior
abdominal
wall
C: AUC 5 0 Not
evaluable
Table  2.1  Patient  details:  Patient  order  corresponds  with  data  in  Figures  2.2  &  2.3.
N: patient number.  *A 11 chemotherapy regimens were given i.v. and repeated every three weeks 
unless  otherwise stated.  Chemotherapy drugs: A: adriamycin; B: bleomycin; C: carboplatin; D: 
docetaxol; E: epirubicin; Etop: etoposide; G: gemcitabine; M: methotrexate; T: Paclitaxel.  PO: 
orally, AUC: area under the curve, bd: twice daily.  fCarboplatin dose calculated according to AUC 
(area under the  plasma-concentration time  curve)  based on method described  by Calvert  et  al 
(Calvert  et  al.,  1989).  Abased  on  REGST or CA-125  criteria.  # Not  evaluable:  patient  only 
received 1  cycle of chemotherapy.
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Patient
number
Total
voxels
non-enhancing 
voxels (%)
enhancing voxels 
with modelling 
failures (%)
1 849 37.3 5.5
2 5119 17.2 2.1
3 1375 4.8 5.1
4 2179 12.9 8.8
5 858 3.5 2.0
6 2317 47.8 28.1
7 1299 38.0 15.5
8 3128 12.3 5.3
9 3735 25.9 9.7
10 2207 11.1 19.7
11 1515 15.2 8.1
12 2889 2.5 15.6
13 149 0.0 7.4
14 226 10.6 36.7
15 1679 5.8 7.2
16 245 1.2 4.5
17 1149 1.5 12.9
18 4664 7.5 14.3
19 3445 3.7 39.8
20 1789 13.8 18.3
Table 2.2: Tumour voxel numbers (central tumour slice).
^-parameters T2*-parameters
N
j^trans vc (%) K> IAUGC rBV MTT rBF V
1 0.152 33.84 0.449 2.19 86.4 25.1 3.41 12.14
2 0.244 46.49 0.524 4.30 317.0 28.6 10.925 16.96
3 0.233 39.21 0.594 4.24 266.7 25.8 10.12 22.62
4 0.252 40.71 0.620 5.34 241.7 26.3 9.47 20.23
5 0.270 52.22 0.517 5.65 83.2 22.5 3.58 16.21
6 0.207 27.12 0.763 2.14 59.8 27.7 1.46 12.28
7 0.349 38.32 0.911 5.30 163.4 23.1 6.50 21.04
8 0.282 38.37 0.736 5.57 308.9 23.4 12.94 16.47
9 0.284 36.83 0.772 4.23 294.4 24.3 11.89 9.08
10 0.311 34.16 0.911 4.90 311.2 26.0 11.75 20.03
11 0.243 36.85 0.660 4.90 136.2 26.8 4.9 25.46
12 0.327 27.62 1.184 4.82 217.3 22.8 9.29 26.39
13 0.405 47.71 0.849 9.50 150.5 21.2 7.10 17.13
14 0.511 45.05 1.135 8.44 280.3 23.9 11.86 36.51
15 0.433 30.48 1.419 6.82 373.8 23.7 15.62 16.6
16 0.500 48.20 1.037 8.47 308.5 24.3 12.00 31.98
17 0.550 44.20 1.244 9.44 483.0 24.9 19.15 19.12
18 0.630 43.87 1.437 10.56 366.3 22.8 15.71 28.15
19 0.589 65.21 0.903 12.08 425.7 26.2 16.32 19.51
20 1.081 40.28 2.684 9.04 400.1 25.1 16.07 28.83
Table 2.3: Baseline MR parameters (day 1) for individual patients
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Figure  2.1  Representative  MRI  maps  (patient 4).  A:  Ti-weighted image with tumour outlined in 
red;  B, C, D: Ktrans maps from day 1, 2 & 3 respectively.  E, F, G: rBV maps from days  1, 2 & 3 
respectively.  H, I, J: R2* maps form days 1, 2 & 3 respectively.
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The absolute % change in MABP and pulse between the mean pre-treatment value (day 1 
and day 2) and day 3 were 7.7% (±1.4) and 8.9% (±2.8) respectively but these changes were 
not significant (paired t-test).  6 patients had changes in MABP  >10% (range 11-21%) and 
3 patients had changes in pulse greater than 10% (range 18-45%) but none of these patients 
had a significant parameter change apart from patient # 1 (decrease in MABP of 12%) (see 
below).
2.3.2  Reproducibility
Tables  2.4 and 2.5 summarise the results  of the  Tr weighted DCE-MRI  reproducibility 
analysis for tumour and muscle (as a representative normal tissue).  Data for Ktrans and 
were  logarithmically transformed  as  variability of  the  difference  between  the  two  pre­
treatment measures was found to depend on their mean values (Bland & Altman, 1996b). 
Therefore,  the  repeatability  expressed  as  a  %  of  group  mean  pre-treatment  value  is 
asymmetric about the mean.  The repeatability for the tumours central slice is given for 
comparison with the 4-slice data.
Table  2.6  summarises  the  results  of  the  T2*-weighted  DCE-MRI  and  R2*  (BOLD) 
reproducibility analysis for tumour.
TUMOUR (all 4 slices)
Ktons (min1 ) ve(%) Kv (m in1 ) IAUGC (mM.s)
mean 0.39 40.6 0.95 6.36
dsd 0.26 4.74 0.23 1.09
r 0.51 9.29 0.44 2.14
r (%) -40.0 to +66.7% ±22.9% -35.9 to +55.9% ±33.7%
Cl (%) -10.8 to +12.1% ±5.1% -9.5 to +10.5% ±7.5%
wSD 0.18 3.35 0.16 0.77
wCV (%) 20.3% 8.3% 17.4% 12.1%
r(%) single 
slice
-39.2 to +64.4% ±26.2% -39.8 to +65.9% ±48.9%
Table 2.4:  Tumour reproducibility analysis for Ti-weighted parameters.  4-slice concatenated 
data.  Ktran s and keP  data are logarithmically transformed.  Mean: group mean pre-treatment value; 
dsd: square root of the mean squared difference; r: individual patient repeatability; r (%): 
repeatability as a % of group mean pre-treatment value; Cl: group 95% confidence interval for 
change as a % of group mean pre-treatment value; wSD: within-patient standard deviation; wCV:
within-patient coefficient of variation.
96Chapter 2 DCF.-MRI measurement of acute vascular disruptive effects of cytotoxic agents: Results
MUSCLE [central slice)
Ktons (min1 ) v.(%) ke« (min1 ) IAUGC (mM.s)
mean 0.15 19.78 0.79 3.79
dsd 0.55 2.59 0.54 1.53
r 1.07 5.08 1.06 2.99
r (%) -65.9 to +192.9% ±25.7% -65.1 to +188.3 ±79.0%
Cl (%) -21.9 to +28.0% ±5.9% -21.6 to +27.5% ±18.1%
wSD 0.39 1.83 0.38 1.08
wCV (%) 47.40% 9.28% 46.55% 28.50%
Table 2.5: Muscle reproducibility analysis for Ti-weighted parameters.  n=19 as one muscle
ROI failed to fit on day 2.
TUMOUR (central slice)
rBV MTT (s) rBF (s1 ) R2* (s1 )
mean 233.4 24.9 9.53 21.6
dsd 64.98 1.19 2.26 5.44
r 127.3 2.34 4.42 10.6
r (%) ±54.5% ±9.4% ±46.4% ±48.6%
Cl (%) ±13.6% ±2.4% ±11.6% ±11.0%
wSD 45.9 0.84 1.60 3.84
wCV (%) 19.7% 3.4% 16.8% 17.5%
Table 2.6: Tumour reproducibility for T2*-'weighted parameters.  rBV and rBF are expressed 
per unit volume of tissue hence rBV has no units and rBF is in s 1 .
2.3.3  Correlation between different parameters
Table 2.7 shows the correlation between different parameters.  Parameters showing very 
strong correlations (>0.8) were Ktrans and k^, Ktrans and IAUGC, and rBV and rBF.
j^trans
ve 0.42 NS
kep 0.87
p <0.0001
-0.03 NS
IAUGC 0.86 
p <0.0001
0.68
p=0.01
0.58
p=0.01
rBV 0.69
p <0.001
0.28 NS 0.59
p=0.01
0.55
p-0.01
MTT -0.40 NS -0.14 NS -0.34 NS -0.40 NS 0.1 NS
rBF 0.77
p <0.0001
0.33 NS 0.64
p<0.01
0.65
p<0.01
0.96
p <0.0001
-0.05 NS
R / 0.51
p<0.05
0.25 NS 0.54
p-0.01
0.44 NS 0.23 NS -0.07 NS 0.28 NS
j^trans
ve ke„ IAUGC rBV MTT rBF r2*
Table 2.7:  Correlation between baseline (day 1) parameter values.  Values showing strong 
(>0.6) or veiy strong correlation (>0.8) shown in bold. NS: not significant.
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2.3.4  Response
2.3.4.1  Tp weighted DCE-MRI parameters
Figure  2.2  shows  tumour  pre-treatment  values  (mean  of  the  two  pre-treatment 
examinations),  the  post-treatment  values  and  repeatability ranges  for  Ktr a n s,  ve,  and 
IAUGC respectively for each patient.  Patients are ordered by mean pre-treatment Ktr a n s to 
demonstrate  that the  repeatability range  is  dependent on the  mean pre-treatment value. 
There were no significant changes post-treatment in Ktr a n s (Figure 2.2 A).  One patient had 
a significant decrease in ve (# 11) (Figure 2.2 B).  One patient had a significant increase in 
^  (# 7) (Figure 2.2 C). Two patients had a significant increase in IAUGC (# 2 and # 10) 
and one patient (# 11) had a significant decrease in IAUGC (Figure 2.2 D).
When data were analysed for the group as a whole, there were no significant changes  in 
Ktrans,  kgp  or IAUGG  However,  there  was  a  5.5%  decrease  in  ve  that  was  marginally 
significant, as the group 95% confidence interval for ve was ±5.1% (see Table 2.4).
2.3.4.2  T/r-weighted DCE-MRI and R /r (BOLD) parameters
Figure  2.3  shows  tumour  pre-treatment  values  (mean  of  the  two  pre-treatment
examinations), the post-treatment values and repeatability ranges for rBV, MIT, rBF and 
R2* respectively for each patient.  Patients are ordered by mean pre-treatment Klrans as for 
Figure 2.2.
3  patients  had  a  significant  increase  in  rBV  (# 7,  # 15,  # 17)  and  one  had  a  significant 
decrease in rBV (#1).  1 patient had a significant increase (# 16) and 1  patient a  significant
decrease (# 1) in MTT.  The same three patients had an increase in rBF  (# 7,  # 15, # 17) and
two had a significant decrease (# 1 and #16).
When patients were analysed as a group, there were no significant changes in rBV, MTT or 
rBF.
One  patient had a significant increase  in R2*  (# 1).  There  was  no  significant change  in 
group R2*.
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Figure 2.2: Ti-weighted parameters: A: Ktrans, B: ve, C: keP, D: IAUGC  The mean pre-treatment 
values (grey circle), post-treatment value (black square) and the repeatability range for each 
parameter.  Significant day 3 values are marked with an arrow.  Patients are ordered by mean  pre­
treatment Ktrans.
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parameter are shown.  Significant day 3 values are marked with an arrow.  Patients are ordered by
mean pre-treatment Ktrans.  # missing data
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2.4  Discussion
2.4.1  T rweighted DCE-MRI parameters
2.4.1.1  Reproducibility
The reproducibility analysis was very similar for the concatenated 4-slice and the single slice 
data (see Table 2.4) -  therefore, it would be reasonable to use a single central tumour slice 
for subsequent studies.
The reproducibility analysis can be compared with other studies.  For the phase I trial of 
CA-4-P  performed  at  Mount  Vemon  hospital,  Galbraith  et  al.  reported  an  individual 
patient repeatability (as % of mean pre-treatment value) for tumour Ktrans for a group of 16 
patients of -45 to  +83% (Galbraith et al., 2002a).  The improvement between Galbraith et 
al.’s study and the current study is probably due to the use of a power injector and scanning 
on consecutive days -  whereas Galbraith et al.’s study used manual injections and patients 
had repeat scans up to a week apart.  A reproducibility analysis was also performed for the 
phase I trial of ZD6126 (Evelhoch et al., 2004).  For 19 patients that were scanned 2-6 days 
apart, isCV was 18% for tumour IAUGG  From the data given in the paper, the individual 
patient  repeatability  (as  %  of  mean  pre-treatment  value)  can  be  calculated  as  ±48.9% 
(Evelhoch et al., 2004).  In comparison, IAUGC reproducibility in the current study was 
±33.7% (4-slice) and ±48.9% (central slice).
Reproducibility is not likely to improve significantly unless an individualised AIF is used. 
The change in contrast agent concentration in tumour-feeding arterioles  is  approximated 
by imaging an artery within the  same image  slice.  It is technically difficult to obtain an 
individual AIF due to flow and pulsation artefacts within the chosen artery and, also, T2* 
effects  can  reduce  signal  intensity  in  regions  of  high  contrast  agent  concentration, 
particularly at the top of the  bolus  passage  (Rijpkema et al., 2001; van Laarhoven et al.,
2003).  However,  techniques  for  measuring  individual  AIF  have  been  published  that 
improve  reproducibility -  e.g. the  repeatability was ±20% for k^ for a set of  11  patients 
with  solid  tumours,  using  an  AIF  obtained  from  the  carotid  or  internal  iliac  artery 
(Rijpkema et al., 2001; van Laarhoven et al., 2003).  An alternative strategy is to normalise 
to another tissue to correct for any change in cardiac output using a ‘vascular normalisation 
function’.  For example, repeatability for 11 patients with liver metastases, was ±27% for
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kgp using spleen to obtain a vascular normalisation function (van Laarhoven et al., 2003). 
This approach may not improve reproducibility, however, if a particular treatment also has 
an effect on the selected normal tissue.  For, example CA-4-P produces  ~7-fold reduction 
in blood flow in the spleen at 6 hours (measured using the IAP method in rat) (Tozer et al., 
1999), so spleen maybe an inappropriate comparator for vascular disruptive agents.
Mean pre-treatment parameter values were significantly lower for muscle than for tumour 
(unpaired  t-test).  Consequently,  due  to  an  increase  in  noise  and  variability,  the 
reproducibility analysis for muscle was much worse than for tumour (see Tables 2.4 and 
2.5).  This has been noted by other authors using MRI (Evelhoch et al., 2004; Padhani et 
al., 2002)  and the  inherent variability of muscle blood flow measurements  has  also been 
observed  using  the  IAP  method  (Tozer  et  al.,  1999).  It  had  been  proposed  that 
normalisation  of  tumour  parameter  values  to  muscle  might  improve  reproducibility 
(Evelhoch et al., 2001).  However, this was based on murine data and does not appear to 
be  translated into  human studies  (Evelhoch et al., 2004).  That reproducibility is  worse 
when normalised to muscle has been confirmed using our data (for example, the individual 
repeatability  for  Ktrans  becomes  -71.9%  to  +255.8%  when  the  concatenated  data  is 
normalised to the muscle ROI).
It is not clear whether the poor muscle reproducibility is due to inherent variability or is a 
reflection of changes  in  cardiac  output.  Each  patient’s  blood pressure  and pulse  were 
recorded before imaging -  as an indication of cardiovascular status - but changes in these 
parameters did not correspond to MR parameter change.  Measurement of cardiac output 
prior to imaging would help settle this issue.
2.4.1.2  Response
Our data show no significant change  in group or individual Ktrans  at 24 hours  following 
treatment  with  cisplatin  or  taxane  based  chemotherapy.  In  comparison,  at  24  hours 
following treatment with >52 mg.m2  CA-4-P, a significant mean reduction in group Ktran s 
of 29% was observed in a phase I trial for a group of 16 patients (Galbraith et al., 2003). 
Significant reductions  in group ve and IAUGC (of  11%  and  18% respectively) were also 
observed in the CA-4-P phase I trial.
Given the wide within-patient variation in Ktians and IAUGQ it is not possible to confirm 
that the cytotoxic agents tested have no effect on tumour vascularity.  However, based on
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the results from this study, one is unlikely to expect large anti-vascular effects (and hence 
significant reductions in DCE-MRI kinetic parameters) in the acute setting due to cytotoxic 
agents alone.  Therefore, if reductions in DCE-MRI kinetic parameters are seen in phase I 
trials of combination cytotoxic and vascular disruptive agents, one may presume they are 
due to the vascular disruptive agent.
These conclusions are supported by animal data.  Chaplin and Hill (Chaplin & Hill, 2002) 
compared the effects of CA-4-P with a number of cytotoxic agents, including cisplatin and 
paclitaxel, in the murine CaNT tumour, using functional vascular volume (measured using 
Hoechst 33342) to assess vascular disruptive activity.  No reduction was seen with any of 
the cytotoxic agents whereas a >80% reduction was seen following treatment with CA-4-P 
at 24  hours  following  drug  administration  (Chaplin  & Hill,  2002).  The  only group  of 
cytotoxic agents that has been found to have vascular disruptive activity in animal models is 
the vinca alkaloids.  However,  sustained effects  are  only seen at close to the  maximum 
tolerated dose (MTD) (Baguley et al., 1991; Chaplin et al., 1996; Hill et al., 1993; Hill et al., 
1995; Sersa et al., 2001).
The reason for the small reduction in group ve is uncertain.  For the one patient who had 
significant reduction in individual ve, the magnitude of reduction was only just outside the 
repeatability range  (see Figure 2.2).  An acute reduction in ve may occur if the ability of 
Gd-DTPA to access the extracellular extravascular space is reduced (Maxwell et al., 2002). 
Otherwise, it is plausible that early loss of cytokine production (e.g. VEGF) by tumour cells 
in response to chemotherapy results in a reduction of vascular permeability and interstitial 
fluid pressure that could reduce ve.  Such a change in permeability might not be detected by 
changes in Klrans, as Ktrans is flow-dominated in tumours (Maxwell et al., 2002; Tofts, 1997).
Two patients had small but significant increases in IAUGC (see Figure 2.2).  One patient 
(# 10) went on to have a partial response to chemotherapy whereas the other (# 2) was not 
evaluable for response (see Table 2.1).  These increases do not fit into a pattern consistent 
with an anti-vascular effect (see above)  and the cause for this effect is also uncertain but 
could  be  related  to  increased  blood  flow  resulting  from  reductions  in  interstitial  fluid 
pressure.  Griffon-Etienne et al. reported on the use of intravital microscopy to measure 
red  cell  flux  and  found  an  increase  in  the  first  few  days  following  administration  of 
paclitaxel or docetaxel (Griffon-Etienne et al., 1999).  An increase in relative tumour blood 
flow rate  has  also  been  seen  following  cyclophosphamide  and  5-fluorouracil  (measured
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using the 8 6 RbQ method) (Braunschweiger,  1988; Li et al., 1991).  These changes may be 
due to reduced blood vessel compression secondary to tumour cell kill rather than a direct 
anti-vascular effect (Griffon-Etienne et al., 1999).
The day 1 and 2 values were checked for the patients with significant parameter changes 
and no anomalies found.  Significant changes were only just outside the repeatability range 
(see Figure 2.2) and it is possible that the small changes seen in ve and IAUGC are due to 
chance rather than real events.  A statistical correction factor can be applied for multiple- 
parameter comparisons -  the Bonferroni correction (Bland & Altman,  1995).  However, 
application of the Bonferroni correction would be too conservative in this instance, as the 
measured parameters are not independent of each other.
2.4.1.3  Correlation between Tr weighted parameters
Ktran s was significantly correlated with k^ but not with ve, as would be expected.  IAUGC 
was  found to  correlate very strongly with Ktrans  and strongly with ve  (see  Table  2.7), - 
reflecting its value as a ‘summary’ Tr parameter.
2.4.2  T2*-weighted DCE-MRI parameters: rBV, MTT and rBF
2.4.2.1  Reproducibility and res  pons e
Jackson et al. have performed a reproducibility analysis for rBV for 11 patients with glioma 
(scanned 36-56  hours  apart)  and for 5  patients  with  hepatic  neoplasms  (scanned 48-56 
hours apart) (Jackson et al., 2002; Jackson et al., 2001).  Unfortunately, the analysis is not 
directly comparable with our data as different reproducibility statistics are quoted.
A  reproducibility  analysis  was  not  performed  for  muscle  T2^-weighted  DCE-MRI 
parameters as the reduced field of view meant that imaging wrapping obscured the muscle 
ROI for the majority of patients.
As for the Tr weighted DCE-MRI parameters (except ve ), there were no significant changes 
for the group for these parameters but a few individuals had either significant increases or 
decreases in certain parameters  (see Figure  2.3).  It is  difficult to comment about these 
results, as the validity of the application of this technique to visceral tumours is not known 
(see below).
104Chapter? DCF.-MRI measurement of acute vascular disruptive effects of cytotoxic agents: Discussion
rBV and rBF correlated strongly with each other (as would be expected) and also correlated 
strongly with Ktrans,  and IAUGC (especially rBF).  The fact that significant individual 
changes  were  not  consistent  across  different  parameters,  suggests  that  they  might  be 
artefactual.
2A.2.2  Potential problems with this technique
The potential problems of applying the T2* DCE-MRI technique for measurement of rBV 
and rBF to visceral tumours include:
1.  Tj effects will be worse than in the brain due to tumour vessel permeability (see 
Section 1.5.3.2);
2.  in the brain, it is possible to normalise to the contralateral hemisphere, there is no 
suitable equivalent for visceral tumours;
3.  there  are  no validation studies  comparing this  technique  with other methods  of 
measuring tumour blood flow in visceral tumours.
We attempted to optimise the technique by using a double  dose  of contrast agent, pre­
enhancement  (from the  immediately preceding Tr dynamic  sequence)  and a Y-variate  fit 
rather than the raw AR2*-data (see Section 1.5.3.2).  However, the approximation of MTT 
by the full-width half-maximum of the AR2*-curve is likely to have led to an overestimation 
of the true MTT and an underestimation of rBF (Perthen et al., 2002).
In practise, a Y-variate function may be fitted to the AR2*-curve as long as the initial rise 
and the peak of the curve are clearly delineated.  Figure 2.4 shows a AR2*-curve and T- 
variate  fit  for  a  glioblastoma  multiforme  (brain  tumour)  and  a  pelvic  carcinoma  for 
comparison.  However,  if  Tj  effects  occur during  the  first  half  of the  curve,  then  its 
maximum height will be reduced and rBV underestimated.
It is not known whether normalising to an area of muscle in the same imaging slice would 
improve  measurement accuracy, as  a muscle  reproducibility analysis was  not performed. 
However,  if liver tumours  are  imaged, then normalising to  spleen might be  appropriate 
(although  as  for ^-parameters,  this  will  be  a  problem  if  a treatment  intervention  also 
affects splenic blood flow).
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Given all these problems, the values obtained for rBV and rBF in visceral tumours using 
T2'^-weighted  DCE-MRI  are  not  likely to  be  accurate.  However,  as  with  ^-weighted 
parameters, they may still be useful for assessment of response to treatment.  If change in 
rBF  (measured  using  MRI)  in  response  to  an  agent  or  intervention  was  found  to  be 
positively correlated with change in tumour blood flow measured using a ‘gold standard’ 
technique  (such as  the  1 2 5 IAP  or 8 6 RbQ methods), then this  MR technique  would be  a 
useful addition to existing methods of investigating tumour microcirculation.
0 50 100
Time (s)
AR
100
Time (s)
Figure 2.4: AR2V  curves and T- variate fits for (A) glioblastoma multiforme and (B) pelvic
tumour (with thanks to Dr NJ Taylor).
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Despite the caveats, we have obtained a reproducibility analysis for these parameters and 
have found that there are no significant changes  in rBV, M IT or rBF for the group of 
patients  following chemotherapy.  rBV and rBF also correlated strongly with Ktrans.  In 
ongoing studies at Mount Vernon investigating the acute effects of vascular disruptive and 
anti-angiogenic  agents,  T2^-weighted  parameters  are  being  measured  in  addition  to  the 
usual Tr weighted parameters.  Hopefully, this will provide further information regarding 
the usefulness or otherwise of including rBV and rBF measurements in the assessment of 
these agents.
2.4.3  R2* (BOLD)
The mean baseline (day 1) R2* value was 20.8 (±1.6) s'1.  Rijpkema et al. (Rijpkema et al.,
2002)  reported a mean baseline R2* of 29.56 (±1.29) s'1  for 11 patients with head and neck 
squamous cell carcinomas  (also measured using a  1.5 T system).  The difference may be 
due to the higher levels of hypoxia seen in head and neck squamous cell carcinomas.
We have performed a reproducibility analysis for R2*, which will be helpful for comparison 
with  future  studies.  There  were  no  changes  for the  group  in  R2*  post-treatment with 
chemotherapy but one patient had a significant decrease.  R2* did not correlate strongly 
with any of the other parameters.  The individual patient repeatability for R2* was ±7.7% 
for 13 patients with prostate carcinoma (Taylor et al., 2002).  However, for this study, the 
two scans were performed on the same day, 30-40 minutes apart and the patient remained 
still in the scanner throughout.  In comparison, the individual patient repeatability for R2* 
for the current study was ±48.6%;  showing that the necessity of repositioning the patient 
in  the  scanner  and  a  24-hour  interval  between  scans  worsens  reproducibility.  A 
reproducibility analysis  of  kidney R2*  measurements  performed  in  8  normal  volunteers 
reported  a  wCV  of  12%  for  both  kidney  cortex  and  medulla  for  four  separate 
measurements  spread over 3-10  months  (Li et al., 2004).  The  improved reproducibility 
compared to our data is likely to be due to the fact that kidney tissue is more homogeneous 
than tumour.
R2* measurements made at 24 hours following an anti-vascular intervention are probably
not likely to be very helpful, as the presence of necrosis, haemorrhage and/or oedema will
influence R2* measurement (Robinson et al., 2003a; Robinson et al., 2003b).  However, R2*
measurements made very early following administration of a vascular disruptive agent may
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be indicative of acute blood vessel shutdown as R2* is sensitive to hypoxia.  Robinson et al. 
detected an increase  in R2* (consistent with an increase  in hypoxia)  at 35  minutes  after 
administration of the vascular disruptive agent, ZD6126, in an animal model (Robinson et 
al., 2005).  The increase in R2* at this time-point was associated with blood flow shutdown 
as indicated by reduced tumour uptake of Hoechst 33342.  Gross  et al. investigated the 
effects of a novel photodynamic therapy drug (that acts as a vascular disruptive agent) in 
melanoma xenografts using BOLD-MRI (Gross et al., 2003).  An increase in R2* was seen 
within  a  few  minutes  of  illumination  (to  activate  the  drug)  -   consistent  with  oxygen 
consumption by the photochemical reaction and acute blood vessel shutdown (Gross et al.,
2003).  For future studies, R2* could be used to determine optimal timings for DCE-MRI 
studies of vascular disruptive agents.  The advantages of using R2* for such a purpose are 
that it is completely non-invasive, is relatively straightforward and can be repeated without 
delay.
2.4.4  Conclusions
The  hypothesis  that  taxane/platinum-based  chemotherapy  regimens  do  not  cause 
significant anti-vascular disruptive  effects within 24  hours  of treatment,  as  measured by 
DCE-MRI, has been proved -  at least for the parameter Ktrans.
This is the first demonstration that cytotoxic agents differ from vascular disruptive agents 
in their effect on DCE-MRI parameter, thus validating the use of DCE-MRI a biomarker 
of targeting activity.
In addition, a  reproducibility analysis  was  performed for T2*-weighted parameters:  rBV, 
rBF, MTT and for R2*.  The usefulness of these parameters for the assessment of vascular 
disruptive agents remains to be determined.
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Chapter 3  The acute anti-vascular effects of CA-4-P on the SW1222 
tumour as measured by DCE-MRI 
3.1  Introduction
These experiments detailed in this chapter were part of the pre-clinical work required for 
the  Cancer  Research  UK  (CR-UK)  phase  I/II  trial  of  CA-4-P  in  combination  with 
radioimmunotherapy  (RIT),  using  1 3 1 Iodine  (1 3 1 I)-labelled  A5B7  a  murine  anti- 
carcinoembryonic  antigen  (CEA)  monoclonal  antibody,  in  advanced  gastrointestinal 
carcinoma.
The  purpose  was  to  use  DCE-MRI  to  investigate  the  acute  effects  of  CA-4-P  on the 
human colon carcinoma xenograft, SW1222 in order to establish whether a dose-response 
relationship  could  be  determined and  also  the  magnitude  and  duration  of anti-vascular 
effect at a ‘clinically relevant’ dose (see below).
3.1.1  Radioimmunotherapy
In RIT,  a  radiolabelled antibody localises  to  a tumour-associated antigen, thus  targeting 
radiation directly to a tumour.  1 3 1 I is  the  most commonly used radio-isotope  (Napier & 
Begent,  1998).  It has  a beta  ((3)  emission  of moderate  energy (0.61  MeV)  which has  a 
maximum particle range of 2 mm (equivalent to  -40 cell diameters) and also a gamma (y)- 
emission that enables imaging with a y-camera to quantify normal tissue and tumour bio­
distribution  (Goldenberg,  2002).  In both clinical and animal studies, the  dose-limiting 
toxicity for RIT is myelosuppression as the bone marrow is perfused by blood containing 
radioactivity and  also  is  irradiated by y-rays  from radio-isotope  in  neighbouring  organs 
(Ledermann et al., 1991; Napier & Begent, 1998).
The  majority of  studies  investigating  RIT in  colorectal carcinoma have  used antibodies 
raised  against  CEA  (Napier  & Begent,  1998).  CEA  is  expressed  by a  wide  range  of 
common  epithelial  malignancies;  but  the  highest  concentrations  are  seen  in  colorectal 
adenocarcinomas (Chung et al., 1994; Goldenberg et al., 1976).  Normal tissues, especially 
colonic  mucosa,  may show  very weak positive  staining  for  CEA  (Chung  et  al.,  1994; 
Goldenberg et al., 1976).
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RIT has produced high response rates and has led to long term remissions in radiosensitive 
tumours, such as non-Hodgkin’s lymphoma, (Kaminski et al., 2000; Press et al., 1993) but 
has had only limited success in solid tumours (Goldenberg, 2002; Napier & Begent, 1998). 
In the  case  of colorectal carcinoma, only a few responses  have been seen in phase I/II 
trials - particularly with bulky tumours (Lane et al., 1994; Ledermann et al., 1991; Napier & 
Begent, 1998).  The reasons for the poor responses seen in solid tumours are that they are 
more  radioresistant  than  lymphomas  and  there  is  non-uniform  antibody  distribution. 
Antibody delivery is compromised in poorly-vascularised tumour regions and, even in well- 
vascularised  regions,  antibodies  may not  be  extravasated  efficiently (Jain,  1989; Jain  & 
Baxter,  1988).  A  comparison  of  stained  histological  sections  with  radioluminography, 
showed that most anti-CEA antibody was retained in the outer, well-perfused areas with 
little antibody retention in poorly-vascularised tumour regions (Flynn et al., 1999; Pedley et 
al., 2002).
Tumour  size  is  another  important  factor:  an  inverse  logarithmic  relationship  between 
tumour size and 1 3 1 I-labelled anti-CEA antibody uptake into tumour was found in patients, 
with absolute antibody uptake being the most important factor determining radiation dose 
to  the  tumour  (Behr et  al.,  1997).  Patients  with  small volume  disease  have  improved 
response rates: if tumour masses are <3 cm then objective response rates of up to 26% are 
seen (Behr et al., 1999; Behr et al., 2002).
The  limited  effectiveness  of  RIT  as  a  single  agent  in  colorectal  cancer  has  led  to  its 
investigation in combination with other anti-cancer therapies.  The  combination of 1 31 I- 
A5B7 and a vascular disruptive agent, such as CA-4-P, is an obvious choice, due to their 
complementary actions (as CA-4-P is most effective in the tumour centre, with sparing of 
the tumour rim (Dark et al., 1997).  1 3 1 I-A5B7 (at 7.4 MBq intravenously) together with CA- 
4-P  (at 200  mg.kg1   intraperitoneally, given 48  hours  after the  antibody)  has been tested 
using  SW1222  colorectal  xenografts  grown  in  nude  mice  (Pedley et  al.,  2001).  The 
combination eradicated tumours in 5/6 mice (85%) with no evidence of tumour re-growth 
when the experiment was terminated  >9  months later.  As single agents, CA-4-P had no 
effect  on  tumour  growth  whereas  1 3 1 I-A5B7  produced  significant  growth  inhibition  of 
about 35 days but no cures.  The addition of CA-4-P increased trapping of 1 3 1 I-A5B7 in 
tumours with an average of 90% more radio-antibody retained at 96 hours following 1 3 1 I- 
A5B7  administration  compared  to  controls  treated  with  antibody alone  (Pedley et  al., 
2001).
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The combination of 1 3 1 I-A5B7 (18.5 MBq i.v.) and the vascular disruptive agent, DMXAA 
(27.5 mg.kg'1  intraperitoneally, given 48 hours after the antibody, produced similar results 
in another colorectal xenograft, LS174T (Pedley et al., 1996).
The combination of 1 3 1 I-A5B7 and CA-4-P may be effective for two reasons.  Either the 
mechanism is simple additive killing of the tumour centre by CA-4-P and the rim by 1 3 1 I- 
A5B7,  or,  CA-4-P  may enhance the  effect of 1 3 1 I-A5B7 by increased antibody retention 
following CA-4-P-induced vessel collapse (Pedley et al., 2001).
The timing of vascular disruptive agent administration is important as it affects the level of 
antibody retention in tumour.  Maximum tumour levels  of 1 3 1 I-A5B7  are  reached 24-48 
hours  after administration  (Pedley et al.,  1994).  The  administration of DMXAA at this 
time (48 hours after 1 3 1 I-A5B7) resulted in significantly higher antibody retention compared 
to controls treated with antibody alone at assessment a further 48  hours  later (96 hours 
after 1 3 1 I-A5B7).  However, if DMXAA was given either 3 hours before or concomitantly 
with 1 3 1 I-A5B7, antibody retention was significantly reduced (Pedley et al., 1996).
3.1.2  Rationale for study
Following  on  from  the  successful  preclinical  studies  using  the  SW1222  (and  other) 
colorectal xenografts, a phase I clinical trial of the combination of 1 3 1 I-A5B7 and CA-4-P 
was  proposed  in  patients  with  advanced  gastrointestinal  carcinoma  (the  trial  started  in 
January 2004).  The schedule for the clinical study is given in Table 3.1.  The timing of the 
combination  treatment  in  Week 2  (CA-4-P  given  48  and  72  hours  after  1 3 1 I-A5B7)  is 
designed to  ensure  maximum antibody retention.  The  starting dose for CA-4-P was  33 
mg.kg"1 , increasing to 50 mg.kg'1 , if tolerated.  A single dose of CA-4-P is given alone in 
Week  1  so  that DCE-MRI  examinations  may be  performed to  measure  CA-4-P’s  acute 
anti-vascular effect.  (DCE-MRI  examinations  cannot  be  performed  in  Week 2  as  the 
patient has to be isolated for up to 5 days following 1 3 1 I-A5B7).  The DCE-MRI data will 
be related retrospectively to patient outcome to see if the magnitude of reduction in DCE- 
MRI kinetic parameters due to CA-4-P can predict response to the combination treatment.
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Week 1 Monday DCE-MRI examination
Tuesday DCE-MRI examination
Wednesday CA-4-P
DCE-MRI examination 4-6 hours later
Week 2 Monday mI-A5B7
Wednesday CA-4-P
Thursday CA-4-P
Weeks 3-8 Wednesday CA-4-P
Table 3.1: Clinical Trial Schedule
Despite the good effect of the combination in animal studies (Pedley et al., 2001), the dose 
of CA-4-P was very high and there is no information on whether lower doses (which may 
be more clinically relevant) are effective.  Also, there is no information on how DCE-MRI 
effects relate to antibody retention and therapeutic efficacy.
The  aim of this  pre-clinical study was therefore to determine a dose  response and time- 
course  for CA-4-P  using  DCE-MRI  in  the  SW1222  tumour.  The  results  will  provide 
information  regarding  the  magnitude  of  change  in  vascular  parameters  that  might  be 
anticipated  in the  clinical trial  and help  relate  the  change  in vascular parameters  to  the 
therapeutic effects of the CA-4-P/1 3 1 I-A5B7 approach in the same animal model (Pedley et 
al., 2001).
3.1.3  Study objectives
The  objectives  were  to  determine  if  there  were  any  changes  in  the  quantitative  MR 
parameters  (IAUGC, Ktran s and ve ) using the same tumour and strain of mice (MF1 nude 
females) as used in the therapeutic study (Pedley et al., 2001).  The arterial input function 
was  determined,  as  this  is  required  for  calculation  of  the  parameters  Ktran s  and  ve. 
Relaxation parameters (T1 5  T2  and T2*) were calculated.  Histological measures of CA-4-P 
effect were  also  determined  in terms  of the  functional vascular volume  (using  Hoechst 
33342) and percentage tumour necrosis.
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3.2  Methods
3.2.1  Mice and tumours
SW1222 cells  (provided by Dr RB Pedley, Royal Free Hospital) were maintained in L-15 
(Leibovitz)  medium (Life  Technologies,  UK)  supplemented with  10%  foetal calf serum 
(Sigma,  UK)  plus  2  mM  glutamine  (Life  Technologies)  and  incubated  in  a  humidified 
incubator at 37° C in air-5%C02.  5xl06  cells were implanted subcutaneously onto the rear 
dorsum of 4-8 week old female MF1  nude  mice  (Harlan UK ltd, Bicester)  anaesthetised 
with Metofane (methoxyflurane, Janssen Pharmaceuticals, Ontario, Canada).  Animals were 
selected  for  treatment  after  approximately  2-4  weeks  when  their  tumours  reached  a 
geometric mean diameter (GMD) of 6-9 mm.  All animal experiments were performed in 
full compliance with government regulations and UKCCCR guidelines on animal welfare 
and were approved by the local Ethical Review Committee (Home office licence numben 
PPL 70/4552).
3.2.2  Drug treatments
Animals  either  received  intraperitoneal  (i.p.)  injections  of  CA-4-P  (Qxigene  Inc. 
Watertown,  MA,  USA)  or  0.9%  saline.  CA-4-P  was  dissolved  in  0.9%  saline  at  a 
concentration of 10 mg.ml1 .
Mice were treated with either CA-4-P (at 30, 100 or 200 mg.kg1 ) or 0.9% saline at either 4 
or 24 hours prior to DCE-MRI -  making 8 treatment groups in total.  The time recorded 
was the time from drug treatment to injection of contrast agent (Gd-DTPA)  during MR 
imaging.  A window of ± 15 minutes for the 4-hour time point and ± 60 minutes for the 
24-hour time point was allowed.
3.2.3  MRI protocol
Each mouse was  sedated with an i.p.  injection of 0.3  ml.kg1   Hypnorm (fentanyl citrate
0.315 mg.ml'1  &fluanisone 10 mg.ml'1  -  Janssen-Cilag, UK) that had been diluted 1:10 with 
water.  The  mouse  was  then  anaesthetised  temporarily with  Halothane  (Merial Animal 
Health  ltd,  Harlow,  UK)  vaporised using a  50:50  mixture  of oxygen and nitrous  oxide 
(both BOQ UK)  so that an intravenous  (i.v.)  line could be placed in a tail vein and the 
mouse  restrained  in  a Perspex jig.  The  mouse  was  then placed  in  a  6  cm quadrature 
birdcage  coil  in  a  4.7  T Varian  MR system  for scanning.  The  temperature  inside  the
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magnet was  maintained to 35-37 ° C using a hot air blower and mouse temperature was 
monitored continuously via a fine copper rectal thermocouple.  The rectal thermocouple 
did produce local field inhomogeneities but these did not impact on the tumour ROI.
The following MRI sequences were performed:
1.  Initial Tj and T2  weighted images to select a suitable plane through the tumour centre
2.  Spin echo sequence with two echo times to estimate baseline T2: TE  11 & 60 ms, TR 
1000 ms, FOV 40 x 45 mm, slice thickness 2 mm.
3.  Multi-gradient echo sequence to calculate baseline T2*: TE 4-32 ms, TR 234 ms, FOV 
40 x 45 mm, slice thickness 2 mm, flip angle 45°, 8 echo times.
4.  Inversion recovery (IR) sequence to calculate pre-contrast tumour Tj values: TE 10 ms, 
TR2420 ms, inversion times (IR) 100, 400, 800,1600 &2400 ms.
5.  A 100-image dynamic gradient echo sequence: TE  2.5  ms, TR 60 ms, flip angle 70°, 
FOV 40x45 mm, in-plane resolution 0.16 mm x 0.45 mm, slice thickness 2 mm, time 
resolution  6  s,  100  images  in total.  Gd-DTPA was  injected as  an  i.v.  bolus  at  0.1 
mmoLkg1  (0.1 mmoLml'1  concentration) during the sixth acquisition over 5 seconds via 
an infusion pump. Contrast was injected for a total of 6 seconds to allow for the dead 
space in the i.v. line, estimated to be 5 pi.  A 25 g mouse would therefore receive 25 pi 
of contrast agent solution.
After scanning, mice were killed by cervical dislocation.
3.2.3.1  Determination ofrelaxivity
The  relaxivity,  q,  (in  mMVs'1 )  of  a  given  contrast  agent  is  defined  as  the  change  in 
relaxation  rate  per  unit  of  contrast  agent  concentration  (Donahue  et  al,  1994).  q  is 
required for calculation of the concentration of Gd-DTPA in plasma or tissue (see Section 
1.5).  A set of Gd-DTPA plasma reference tubes  was  made using blood obtained from 
non-tumour bearing mice.  Blood samples (~0.5 ml per mouse) were centrifuged at 10,000 
rpm  for  2  minutes  to  obtain  plasma.  10  reference  tubes  (ranging  from  0  to  1  mM 
concentration)  were  made  by adding 20  pi of Gd-DTPA (at varying concentrations)  or 
saline to 200 pi of plasma.  The reference tubes were placed in the magnet (at 35 °Q and
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their Tt values calculated using an inversion recovery MRI sequence: TE  10 ms, TR 6005 
ms, inversion times  (IR)  100, 250, 500,  1000, 2000, 4000 & 6000 ms.  A graph of  1/Tj 
versus Gd-DTPA concentration was then plotted and q calculated as described in Section 
1.5.
3.23.2  Arte rial input functio n
The  arterial  input  function  (AIF)  is  required  for  derivation  of  quantitative  kinetic 
parameters such as Ktians.  It is technically very difficult to obtain an AIF for individual mice 
so a cohort mouse AIF was determined instead.  AIF was estimated using two different 
methods: in urn imaging of blood vessels and by estimating the Gd-DTPA concentration in 
blood samples from individual mice.
3.2.3.2.1  In vivo method
Non-tumour bearing MF1  nude  mice  (n=5) were anaesthetised for i.v. cannulation then 
sedated and placed in a jig in the scanner as above.  A suitable transverse slice in which 
large vessels could be seen clearly (just superior to the kidneys) was chosen.  A 100-image 
dynamic gradient echo sequence was acquired: TE  1.5 ms TR 30 ms, flip angle 30°, slice 
thickness 2 mm, FOV 40 x 45 mm, in-plane resolution 0.31 x 0.45 mm, time resolution 3 s. 
Gd-DTPA was injected after 30 seconds  (0.01  mmolkg'1 , 1/ 10th of the dose used above, 
but in the same volume) as an i.v. bolus over 5 seconds, as before.  Contributions from in­
flow effects were  minimised by pre-saturation of signals outside  of the  slice selected for 
imaging.  Voxels from major blood vessels  (inferior vena cava and aorta) were identified 
from a Tr weighted gradient-echo image obtained without pre-saturation, since the vessels 
showed up as high signal intensity due to flow into the slice.  The mean signal intensity of 
these Vessel' voxels (a combination of the inferior vena cava and the aorta) was calculated 
for the dynamic MRI sequence.
3.23.2.2  Blood sampling method
Animals used for the in mn method above were killed at  — 4-5 min after injection of Gd- 
DTPA and plasma samples  obtained.  Additional animals were treated similarly (but not 
placed in the MRI magnet) and were killed at 1-2 min or 10-12 min to provide additional 
time points (14 animals used in total).  The Tj values of the plasma samples were measured 
using an inversion recovery sequence as described above and the Gd-DTPA concentration 
estimated.
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Data obtained from both blood sampling and in uw methods were simultaneously fitted to 
a  bi-exponential  model  (see  Section  1.5).  The  values  obtained  were  compared  with 
standard mouse AIFs from the literature (Checkley et al., 2003a; Furman-Haran et al., 1996; 
Lyng et al., 1998).
3.2.33  Data pro cess ing
Images were processed using Matlab version 5  (The Mathworks, Nantick, MA USA).  A 
region of interest (ROI) was drawn around the tumour using the initial Tr weighted image. 
Data were analysed on an individual pixel by pixel basis.  Individual images were reviewed 
and the ROI adjusted if there had been movement.  Individual images that were blurred 
due  to  excessive  movement  were  removed.  One  mouse  had  abnormally high baseline 
signal intensity values (thought to be due to movement in and out of the imaging plane), so 
was rejected.
The  change  in  signal intensity due  to  contrast medium accumulation  in each pixel was 
calculated  over the  imaging  period.  This  was  then  converted  into  Tj  relaxation  time 
changes  using the  method described by Hittmair et al (Hittmair et al.,  1994).  Tj(0) was 
determined using the  inversion  recovery sequence.  The  concentration of Gd-DTPA in 
each  ROI  pixel  present  at  time  t,  can  then  be  calculated  (see  Section  1.5  and  the 
Appendix).
3.23.4  Calculation of  M RI parameters
Representative parameter values  were  calculated for tumour and muscle ROIs using the 
median of all pixels in each ROI.  Mean parameter values for each treatment group were 
then calculated from this data.
IAUGC (mMLs)  was  calculated for the  first 90  seconds  post-contrast  (Evelhoch,  1999). 
Ktrans (min1 ) and ve (%) were obtained by fitting the Tofts’ model (Tofts et al., 1999; Tofts 
&  Kermode,  1991)  to  the  Gd-DTPA  concentration-time  data  using  the  standard  AIF 
obtained for the MF1 mice (see above).
For the relaxation parameters, Tj was calculated from the inversion recovery sequence, T2  
was  estimated  from the  signal intensities  at the  two  echo times  measured and T2* was 
calculated using the method described in Chapter 4.
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3.2.3.5  IAUGC spatial heterogeneity
The spatial heterogeneity of IAUGC values was evaluated using Matlab version 5.  Mean 
IAUGC values  were  calculated for three  regions  determined by their distance  from the 
edge  of the  tumour:  rim  (within  4  layers  of pixels  from the  edge,  corresponding  to  a 
distance  of  < 1  mm); intermediate  (5-10 layers from the  edge, or 1-3  mm); centre  (>10 
layers from the edge, or >3 mm).
3.2.4  Histological parameters
Tumours were excised from mice after imaging for histological analysis.  Mice were killed 
by cervical dislocation and tumours excised and cut in half in the same plane as the MRI 
slice  used  for  scanning.  One  half  was  fixed  in  formalin  (Sigma-Aldrich,  UK)  for 
subsequent staining of a central tumour section with hematoxylin and eosin (H&E - Sigma- 
Aldrich, UK) and for alpha-smooth muscle actin aSMA (Sigma-Aldrich, UK).  The other 
tumour half was placed in zinc fixative for subsequent staining of a central tumour section 
for CD31 antigen1  (Pharmagen, UK).  1 litre zinc fixative consists of 0.5 g calcium acetate, 
5.0 g zinc acetate and 5.0 g zinc chloride (all Sigma-Aldrich, UK) plus 0.5 M Tris buffer at 
pH 7.4 [12.1  g Tris base (FSA laboratory supplies, UK), 900 ml deionised water and 81.5 
ml  1.0  N hydrochloric  acid  (VWR,  UK)].  The  method used for immunohistochemical 
staining involved sequential incubation of unconjugated primary antibody specific to the 
target antigen, a biotinylated secondary antibody which reacts with the primary antibody, 
enzyme-labelled  streptavidin  or  avidin  (which  reacts  with  biotin)  and  a  substrate 
chromogen.  The  enzyme  and  substrate  used were  horse  radish  peroxidase  (HRP)  and 
diaminobenzidine (DAB).  Immunohistochemical staining was performed by Mrs Frances 
Daley, Gray Cancer Institute and the details given below.
Tumours  were  embedded  in  paraffin then  4  [im sections  cut  from the  tumour centre. 
Sections were then dewaxed in xylene and rehydrated through grade alcohol (100, 90 and 
70%)  to  water.  Sections  were  washed  in  Tris-buffered  saline  (TBS)  in  between  each 
application of reagent.
CD31 antigen.  Peroxidase blocking reagent (S2001 - DakoCytomation, Ely UK) and then 
serum free  protein block (X0909  -  DakoCytomation,  Ely UK)  were  each applied for 5 
minutes  (to  block  endogenous  peroxidases  and  non-specific  background  staining
1  CD31 antigen, also known as PE CAM-1 (platelet endothelial cell adhesion molecule), is highly expressed on endothelial 
cells, concentrated on the junctions between them.  It is used as a pan-endothelial marker.
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respectively).  Rat anti-mouse CD31  antibody (550274 - Pharmigen BD Bioscience, San 
Diego  CA)  was  then  applied,  diluted  1/500  in  TBS  for  1  hour at  room temperature. 
Biotinylated rabbit anti-rat antibody (E0468 - DakoCytomation, Ely UK) was then applied 
as  the  secondary antibody,  diluted  1/400  in  TBS  for  one  hour  at  room  temperature. 
Avidin complexed with HRP  (Dako ABComplex/HRP, DakoCytomation, Ely UK) was 
applied for one hour at room temperature then DAB solution was applied for five minutes. 
Sections were rinsed in distilled water and counterstained in Gill’s haematoxylin (Surgipath 
Europe Ltd, Peterborough UK) for 5-60 seconds, as a nuclear counter-stain.  Sections were 
washed and dehydrated through graded alcohols, cleared in xylene and mounted in DPX 
(360294HMerck, UK) mounting media.
aSMA.  (All  reagents  for this  method  (except primary antibody)  were  supplied in  the 
Ultravision Mouse Detection kit (TQ-015-HD), Stratech Scientific Ltd, Cambridge UK). 
Sections were blocked with endogenous peroxidase for 15  minutes at room temperature 
then Ultra V block was applied to block reactive immunoglobulins and sections incubated 
for 60-70 minutes  at room temperature.  aSMA antibody (Sigma-Aldrich, UK) was then 
applied,  diluted  1/20,000.  Biotinylated  goat  anti-mouse  antibody and then  streptavidin 
peroxidase  were  applied, each for 10-15  minutes  at room temperature.  DAB was then 
applied  for  five  minutes  with  hydrogen  peroxide.  Sections  then  placed  in  Gill’s 
haematoxylin (Surgipath Europe Ltd, Peterborough UK) for 5-60 seconds.  Sections then 
washed again and dehydrated through graded alcohol’s, cleared in xylene and mounted in 
DPX (360294HMerck, UK) mounting media.
3.2.4.1  Necrosis
The  percentage  necrosis  in  H&E-stained  histological  sections  was  scored  for tumours 
imaged at 24 hours.  Using a grid eyepiece graticule marked in 100 squares, each tumour 
section was assessed at xlO magnification, by scoring each square as undamaged tumour or 
necrosis.  The percentage necrosis was then calculated for each tumour.  In addition, the 
rim of viable tissue remaining was measured for tumours imaged at 24 hours for the  100 
mg.kg1  and 200 mg.kg'1  dose levels.
3.2.4.2  Vas cular maturatio n index
Tumour vascular maturation index was  calculated for the control group (animals treated 
with saline at both time-points) and for the group treated with 30 mg.kg'1  CA-4-P, 24 hours
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prior to  imaging.  The  vascular maturation index was  defined as  the  percentage  aSMA 
staining divided by the percentage of CD31 antigen staining.  The amount of staining was 
determined using  a  random point  scoring  system based  on that  described  by Chalkley 
(Chalkley, 1943; Smith et al., 1988).  An eyepiece graticule with a random array of 25 points 
was used and the tumour assessed at x40 magnification.  Points falling on areas of staining 
were recorded as positive.  This procedure was repeated over different areas of tissue until 
a total of 120 fields had been scored.  The total score was then divided by 30 to give the 
percentage staining for that tumour.  Vascular maturation index was expressed as the mean 
value for each tumour type (± 1 standard error of the mean).  Separate sections taken from 
the  tumour centre  had to  be  used for aSMA and CD31  antigen  staining as  they have 
different fixing methods.
3.2A.3  Functional vascular volume
The measurement of functional vascular volume was performed by Dr SA Hill and Ms GA 
Lewis,  in  a  separate  experiment.  Functional  vascular  volume  was  assessed  in  control 
tumours and at 4 or 24 hours following treatment with 30, 100 or 200 mg.kg1  of CA-4-P 
using  Hoechst  33342  (Sigma-Aldrich, Dorset,  UK)  as  reported previously (Smith  et al., 
1988).  The fluorescent DNA-binding dye was dissolved in 0.9% saline at a concentration 
of 6.25 mg.ml'1  and injected i.v. at a dose of 10 mg.kg1 .  Tumours were excised and frozen 
1 minute later.  Sections were cut at three levels through the tumour and observed under 
UV  light  illumination.  Perfused  vessels  were  identified  by their  fluorescent  outlines. 
Vascular volumes were  determined using a random point scoring system (based on that 
described by Chalkley (Chalkley, 1943; Smith et al, 1988).  At least 100 fields were scored 
at each of the tumour levels.
3.2.5  Statistical analysis
Kinetic  parameters  were  analysed  using  a  statistical  software  package  (JMP  Statistics, 
version  3.2.6.  SAS  Institute  Inc.,  Cary,  North  Carolina,  USA).  A one  way analysis  of 
variance (ANOVA) was used to look for a significant difference between treatment groups. 
If  the  ANOVA was  significant  (p<0.05)  then  an  appropriate  post-test  comparison  of 
individual means  was  performed to  look for significant differences between dose  levels. 
Linear regression analysis was used to test for a dose-response relationship.
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3.3  Results
There were six animals for analysis per treatment group.  The mean time from implantation 
to treatment with CA-4-P was 21.4 (±0.9) days.  Mean mouse weight was 26.8 (±0.3) g and 
mean tumour GMD was 7.4 (±0.1) mm3.  There were no significant differences between 
the 8 treatment groups for time from implantation, mouse weight, tumour GMD or in the 
time from treatment with CA-4-P to injection of Gd-DTPA (on ANOVA).
3.3.1  Gd-DTPA relaxivity in mouse plasma at 4.7 T
Relaxivity, rt was calculated as 4.195 mM'.s’1  at 35°C (see Figure 3.1).  This is similar to 
other values  quoted  at  4.7  T:  4.02 ±0.14  mMAs'1   (Donahue  et  al.,  1994),  4.3  mMAs1  
(Furman-Haran et al., 1996) and 3.8 mMAs'1  (Checkley et al, 2003b).
2.0
w
H
0.5  - 1/T,  = 0.385 + 4.195*[Gd-DTPA]
o.o
o.oo 0.05 o.io 0.15 0.20 0.25 0.30 0.35
Gd-DTPA (mM) 
Figure 3.1: Gd-DTPA relaxivity in mouse plasma
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3.3.2  Arterial input function for Gd-DTPA in the mouse
The blood-sampling and in-iiw imaging data were simultaneously fitted to a model arterial 
input function (see Section 1.5).
Ca(0 = o[a1 e< "”,')+a2 e(-"1')J
where  D=0.1  mmoLkg'1 ,  the  bolus  dose  of  Gd-DTPA,  ax=  10.19  kg.1'1 ,  m ^  4.65  s'1, 
a2=3.81 kg.1"1  and m2  =0.09 s'1.
3.3.3  MRI parameters
Figure  3.2 shows the change in signal intensity following contrast agent injection for an 
untreated tumour and a tumour treated 4 hours previously with 200 mg.kg'1  of CA-4-P. 
IAUGC maps  of the  same tumours  are  also shown.  The  acute  blood vessel shutdown 
caused by CA-4-P is clearly demonstrated.
33.3.1  IAUGC
Figure  3.3  shows the  mean IAUGC (mM.s)  values for tumour and muscle at 4 and 24 
hours following treatment with CA-4-P.  IAUGC was found to be highly discriminatory 
between dose groups at 4 hours following treatment with CA-4-P (ANOVA, p 0.00001). 
A significant reduction in tumour IAUGC was seen at all dose levels at 4 hours following 
treatment with CA-4-P in comparison with the control group (relative reduction: 38.1%, 
71.6%  and  85.9%  for  30,  100  and  200  mg.kg'1   respectively).  There  was  a  significant 
difference  between treatment groups  (ANOVA, p =0.005)  at 24 hours  with a significant 
reduction at the  100  and  200  mg.kg'1   dose  levels  (relative  reduction 53.8%  and 57.7% 
respectively) but not at 30 mg.kg'1 .  Recovery was greater at the 30 mg.kg dose level than at 
100 mg.kg'1 .  There was no significant difference between any of the treatment groups and 
the control groups for muscle IAUGC
The dose-response relationship for the IAUGC is shown in Figure 3.4.  Linear regression 
analysis  was  highly  significant  for  a  dose-response  relationship  at  4  hours  (r  =-0.80, 
p 0.0001) and significant at 24 hours (r=-0.58, p 0.01) for tumour but not for muscle (r=-
0.02 and -0.17 for 4 and 24 hours respectively).
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Figure 3.2: Change in signal intensity over time due to Gd-DTPA injection in (A): an untreated 
SW122 tumour and (B) in a SW122 tumour treated 4 hours previously with 200 mg.kg-1 CA-4-P 
C: IAUGC maps of the same tumours as in A & B.
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Tumour IAUGC at 4 hours  7 1  Tumour IAUGC at 24 hours
saline  30  100  200
CA-4-P dose
saline  30  100  200
CA-4-P dose
$
7  Muscle IAUGC at 4 hours  7  Muscle IAUGC at 24 hours
l-
s aline  30  100  200
CA-4-P dose
1-
s aline  30  100  200
CA-4-P dose
* significant at p <0.05
Figure 3.3 Mean tumour and muscle IAUGC for each treatment group.
Figures show mean ±standard error of the mean.  N=6 for each treatment group. * indicates 
significant at p <0.05 CA-4-P dose in mg.kg-1.
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Figure 3.4 IAUGC dose-response relationship for tumour and muscle.  Figures show mean 
Tstandard error of the mean.  n=6 for each treatment group.  * indicates significant at p<0.05.
CA-4-P dose in mg.kg1.
Analysis  of pooled control groups  showed that tumour rim, intermediate and central areas 
had  different baseline  mean  IAUGC  values:  4.74  mM.s,  3.36  mM.s  and  3.0  mM.s  for rim, 
intermediate  and  central  areas  respectively  (highly  significant  differences  between  each 
group  by  paired  t-test).  The  percentage  differences  in  IAUGC  between  each  treatment 
group and the controls  for each  region are summarised in Figure 3.5.  For ever}7 dose and 
time,  the  order  of change  (reduction)  in  the group  mean  IAUGC  was  the  same:  centre  > 
intermediate  >  rim.  The ratio of centre:rim IAUGC was  found to be significantly lower at 
4 hours after 100 and 200 mg.kg 1   CA-4-P and at 24 hours after 100 mg.kg 1  CA-4-P than in 
the corresponding control groups.
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Figure 3.5 Tumour IAUGC spatial heterogeneity, showing difference in change in IAUGC for 
tumour rim (white), intermediate zone (grey) and centre (black) for different doses of CA-4-P. 
Figures show mean ±standard error of the mean.  n=6 for each treatment group.
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3.33.2  K*am  and ve
The results for tumour Ktrans and ve are shown in Figure 3.6.  On ANOVA, there was a 
significant difference between treatment groups at 4 hours following treatment with CA-4- 
P for both Ktrans (p <0.00001) and ve (p <0.001).  A significant reduction in Ktrans at all three 
dose levels and at 100 and 200 mg.kg1  in ve was seen at 4 hours versus control (relative 
reduction: 57.8%, 76.4% and 86.0% for Ktians, and 44.3% and 69.8% for ve, respectively). 
At 24 hours, there was  a significant reduction in Ktrans at 200 mg.kg'1   (relative reduction: 
60.6%) but no significant change in ve at any dose level.  Ktrans and ve did not discriminate 
between groups at 24 hours  (ANOVA not significant).  As with IAUGC, there were no 
significant changes in muscle Ktrans or ve at anytime point or dose level (data not shown).
There  was  also  a  significant  dose  response  relationship  for  Ktrans  on  linear  regression 
analysis: r=-0.72 (p 0.0001) at 4 hours and r=-0.48 (pO.05) at 24 hours.
3.33.3  Relaxation parameters (Tp T2, T /r )
The results are shown in Table 3.2.  There was a significant increase in baseline Tx  at 4 
hours  for  100  and  200mg.kg1   but  no  significant  change  at  24  hours.  There  was  a 
significant increase in T2  at 24 hours for 100 and 200mg.kg1  but no significant changes at 4 
hours.  There was no significant changes in T2* at either time.
saline
4 he
30
mg-kg'1
)urs
100
m g.kg1
200
m g.kg1
saline
24 h
30 
m g.kg!
ours
100
mg-kg1
200
mg-kg1
T ,(s) 1.84
(±0.06)
1.99
(±0.06)
2.05
(±0.06)
2.40
(±0.26)
2.02
(±0.19)
1.96
(±0.15)
2.45
(±0.31)
2.07
(±0.09)
t 2
(ms)
37.5
(±0.8)
39.8
(±4.0)
37.0
(±2.3)
40.1
(±2.1)
40.1
(+1.7)
40.5
(+2.4)
52.3
(±2.7)
50.0
(±1.3)
t 2»
(ms)
6.4
(±0.3)
7.5
(±0.6)
7.7
(±0.6)
6.7
(±0.3)
6.4 
(±0.4) _
7.5
(±0.5)
8.1
(±1.5)
8.2
(±0.6)
Table 3.2: Mean values of relaxation parameters for each treatment group at 4 and 24 hours 
following treatment (± standard error of the mean), values significantly different (p 0.05) to
control are shown in bold.
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Figure 3.6: Mean tumour Ktran s and ve for each treatment group.  Figures show mean 
±standard error of the mean.  n=6 for each treatment group. * indicates significant at p 0.05 CA-
4-P dose in mg.kg-1.
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3.3.4  Histological Parameters
3.3.4.1  Necrosis
Figure 3.7 shows the percentage necrosis scored at 24 hours following CA-4-P.  30 mg.kg'1  
CA-4-P  produced  patchy haemorrhagic  necrosis  whereas  100  mg.kg'1   and  200  mg.kg'1  
produced extensive haemorrhagic necrosis with only a thin viable rim of tumour remaining. 
There was no significant difference between rim thickness between 100 and 200 mg.kg'1  
(mean  rim thickness  407  pm  (±120),  median  204  pm).  There  was  a highly significant 
difference between treatment groups  (ANOVA p 0.0001)  and all three dose levels were 
significantly different  from  control.  The  percentage  necrosis  score  and  the  Ktrans  and 
IAUGC values at each dose level were correlated: -0.80 (p 0.05) and -0.6 (not significant) 
respectively.
Figure  3.8  shows  sections  taken  from  tumours  treated  at  24  hours  with  CA-4-P  to 
demonstrate degree of necrosis at different dose levels, and also CD31 and aSMA staining.
100-,
saline 30  100
CA-4-P dose
200
Figure 3.7: Percentage necrosis seen at 24 hours following CA-4-P (mg.kg-1 ).  Figures show mean 
±standard error of the mean.  N=6 for each treatment group. * indicates significant at p 0.05.
CA-4-P dose in mg.kg1 .
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Figure 3.8: H&E sections showing extent of necrosis at 24 hours following treatment with 
CA-4-P.  A: Saline; B: 30 mg.kg-1; C: 100 mg.kg-1; D: 200 mg.kg-1.  E & F: sections stained for 
CD31  antigen and aSMA staining respectively.  A, E & F at x 20 magnification, rest taken with xlO 
magnification objective, bar represents 200 pm.
t
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33.4.2  Vascular Maturation Index
Some tumour sections showed very faint or no staining for CD31 antigen and had to be 
discarded, leaving 8 tumours from the group treated with saline and 5 tumours from the 
group treated with 30 mg.kg1   CA-4-P at 24 hours prior to imaging for determination of 
vascular maturation index.  The mean vascular maturation index (VMI) was  11.1% (±2.2) 
and 17.9% (±3.4) for the control group and the group treated with 30 mg.kg"1  at 24 hours 
respectively.  However,  there  was  no  significant  difference  between  the  two  groups 
(unpaired t-test).
3.3.4.3  Functional vascular volume
Figure 3.9 shows the percentage functional vascular volume for controls and at 4 and 24 
hours following treatment with CA-4-P.  The reduction in functional vascular volume seen 
with CA-4-P was significant for all dose levels, apart from 30 mg.kg"1  at 24 hours.
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Figure 3.9 Change in functional vascular volume (%) at 4 and 24 hours post CA-4-P. Figures 
show mean ±standard error of the mean.  n=15 for control.  n=ll, 8 & 7 for 30,100 and 200 
mg.kg-1  CA-4-P at 4 hours respectively and n=10,11 and 12 for 30,100 and 200 mg.kg-1  CA-4-P at 
24 hours respectively.  * indicates significant at p <0.05 CA-4-P dose in mg.kg"1.
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3.4  Discussion
3.4.1  MRI parameters
There was a significant decrease in the IAUGC in tumour (but not in muscle) for all three 
dose levels at 4 hours which persisted at the highest dose (200 mg.kg'1 ) at 24 hours.  There 
was a clear dose response relationship both at 4 and 24 hours, highly significant at 4 hours 
(using linear regression analysis of IAUGQ.
The parameters  Ktrans and ve were  less  sensitive  indicators  of CA-4-P effects.  However, 
their  calculation  requires  more  mathematical  modelling  than  for  IAUGC  -  so  more 
variability would be expected.  In particular, the modelling procedure involves use of a Gd- 
DTPA arterial input function (AIF).  The AIF used in the present study was obtained using 
a ‘vessel’ ROI  (a combination of the IVC and aorta as it was not possible to distinguish 
clearly the  two  on MR images)  and a simultaneous  fit of data from in-uw imaging and 
blood sampling.  However, the resultant AIF appears to be a good approximation based 
on:
1.  compatibility with previously published mouse AIF model parameters (Checkley et al., 
2003a; Furman-Haran et al., 1996; Lyng et al., 1998) see Figure 3.10 and Table 3.3.
2.  generally good fitting of tumour and muscle data.
3.  plausible values of Ktrans and ve were obtained.
However,  the  AIF  used  for  modelling  was  obtained  from  a  group  of  mice  and  no 
corrections could be made for individual variability or due to any systemic CA-4-P effects. 
It is  possible, though difficult, to obtain an individual mouse AIF: Zhou et al. extracted 
AIF  from  signal  intensity  changes  in  left  ventricular  blood,  with  tumours  implanted 
subcutaneously on  the  shoulder to  be  in  the  same  imaging  plane  (Zhou  et  al.,  2004). 
Pathak et al. used a tail RF coil to extract an AIF from mouse tail vein, with a second coil 
used to obtain images from a tumour region of interest (Pathak et al., 2004).  However, the 
latter  technique  has  a  temporal  resolution  of  75  seconds  so  is  only  suitable  for 
macromolecular contrast agents.
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Reference a, m, a2 m2 comments
Current study (GCI) 10.19 4.65 3.81 0.09 Simultaneous fit
(Furman-Haran et 
al, 1996)
4.3 0.43 3.2 0.057 Obtained from blood 
samples
(Lyng et al, 1998) 19.33 4.4 2.33 0.05 In vivo imaging (left 
ventricle)
(Checkley et al, 
2003b)
11.95 1.17 4.67 0.054 In vivo imaging aorta 
and IVC
Table 3.3 Parameter values for AIF
  GCI (fit)
  Checkley et al. (in-vivo)
  Furman-Haran et al. (blood samples)
  Lyng et al. (in-vivo) 10 -
time (min) '  i
10 0 2 4 6 8
Figure 3.10: Comparison of mouse standard arterial input functions.  GCI: Gray Cancer
Institute (current study).
3.4.1.1  IAUGC spatial heterogeneity
The analysis of spatial heterogeneity of IAUGC values compared to distance from the edge 
of the tumour provides evidence that in this tumour model:
1.  blood flow is higher towards the tumour rim than in the centre of untreated tumours;
2.  the magnitude of CA-4-P  anti-vascular effects is higher in the tumour centre than in 
the rim.
Previous  quantitative  approaches  to  evaluating  the  spatial  selectivity  of  CA-4-P  (i.e. 
whether the effects are greater in the tumour centre than in the rim) have been inconsistent 
(Maxwell et al., 2002; Maxwell et al., 2000; Tozer et al., 1999).  The sensitivity differences
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between rim and centre in this tumour model are consistent with the hypothesis that CA-4- 
P and RIT may have complementary actions, in a spatial sense (Pedley et al., 2001).
3.4.1.2  M R relaxation parameters
Interpretation of the changes  in MR relaxation times  (Tl5 T2  and T2*)  is uncertain, since 
there  are  several factors  (e.g.  blood oxygenation, blood volume, haemorrhage,  necrosis, 
oedema) which can affect each parameter.  Long relaxation times are associated with high 
fractional tumour water contents, probably due to free interstitial water (Belfi et al., 1991; 
Lyng et al.,  1997; Rofstad et al.,  1994).  The presence of necrosis  and haemorrhage can 
shorten relaxation times, due to the presence of paramagnetic ions Qakobsen et al., 1995; 
Rofstad et al., 1994; Van Bruggen et al., 1990).  Jakobsen et al. (Jakobsen et al., 1995) made 
the distinction between newly formed massive necrosis (e.g. due to vascular damage) and 
necrosis which had developed gradually during tumour growth.  In the case of the former, 
the effect of increased oedema might overshadow the effect of increased concentrations of 
paramagnetic ions —  resulting in longer relaxation times.  This is consistent with our results: 
an increase in Tj identified 4 hours after CA.-4-P (100, 200 mg.kg * ) and an increase in T2  at 
24 hours.
There were no significant changes in T2* at either time point -  although there was a trend 
towards an increase in T2* at the higher dose levels at 24 hours.  This is consistent with the 
decrease in R2* seen at 24 hours following treatment with ZD6126 (Robinson et al., 2005) 
(see the discussion in Chapter 2).
3.4.2  Histological parameters
Changes  in  functional  vascular  volume  and  percentage  necrosis  seen  in  the  SW1222 
tumour following CA-4-P administration are similar to that seen in other tumours (Chaplin 
et al., 1999; Dark et al., 1997; Grosios et al., 1999).  Hill et al. reported that 25 mg.kg'1  of 
CA.-4-P reduced functional vascular volume to  -65%  of control values  at 6 hours, with 
almost complete recovery (to 80-90%) by 24 hours in the CaNT (Hill et al., 2002).  This 
finding is similar to the effect of 30 mg.kg'1  CA.-4-P on the SW1222 tumour: reduction to 
-55%  of control at 4 hours,  recovering to  >90% of control at 24 hours.  The  size  and 
pattern  of  change  in  the  MR parameters  are  similar to  the  changes  seen  in  functional 
vascular volume at the corresponding time points.
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It  has  been  proposed  that  vascular  maturation  index  may  predict  response  to  anti- 
angiogenic  agents  and VEGF withdrawal can lead to  an increase  in vascular maturation 
index,  due  to  regression  of  immature  vessels  (see  Section  1.3)  (Benjamin  et al,  1998). 
Vessel  maturity may also  be  important  in  determining  response  to  vascular  disruptive 
agents.  If immature  vessels  are  more  sensitive to  CA-4-P, then an increase  in vascular 
maturation index might be  anticipated.  This  hypothesis  was  investigated by comparing 
vascular  maturation  indices  calculated  for  control  tumour  and  tumours  that  had  been 
treated with 30 mg.kg'1  CA-4-P 24 hours previously.  This dose and time-point was used as 
necrosis was too extensive at the higher dose levels for aSMA and CD31 antigen scoring 
and the 4-hour time-point was judged to be too early for any tumour vessel regression to 
have  occurred.  There  was  a  trend  towards  an  increase  in  vascular  maturation  index 
following treatment with CA.-4-P but this was not significant.  However, results may have 
been confounded by small numbers and the presence of necrosis in the tumour sections 
from treated animals.
3.4.3  Clinical relevance of this study
DCE-MRI  will be  used  in the  clinical study so that early anti-vascular changes  may be 
related to eventual response to the combination treatment.  There are certain differences 
between the DCE-MRI protocol used here and the protocol that will be used in the clinical 
study.  In the clinical study, patients will have three MRI scans -  two before CA-4-P and 
one 4-6 hours afterwards.  The advantage of this strategy is that patients act as their own 
control and also a reproducibility study can be performed.  Serial MRI measurements are 
technically difficult using mice (requiring repeated venous cannulation) so separate control 
groups were used.
It is assumed that a certain level of anti-vascular response to CA-4-P will be required for 
enhancement of RIT.  The dose of CA-4-P used in the preclinical study of 1 3 1 I-A5B7 and 
CA-4-P was 200 mg.kg'1  (Pedley et al., 2001).  The dose with equivalent effectiveness in a 
human (expressed in mg.m'2 ) can be estimated either using a conversion factor2 (Chodera 
&  Feller,  1978)  or  by  comparison  of  pharmacokinetic  data  (e.g.  AUC  for  the  active 
metabolite  CA4  (Rustin  et al.,  2003))  Whichever method is  used, the  equivalent human
2 The equivalent dose in humans (in mg.m:2 ) for a particular dose in mouse (in mg.kg-1 ) can be calculated by multiplying 
the mouse dose by 3.083 Chodera, A. & Feller, K. (1978). Some aspects of pharmacokinetic and biotransformation 
differences in humans and mammal animals. Int J Clin Pharmacol Bupbarm, 16, 357-60..
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dose for 200 mg.kg'1   in the  mouse  is  approximately 10 times higher than the maximum 
tolerated dose in the phase I clinical trial of CA-4-P as a single agent (Rustin et al., 2003).
The effect of the combination of mI-A5B7 and more clinically relevant doses of CA-4-P 
on  tumour  growth  has  not  been  established.  However,  indirect  evidence  for  the 
supposition that a clinically relevant dose of CA-4-P may still be effective in combination 
with 1 3 1 I-A5B7 comes from a comparison of the effect of these three dose levels on tumour 
antibody retention (Lankester et al., 2004).  SW1222 tumour-bearing mice received a small 
dose of mI-A5B7 and then either 30, 100 or 200 mg.kg'1  CA-4-P i.p. 48 hours later or no 
further treatment  (control).  The mice were bled and tissues  excised 96 hours  after 1 3 1 I- 
A5B7 administration and comparative activity assessed using a y-counter.  All three doses 
significantly increased antibody retention in tumour (increases of 71%, 78% and 90% vs 
control for 30, 100 and 200 mg.kg'1  CA-4-P respectively but not in normal tissues (Dr RB 
Pedley, personal communication).  The percentage increases were not significantly different 
between the three treatment groups.  The timing of CA-4-P in relation to 1 3 1 I-A5B7 was 
based  on  previous  data  showing  that  maximum  efficacy  is  achieved  if  the  vascular 
disruptive agent is given 24-48 hours after the radio-antibody (Pedley et al., 1996) (see the 
introduction to this chapter).
So, while  30  mg.kg'1   of  CA-4-P  produced only a transient decrease  in tumour vascular 
function (and limited necrosis), it still increased antibody retention in tumour significantly. 
It is not clear why this is the case, but it is possible that a significant number of tumour 
vessels  are  permanently lost following treatment and so antibody is  less  likely to escape 
from the tumour.  If antibody clearance from tumour at this time (48 hours) is high, then a 
decrease in tumour blood flow reduction at this time may be particularly beneficial.
The mean reduction in IAUGC seen at 4 hours at the 30 mg.kg'1  dose level (38%) is similar 
to that seen in the phase I clinical study (33% for patients treated at >52 mg.m'2  (Galbraith 
et  al.,  2003).  This  suggests  that  the  30  mg.kg'1   dose  level is  equivalent  to  a  clinically 
relevant human dose.  The dose levels of CA-4-P for the  1 3 1 I-A5B7/CA-4-P clinical trial 
will be 45 mg.m"2  and 55 mg.m'2.  So, reductions of this magnitude might be anticipated to 
occur in the clinical trial.
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3.4.4  Conclusions
There  is  a  clear dose-response  relationship  for treatment with CA-4-P,  in the  SW1222 
tumour.  Significant reductions  in kinetic  parameters  are  seen at clinically relevant drug 
doses  (30 mg.kg'1 )  and are  of a similar magnitude to those  seen in the  previous  clinical 
study (Galbraith et al., 2003).  The data presented here indicate that although a lower dose 
of CA-4-P (30 mg.kg'1  in this case) results in a substantially lower and shorter duration anti- 
vascular effect, there is relatively little difference in radio-antibody retention between the 3 
doses  used.  The  likelihood of this  dose  of CA-4-P  enhancing RIT therefore  probably 
depends  on  the  importance  of  radio-antibody trapping  as  opposed  to  sustained  anti- 
vascular damage as the main mechanism of the interaction.
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Chapter 4  Investigation of tumour vessel maturity using air-5% C02/ 
carbogen and angiotensin II using MRI and intravital microscopy
4.1  Introduction
This chapter contains details of the experiments performed to determine whether BOLD- 
MRI response to a vasoactive agent could provide a functional measure of tumour vascular 
maturation status.
The aim was to determine the utility of air-5% C02 /carbogen breathing and angiotensin II 
(ATII) administration to discriminate between different tumour types on the basis of vessel 
maturity.
Histological vascular maturation index was  determined for three  different tumour types: 
the human colon carcinoma xenograft, HT29 (high numbers of mature vessels), the murine 
mammary  tumour,  CaNT  (very  few  mature  vessels),  and  the  spontaneous  mammary 
tumour, T138 (variable numbers of mature vessels) in mice.
Tumour BOLD-MRI response to air-5% C02/carbogen or ATII was used as a functional 
measure  of vessel maturity and compared to the histological measurements  for all three 
tumour types.  The hypothesis was that breathing 5% C02  (in the form of air-5% C02  or 
carbogen) should cause mature vessels to vasodilate, resulting in an increase in T2*, Aq  and 
BOLD signal intensity in the HT29, a fall in signal intensity or maybe no change  in the 
CaNT  (depending  on  change  in  perfusion  pressure)  and  a  variable  response  in  T138. 
Conversely, an intravenous infusion of ATII should cause mature vessels to vasoconstrict, 
resulting in a decrease in T2*, Aq  and BOLD signal intensity in the HT29, no change or an 
increase in these parameters (due to increased perfusion pressure) in the CaNT and, again, 
a variable response in the T138.
In order to determine whether the vasoactive agents tested were having the hypothesised 
effect, intravital microscopy was used to directly observe HT29 and CaNT tumour vessels 
and  to  determine  the  capacity  of  tumour  blood  vessels  to  vasodilate  or  constrict  in 
response  to  air-5%  C02/carbogen  and  to  ATII  respectively,  and  the  consequence  of 
vasoactivity on tumour blood flow rate.
The effects of the vasoactive agents and anaesthesia on mouse blood pressure were also 
determined in order to aid interpretation of results.
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4.2  Materials and Methods
All animal experiments were  performed in full compliance with government regulations 
and UKCCCR guidelines on animal welfare and were approved by the local Ethical Review 
Committee (Home office license number PPL 70/4552).
4.2.1  Tumours
HT29  human  colorectal  adenocarcinoma  tumour  cells  were  maintained  in  Dulbecco’s 
modified Eagle’s Medium (DMEM, Life Technologies, UK) supplemented with 10% foetal 
calf  serum  (Sigma,  UK),  100  U.ml'1   penicillin  (Sigma,  UK),  100  pg.ml'1   streptomycin 
(Sigma) and 2 mM glutamine (Life Technologies) and incubated in a humidified incubator 
at 37° C in 5% C02/air.
2xl06  cells were implanted subcutaneously on the rear dorsum of female CB17 SQD mice 
aged  10-16  weeks,  briefly  anaesthetised  with  metofane  (methoxyflurane,  Janssen 
Pharmaceutica, Ontario, Canada).  Tumours were selected for scanning approximately 21 
days later at 8-10 mm diameter.
The  murine  adenocarcinoma  NT  (CaNT)  was  maintained  by  passage  between  donor 
animals  (tumour pieces were stored in liquid nitrogen, up to  10 passages from animal to 
animal permitted).  The tumour was implanted subcutaneously on to the rear dorsum of 
10-16 week old female  CBA/Gy f TO mice  (CBA), by injecting 0.05  ml of a cmde cell 
suspension prepared by mechanical dissociation of an excised tumour from a donor animal. 
Tumours were selected for scanning approximately 21 days later at 8-10 mm diameter.
The T138 mouse strain has an inherited predisposition to develop mammary tumours and, 
between 5  and  18  months  of age, >90%  of females develop tumours.  The tumours are 
predominantly  well-differentiated  glandular  or  acinar  adenocarcinomas,  although 
occasionally adenosquamous  carcinomas  and undifferentiated tumours  develop.  Female 
mice were  checked for tumours weekly.  Suitable tumours growing in the flank or groin 
were selected for scanning when approximately 8-10 mm in diameter.  (These tumour sites 
were chosen so that the tumour would not move with respiration).
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4.2.2  Histology: Vascular Maturation Index
Tumours were  excised from mice after BOLD-MRI  imaging (see below) for histological 
analysis.  Mice were killed by cervical dislocation and tumours excised and cut in half in the 
same plane as the MRI slice used for scanning.  One half was fixed in formalin (Sigma- 
Aldrich, UK) and then a central tumour section stained with hematoxylin and eosin (H&E 
-  Sigma-Aldrich, UK)  and for aSMA (Sigma-Aldrich, UK).  The other tumour half was 
placed in zinc fixative for subsequent staining of a central tumour section for CD31 antigen 
(Pharmagen, UK) (see Chapter 3 for method).  Immunohistochemistry was performed by 
Mrs  Frances  Daley,  Gray  Cancer  Institute.  The  vascular  maturation  index  was  then 
calculated for each tumour type (see Chapter 3 for method).
4.2.3  Effect of ATII, air-5% C 02  and carbogen, and anaesthesia on mouse blood 
pressure
SGD, CBA and T138 mice were anaesthetised with 10 mlJkg1  of a mixture of Hypnorm 
(fentanyi citrate 0.315 mg.ml'1  & fluanisone 10 mg.ml"1  - Janssen-Cilag, UK) and Hypnovel 
(midazolam  5  mg.ml'1   -   Phoenix  Pharma,  UK)  diluted  1:1:2  with  water.  Top-up 
anaesthetic was given as an i.p. infusion as required.
The  left  femoral  artery  was  cannulated  and  connected  to  a  physiological  pressure 
transducer (Spectramed, model no. P23XL, Gould Electronics, UK) connected to a chart 
recorder or computer,  in order to  measure  mean arterial blood pressure  (MABP).  The 
effect of ATII  infusion or breathing air-5% C02  or carbogen was then observed.  Mice 
were killed by cervical dislocation at the end of the experiment.
4.2.3.1  Effect of  ATII on mouse blood pressure
After an initial baseline recording, ATII was infused i.v. via a tail vein at 2 pg.kgAmin'1  at a 
concentration  of  10  pg.ml'1   for  approximately  15  minutes.  Blood  pressure  was  then 
recorded for a further 5-10 minutes.  The first two minutes of data following the start of 
the  ATII  infusion was  omitted from analysis  to  allow blood pressure to  stabilise.  The 
average  MABP  before  and  during  ATII  infusion  was  determined  for each  mouse  and 
results compared using a paired Student’s t-test.
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4.23.2  Effect of breathing air- 5% C 02 or carbogen on mouse blood pressure
After an initial baseline recording during which mice breathed air via a mask, air-5% C02
and then carbogen were administered for approximately 8 minutes each at 1 Lmin'1 .  Blood
pressure was then recorded for a further  minutes with the mouse breathing air.  The
first two minutes after the switch from breathing one gas to the next was omitted from
analysis.  The  average MABP was calculated for each treatment block.  Data was then
normalised to the mean pre-treatment value and a one-way analysis of variance (ANOVA)
used to determine if there was a  significant difference in mouse MABP when breathing the
different gas mixtures.
4.23.3  Effect of anaesthesia on mouse blood pressure
In addition, the effect of anaesthesia on mouse blood pressure was determined, using the 
same  anaesthetic  protocol  as  above.  This  work was  performed by Mrs  V Prise  (Gray 
Cancer  Institute),  using  a  non-invasive  tail  cuff  blood  pressure  analysis  system  (Kent 
Scientific  Corporation,  Connecticut,  USA).  MABP  was  recorded  in  unanaesthetised 
animals during anaesthesia.  A paired Student’s t-test was used to determine whether there 
was a significant change in MABP due to anaesthesia.
4.2.4  BOLD-MRI animal studies
Mice were anaesthetised as for the blood pressure experiments.  For the ATII protocol, an 
i.v. catheter was placed in a tail vein for ATII infusion.  Mice were then placed in a 6 cm 
diameter quadrature birdcage coil (Varian, Palo Alto, CA, USA) in a 4.7 Tesla Varian MR 
system.  An  i.p.  infusion  of  Hypnorm,  diluted  1:10  with  water,  was  started  after 
approximately 30 minutes at 3 pl.min1  to maintain a constant level of anaesthesia.  For the 
initial experiments, temperature was maintained using tubing containing circulating warm 
water.  The  mouse’s  rectal  temperature  was  checked  after  scanning  and  any with  a 
temperature  less  than 35°  C were  rejected.  For later experiments, a hot air blower and 
continuous temperature monitoring with a rectal thermocouple was utilised.
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4.2.4.1  B OLD-MRI protocols
Initial  ^-weighted  sagital  and  transverse  scans  were  obtained  for  localisation.  Two 
different BOLD-MRI sequences were used for separate experiments.
A.  A multi-echo, single-slice sequence comprising 8 images acquired every minute for 
32 minutes: TE 5-40 ms in 5 ms steps, TR 117 ms, flip angle 45°, slice thickness 1 mm, 
spatial resolution 0.16 x 0.31 mm, FOV 35 x 40 mm.
B.  A single-echo, multi-slice sequence comprising 1 image acquired per minute for 32 
minutes with 9 transverse slices (7 through tumour and 2 through kidney): TE 20 ms, 
TR 600 ms, flip angle 20°, slice thickness 1 mm, spatial resolution 0.1 x 0.4 mm, FOV 
35 x 40 mm, total imaging time 32 min).
Initial experiments  were  done with the  multi-echo, single-slice  sequence  (A)  from which 
quantitative  images  (T2* and Aq )  as well as  signal intensity can be generated (see below). 
The  intention was to obtain values for T2* and Aq  in order to discriminate between any 
change in oxygenation from change in blood flow (see Section 1.5.4).  However, on initial 
analysis, there was a problem with data fitting such that there was correlation between T2* 
and  Aq ,  whereas  they should  be  independent  variables.  Therefore,  it  was  decided  to 
continue with the single-echo, multi-slice sequence (B).  Only signal intensity data could be 
obtained from this sequence  (so change in oxygenation and flow could not be separated) 
but it had the  advantage  of being a multi-slice  sequence, so  normal tissue  (kidney)  data 
could also be acquired.  Subsequently, improved analysis software became available and the 
data from the multi-echo, single-slice sequence (A) was re-analysed.
ATII protocol: after an initial 8 background images had been acquired, ATII (Sigma, UK) 
was infused at 2 pg.kgVmin1  i.v. (at 10 pg.ml'1  concentration) for 16 images, then a further 
8 images were acquired after stopping the ATII infusion.  This dose-rate and concentration 
of ATII has been used previously in mice (Hirst et al., 1991; Trotter et al., 1991).
Gas breathing protocol: scanning time was divided into 8 minute treatment periods with 
the mouse breathing air, air-5%  C02, carbogen, then air again for the  1st, 2nd, 3rd  and 4th 
treatment periods  respectively -  all at  1  Lmin1   (all gases  obtained from BOC,  UK).  A 
vacuum-based gas  scavenger was used to minimise changes in oxygen content within the 
magnet bore.
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Experiments using the gas breathing protocol were delayed until the gas-scavenger could 
be acquired.  As preliminary results with the single-echo multi-slice sequence were negative 
for CaNT, the experiment was not repeated using the multi-echo single-slice protocol for 
this tumour.
4.2A.2  Image Analysis 
Multi-echo single-slice sequence
Images were processed using Matlab version 5  (The Mathworks, Nantick, MA USA).  A 
region of interest (ROI) was drawn around the tumour using the initial Tr weighted image 
(Figure  4.1).  T2* (ms) and Aq  (arbitrary units) pixel-maps were then calculated for each 
time-point using in-house computer software  (Time Resolved Image Analysis, version 2) 
from the equation below - see Section 1.5.4.
TE
S = A0e  T > *
The  images  produced at odd and even echo  times  were  symmetrical.  Alternate  images 
were then reversed so that the whole series of images could be used for T2* calculation. 
However, when this was done, it was observed that those images produced at odd echo 
times  had different signal intensity to those produced at even echo times  (i.e. they were 
predicting different Aq  values)  and also had a slightly different position.  Therefore, only 
one set of echo times could be used for T2* calculation (the odd echo times: TE 5, 15, 25, 
and 35 ms).
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Figure 4.1: A: A natom ical T i-w eighted im age (baseline, pre-contrast) show ing transverse section 
through SC ID  m ouse w ith dorsal subcutaneous tum our (HT29).  B: corresponding B O L D  image
(anim al breathing air).
A:
Image blocks 
used for analysis
Image number__ 8
ATII
16 24 32
B:
Image blocks  __
used for analysis
Image number__
air 5% C 0 2 carbogen air
8 16 24 32
Figure 4.2 D iagram  to show  B O L D -M R I protocol for the A TII (A) and gas breathing
experim ents  (B).
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Animated  GIF  images  were  generated  using  ImageMagick  (ImageMagick™  6.0.4 
www.imagemagick.org)  and  used  to  check  for  movement  with  the  GIMP  animation 
playback feature (GNU Image Manipulation Program, www.gimp.orgk  Individual images, 
during  which  movement  was  occurring,  were  excluded  and  the  ROI  re-positioned  for 
subsequent  images,  if  necessary.  Animals  were  excluded  from  analysis  if  there  was 
movement in and out of the imaging plane throughout the experiment.
For both protocols the first image was not used (as  it was not fully saturated).  For the 
ATII  protocol,  the  1st  four images  following  onset  of ATII  infusion  and the  2  images 
immediately after the end of the infusion were excluded (to allow for the ATII infusion to 
take effect/wear off).  The remaining images during the ATII infusion were divided into 3 
treatment blocks  of 4  images  each for analysis.  For the  gas-breathing protocol, the  1st 
image  of  each  of the  4  treatment  blocks  (air,  air-5%  C02,  caibogen,  air)  was  excluded 
(Figure 4.2).
The median values  of tumour T2* and \  were determined for each image and then the 
mean of these median values obtained for each treatment block.  The mean values for each 
treatment block were then averaged to obtain mean values for each tumour group and then 
normalised to the mean baseline value.  T2* and Aq values for each treatment block were 
then  compared  using  ANOVA.  If  the  ANOVA  was  significant  (p<0.05),  then  an 
appropriate post-test comparison of individual means was performed to look for significant 
differences between treatment blocks.
In addition, tumour response on an individual pixel basis was evaluated -  as response in a 
proportion of vessels within a tumour might not be detected if T2* and Aq  are calculated 
for the whole tumour ROI.  The percentage of individual pixels with significantly higher or 
lower values of T2* and Aq  for each treatment block compared to baseline were measured 
(using a t-test for unknown and unequal variances).
Single-echo, multi-slice sequence
Images  were  processed as  above using Matlab version 5  (The Mathworks, Nantick, MA 
USA).  ROIs  were  drawn  around the  tumour and  kidney using the  initial Tr weighted 
image.  Animated GIF images were used to check for movement as before.  The  mean 
signal intensity at each time-point was calculated for the central tumour slice (slice 6), for 5 
central tumour slices concatenated together (slices 4-8) and for a single kidney slice (slice
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2).  Images at the start of treatment blocks were excluded as for the multi-echo, single-slice 
protocols (see above).  Mean signal intensity was then determined for each treatment block 
and analysed as above.
4.2.5  Intmvital Microscopy
Mice  were  anaesthetised  and  ATII  and  air-5%  C02 /carbogen  administered  as  per the 
BOLD-MRI  protocol.  In  addition,  a control group was  used for each protocol (saline 
infusion for ATII protocol and air for gas breathing protocol) so that the effect of time and 
repeated observations on parameter stability could be assessed.
’ Window chambers were surgically implanted into the dorsal skin of male SQD and CBA 
mice  weighing  — 30-35  g,  for  HT29  and  CaNT  tumours  respectively.  The  window 
chambers consisted of a double-sided aluminium frame containing parallel glass windows 5 
mm in  diameter and  held  -0.35  -  0.4  mm apart,  producing  a cylindrical chamber  (see 
Figure 4.3).  Surgery was carried out under general anaesthesia using i.p. injection of 0.2 ml 
of a Hypnorm and Hypnovel mixture, diluted 1:1:2 with water.  Animals were kept warm 
using  heated  pads  throughout  the  surgical  procedure  and  aseptic  technique  was  used 
throughout.  The dorsal skin was shaved and remaining stubble removed with a depilatory 
cream (Nair® , Carter-Wallis ltd, Folkestone, UK).  The window chamber frame, with one 
glass  window already in place,  was  secured to  the  dorsal  skin  flap  using  stainless  steel 
screws  and  sutures,  sandwiching  a  double  layer  of  skin.  A  circular  full  skin  section 
approximately  15  mm  in  diameter  was  surgically removed,  exposing  the  fascia  of  the 
opposing skin layer.  This  fascia was  removed and tumour fragments  of  — 1  mm in size 
were placed onto the exposed subcutaneous skeletal muscle.  Subcutaneous transplants of 
HT29 and CaNT tumours were used as donors.  The window chamber was then filled with 
sterile saline and the second glass window secured in place with a brass clip.  Animals were 
given an i.p. injection of 0.5 ml dextrose-saline and a s.c. injection of 0.1 ml (0.3 mg.ml'1  
concentration) of buprenorphine (® Vetergesic, Reckitt & Coleman Products ltd, Hull, UK) 
immediately after surgery,  to  provide  post-op hydration and analgesia respectively.  1% 
chloramphenicol ointment (Martindale Pharmaceuticals ltd, Romford, UK) was applied to 
the  sutures  and screws  to prevent infection.  Animals were kept on a warmed pad until 
recovery from anaesthesia.
Subsequently, animals were  kept in a warm room at  — 30° C (humidity 55 +10%).  They 
were fed a soft diet and weighed and checked daily until the day of the experiment.
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tumour aluminium frame
B
glass  window
tumour
aluminium frame
dorsal skin flap
Figure 4.3: A: w indow  cham ber secured in m ouse dorsal skin flap  (from  (Jain et al, 2002); B: 
diagram  to show  w indow  cham ber in cross-secdon.  C: H T29 tum our grow ing in cham ber, viewed
w ith x2.5 objective.
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4.2.5.1  Method for labelling of red blood cells with Dil
The  fluorescent  marker,  Dil  (1, T- dioctadecyl- 3,3,3 ’,3  tetramethylindocarbocyanine
perchlorate,  D-282,  Molecular  Probes  Europe  BV,  Leiden,  The  Netherlands),  which 
effectively binds to cell membranes (Unthank et al., 1993) was dissolved in ethanol (5 mg 
Dil in 10 ml in ethanol) and then stored in Eppendorf tubes (in 1 ml aliquots), wrapped in 
aluminium foil, at -20° C
Blood was obtained under deep terminal anaesthesia.  Donor SCID and CBA mice were 
anaesthetised with Metofane  (methoxyflurane, Janssen Pharmaceutica,  Ontario,  Canada). 
The chest cavity was then opened, the great vessels  cut and blood (-0.5-1  ml)  collected 
from the chest cavity using a heparinised syringe.
Red blood cells were labelled with Dil following published protocols (Kimura et al., 1996; 
Unthank et al., 1993).  Red blood cells were separated from plasma by centrifugation (3000 
rpm at 4°C for 5 min), the buffy coat (white blood cells) removed by aspiration, and the red 
blood cells  washed in sterile  phosphate-buffed saline  (PBS).  This  process  was  repeated 
twice.  50  pi  of  packed  red  blood  cells  were  re-suspended  in  5  ml  of PBS  and  then 
incubated with 50 pi of Dil for 30 minutes at room temperature.  After incubation, any 
unbound dye was removed by centrifugation (3000 rpm at 4° C for 10 min), aspiration and 
two washings with PBS.  The Dil-red blood cell pellet was then re-suspended in 0.95 ml of 
PBS to give  a concentration of 50  pi Dil-labelled red blood cells.ml'1 .  The labelled red 
blood cells were stored in Eppendorf tubes, wrapped in aluminium foil, at 4° C and used 
within 4 days.  Viability and uniformity of labelling were checked by microscopy prior to 
use.
4.2.5.2  Intrautal micros copy experiments
Intravital microscopy was carried out when tumours had reached >2 mm in diameter (— 10- 
15 days after surgery).  An inverted Nikon Diaphot 200 fluorescence microscope was used 
that  had  a  stage  modified  in-house  for taking  mice.  Animals  were  anaesthetised with 
Hypnorm and midazolam as above, and top-up anaesthesia given as per the BOLD-MRI 
experiments  via an  i.p.  infusion.  Animals  were  then placed on the  stage  such that the 
window chamber was located centrally above the objectives using locating screws.  Rectal 
temperature  was  maintained  between  35  and  37  °C throughout the  experiment  using  a 
thermostatically controlled heating pad beneath the animal, an infrared overhead lamp and 
gauze padding.
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Before the start of each experiment, an aliquot of Dil (-0.05 ml) was injected i.v.  Tumour 
preparations  were  alternately viewed under transmitted visible  light  (for the  subsequent 
measurement  of vessel  diameter)  and under fluorescence  s- illumination using  a  100-W 
mercury arc  lamp  (for the  subsequent measurement of red blood cell flux and velocity 
under fluorescence conditions).  Fluorescence was set up to excite and detect the emissions 
from  red  blood  cells  labelled  with  Dil  (550  and  565  nm  wavelengths  respectively. 
Window chamber preparations  were viewed under transmitted light using x2.5, xlO and 
x20 magnification objectives.  A tumour region of interest (ROI) was then selected using 
the x20 magnification objective that included a range of differently sized vessels in which 
red blood cells could be viewed clearly under visible and fluorescence illumination.  At each 
time point, this ROI was monitored for 30 s using transmitted light and then for 60 s using 
s-iUumination  using  the  x20  magnification  objective.  Observations  were  recorded  in a 
digital format, using a Sony DSR-30P digital videocassette recorder, for subsequent off-line 
analysis  (25 frames per second).  If possible, a skin arteriole within the window chamber 
was  also  viewed under transmitted light at each time  point  (for  ~5  s)  so that diameter 
measurements could be made.  Skin arterioles were identified by their shape, direction of 
blood flow and close association with veins.  XY stage micrometers could be used to return 
to  a  specific  ROI  (to  within  <10  pm)  when required.  Return to a specific  focal plane 
within the ROI  (Z  direction)  could be ensured by reference to specific vascular features 
within the field of view.
For the  ATII  protocol,  experiments  were  performed using  both the  HT29  and  CaNT 
tumours.  After baseline  observations  had been  made,  either ATII  (2  pg.kg'1 .min'1 ,  10 
pg.ml1  concentration, the same dose as used for the BOLD-MRI experiments) or saline (at 
same infusion rate as for ATII) was infused for 15 minutes.  Observations were then made 
at  5,  9,  13  and  20  minutes  after the  start  of the  infusion  (the  final observation was  5 
minutes after the infusion had ended).
For the  gas-breathing protocol, experiments were performed using HT29  tumours  only, 
because  of the  difficulties  encountered with the  CaNT tumours in the ATII studies  (see 
Results).  Animals  breathed air at  1  Lrnin1   through a mask while baseline observations 
were  made.  For the  treatment  group,  the  gas  was  then  switched to  air-5%  C02, then 
caibogen,  then  back  to  air  again  for  periods  of  8  minutes  each.  The  control  group 
breathed air throughout the experiment.  Observations were made 5 minutes into each gas-
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breathing period (e.g. at 5,  13  and 21  minutes).  Observations were made in the control 
group at the same times.
After the  experiment was  completed,  animals were  killed by cervical dislocation.  Some 
tumours were placed in formalin and subsequently stained for aSMA for comparison with 
subcutaneous tumours.
4.2.5.3  Data analys is fo r intravital m icros copy
The  analysis  was  performed  off-line  using  the  video  recordings  made  during  the 
experiments.  Measurements were made with the aid of an image overlay hardware system 
(DAVID,  Dimensional Analysis  and Video  Insertion Device, Brian Reece  Scientific  ltd, 
UK).  This was calibrated using microscope distance standards (1, 10 and 100 pm) so that 
the distance between any pairs of selected pixels could be directly read out on the image, in 
microns.  A transparency was placed over the video screen so those vessels  suitable for 
analysis could be marked and tracked for subsequent time points (Figure 4.4).  Usually 3-4 
vessels were chosen per ROI.  Suitable vessels were considered to be  >10 pm in diameter 
and contained flowing red cells.
Average  diameters  were  calculated  from  5  measurements  made  per vessel.  For  each 
measurement, a line was drawn perpendicular to the red blood cell column and its length 
measured  using  the  ‘DAVID’  system,  under  transmitted  light  conditions.  Diameter 
measurements were also made for a skin arteriole, where possible.
Red blood cell velocity and flux in all selected vessels were calculated from recorded data 
on fluorescence e-ihumination.  At least 10 fluorescent red blood cells were monitored for 
velocity measurements  over 60  s  of recorded images.  Velocity was  calculated in puts'1  
from the  number of video  frames  taken  for each red blood cell to travel between two 
points of measured distance, marked on the vessel image.  If, at subsequent time points, no 
red blood cells were  observed within the  observation period, a value of 0.85  pirns'1  was 
assumed  -   the  maximum  possible  velocity  of  red  cells  if  none  appear  during  the 
observation period  (Tozer et al., 2001).  Changes  in red blood cell flux were  calculated 
from the  number of  fluorescent  red blood  cells  crossing a  single  point  marked on the 
vessel  image  within  the  observation  period  (~1  minute).  Blood  flow  rates  through 
individual  vessels  were  calculated  from  the  red  blood  cell  velocity  and  diameter
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m easu rem en ts  d escrib ed   ab o v e  (b lo od   flow   rate  =   velocity  x  TC/4  x  (diam eter)2).  T his 
assum es  th at  th e  red   b lo o d   cells  are  travelling  w ith  bulk  plasm a  flow .  A   few   red  cells, 
w hich  w ere  o b serv ed   to   be  travelling  slow er  th an   the  m ajority,  w ithin  a  particular  vessel, 
w ere n o t u sed   fo r velocity calculations.
4►ZOOM  XI  OBJ  X2 5
AVERAGE  19 1:43  UM  
COUNT  105
Figure 4.4: video intravital m icroscopy im ages view ed w ith transm itted (upper) and UV light 
(lower), w ith D A V ID  softw are, to show  m ethod for identifying vessels for m easurem ent.  The 
lines dem arcate  the section o f vessel used for velocity m easurem ents, arrows show  direction of
flow  (H T29  tum our show n).
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4.2.5.4  Statis tics for intravital micros copy
Statistical analysis was  carried out using JMP Statistics  (version 3.2.6, SAS Institute, Inc, 
Cary, North Carolina, USA).  Intravital microscopy data were fitted to a multivariate model 
(MANOVA) with repeated measures to determine the effects of the different treatments 
on vessel diameters  and red blood cell velocity, flux and blood flow rate.  Analysis was 
performed using the percentage change of values from baseline rather than absolute values. 
Responses  were  fitted  to  effects  using  least  squares.  The  effect  of  variation  between 
individual vessels was accounted for by using a nested design, and any variation between 
animals was  described as  random.  Differences  in response caused by treatment or time 
were tested for significance  using an approximate F test based on comparison with the 
matrix  for  the  hypothesis  sum  of  squares  and  cross  products  with  the  matrix  of  the 
residual.  Differences  in  response  were  described  as  significant  if  the  probability 
corresponding to the F value was  0.05.
It  is  not  possible  to  represent  the  MANOVA  analysis  using  simple  error  bars.  For 
graphical presentation, the mean parameter value was taken for each mouse and then the 
overall mean value plus the standard error of the mean determined for each time-point.
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4.3  Results
4.3.1  Histology: Vascular maturation index
H&E  sections  showed  HT29  tumours  to  be  moderately-to-well  differentiated,  well- 
vascularised tumours.  In comparison, CaNT tumours were poorly differentiated and less 
well vascularised but tended to have larger, more sinusoidal vessels than the HT29.  T138 
tumours  showed  variable  differentiation  and  the  majority had  cystic  areas  and  areas  of 
haemorrhagic  necrosis.  The  differences  in  vascularisation  between  these  tumours  are 
bome out by their functional vascular volumes (measured with Hoechst 33342): 6.3 ±0.4% 
(9 animals), 4.2 ±0.2% (10 animals) and 8.9 ±1.1% (15 animals) for HT29, CaNT and T138 
respectively -  Dr SA Hill, personal communication.
Vascular maturation index varied widely between these tumour types: 68.2 ± 7.2%,  1.6 ± 
0.6% and 11.5 ± 2.3% for HT29, CaNT and T138 respectively (Figure 4.5).  Figure 4.6 
shows  H&E  sections  of the  three  tumours.  Histological sections  demonstrating  aSMA 
and CD31 antigen staining are shown in Figure 4.7.
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Figure 4.5: Vascular maturation index for HT29, CaNT and T138 tumours
■ HT29
□ CaNT
□ T138
vascular maturation index
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w m * § .
Figure 4.6:  H & E  histological sections. A: H T29, B: C aN T  and C: T138 tum ours.  The bar 
represents  100 pm .  All sections view ed w ith x20 m agnification objective.
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Figure 4.7: H istological sections to show  OtSMA and CD31  staining.  A: H T29, OcSMA; B: H T29, 
CD 31  antigen; C: C aN T , CXSMA; D: C aN T , C D 3 antigen, E: T138 OtSMA; F: T138, CD31  antigen. 
Bar represents  100 pm .  All sections view ed w ith x20 m agnification objective.
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4.3.2  The effect of treatment on mouse MABP
Figure 4.8 shows the effects on MABP of ATII infusion (A), breathing air-5% C02  and 
carbogen  (B)  in  anaesthetised  mice,  and the  effects  of  anaesthesia  (C).  For graphical 
presentation, the average MABP for each mouse strain is shown at each time point.
There was a significant increase in mouse MABP during ATII infusion for all three mouse 
strains.  Blood pressure rose rapidly following onset, remained stable during ATII infusion 
then decreased rapidly after termination of the ATII infusion.  The average time for blood 
pressure to rise following the start of the ATII infusion was 2 minutes (range 1-3 minutes). 
The average time for blood pressure to fall following the end of the ATII infusion was 2.5 
minutes (range 1-5 minutes) (Figure 4.8 A).
There was no significant change in average MABP when breathing air-5% C02  or carbogen 
compared to  breathing air alone for any of the three  mouse strains  (ANOVA)  or when 
individual treatment blocks were compared to baseline values (control) (Figure 4.8 B).
Induction  of  anaesthesia  caused  a  significant  decrease  in  MABP  for  all  3  mice  strains 
(-27%, -16% and -35% for T138, SQD and CBA mice respectively) which then remained 
stable  for the  rest  of  the  experiment  (Figure  4.7  C).  Average  MABP values  for un­
anaesthetised and anaesthetised mice MABP are shown in Table 4.1.  CBA MABP (both 
anaesthetised and unanaesthetised) was significantly lower than that of SQD or T138 mice.
T138 SCID CBA
Unanaesthetised, tail cuff 118.2 ±7.3 121.1 ±2.7 96.8 ±3.9
Anaesthetised, tail cuff 87.9 ±3.0 101.4 ±3.3 63.5 ±1.9
Anaesthetised, femoral artery 
cannulation (prior to ATII)
71.7 ±2.4 95.3 ±9.3 61.6 ±3.7
Anaesthetised, femoral artery 
cannulation (prior to carbogen)
64.3 ±0.8 90.4 ±1.1 59.8 ±1.0
Table 4.1: Comparison of baseline MABP (in mmHg ± 1 standard error).  There was a significant 
difference between MABP in anaesthetised and unanaesthetised mice (tail cuff experiment) for all
three mouse types (p<0.05).
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Figure 4.8 A: The effect of ATII infusion on mouse MABP.  The graph is truncated during ATII infusion 
due to variable infusion times.  B: Effect of breathing air-5% CO 2 or carbogen on mouse MABP. C: MABP 
before (time 0) and during anaesthesia.  Graphs show mean +SEM
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4.3.3.1  Multi-echo single slice sequence: ATII protocol
A few individual images had to be excluded as there was movement in and out of plane 
when images were viewed using GIMP software (mean 2 images per mouse, range 0-6).
The average baseline values for T2* (the mean of the median ROI value for each animal) 
were 11.1 ±1.6, 13.7 ±2.4, 12.9 ±3.0 and 7.7 ms for T138, HT29 and CaNT tumours and 
normal kidney (from one of the  Tl38s)  respectively,  (Aq  is  in arbitrary units so baseline 
values were normalised to 100, see Methods).
Baseline tumour R2* values (obtained by taking the reciprocal of the median baseline T2* 
values  and then averaging for each tumour group)  were  77.3  ±9.9, 90.7 ±11.4 and 75.5 
±10.5 s'1  for HT29, CaNT and T138 respectively.  These are similar to R2* values at 4.7 T 
for other tumours quoted in the literature (Robinson et al., 2003).
There were no significant change in T2* or Aq  as a result of ATII infusion on ANOVA for 
any tumour type  (n=6  for each  tumour group),  although  there  was  a  trend towards  a 
decrease in Aq  in response to ATII for HT29 and an increase in Aq  in response to ATII for 
CaNT (Figure  4.9).  In contrast, Aq  decreased to  -80% in the section of normal kidney 
imaged (see above).
The percentage of individual pixels that had significantly higher or lower values of T2* and 
Aq   during  ATII  infusion  compared to  baseline  were  measured,  but no  clear pattern  of 
response was seen.
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Figure 4.9: Mean percentage chage from baseline for T 2* and Ao for the ATII protocol (multi­
echo, single slice sequence).  Graphs show mean +SEM.
4.3.3.2  Multi-echo single slice sequence: gas breathing protocol
Three SCID  and  two T138 mice were  excluded  from the gas-breathing study as  there was
movement  in  and  out  o f plane when  the images  were viewed using GIMP  software.  No 
individual images had to be excluded.
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For the gas-breathing protocol, the average baseline values for X,* (the mean of the median 
ROI  value  for  each  animal)  were  27.3  ±8.0  and  19.8  ±6.8  ms  for  T138  and  HT29 
respectively.  Baseline R,* values were 48.6 ±11.0 and 66.7 ±12.3  s1   for T138  and HT29 
respectively.  Again,  there was  no  significant  change in T2*  or A0  with  breathing air-5% 
C 02 or carbogen compared to baseline for any tumour type (n=5 for each group)  (Figure 
4.10).
I he percentage of individual pixels that had significantly higher or lower values of TA and 
A0 during air-5% C02  and carbogen compared to baseline were measured —  but again no 
clear pattern of response was seen.
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Figure 4.10: M ean percentage change in T 2* and An for gas-breatliing protocol com pared to 
baseline  (m ulti-slice, single echo sequence).  G raphs show m ean ±SEM .
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4.3.33  Single-echo multi-slice sequence: A TII protocol 
No animals or individual images had to be excluded due to movement.
There was no significant change in BOLD signal intensity (TR=600 ms, TE= 20 ms, a= 
20°) for HT29 (n=6), CaNT (n=6) or T138 (n=5) tumours in response to ATII.  There was 
no difference between tumour response for the single central slice and when averaged over 
5 slices.  However, there was a significant decrease in BOLD signal intensity in the kidney 
for all three mice strains.  Figure 4.11 (A) shows the mean percentage change in BOLD 
signal intensity compared to baseline for the three tumour types and for kidney.
Figures 4.12 & 13 show a series of BOLD signal intensity images before, during and after 
ATII infusion for a HT29 tumour ROI and a kidney ROI respectively.
4.3.3.4  Single-echo multi-slice: gas breathing protocol 
No animals or individual images had to be excluded due to movement.
There was an increase in BOLD signal intensity for T138 tumours in response to breathing 
carbogen  compared  to  baseline  that  just  reached  significance  on  post-test  analysis 
(p =0.046).  However, no other significant changes were seen for the different tumours or 
for kidney in response to breathing air-5% C02  or carbogen.  Figure 4.11 (B) shows the 
mean  percentage  change  in  BOLD  signal  intensity compared to  baseline  for the  three 
tumour types (n=6 for each treatment group).
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Figure 4.11: Mean percentage change in signal intensity for ATII protocol (A) and gas-breathing 
protocol (B)  (single echo, multi-slice sequence).  Graphs show mean +SEM.
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Figure 4.12: Images and graph to show BOLD signal intensity change with ATII infusion for 
HT29 tumour ROI (same animal as in Figure 4.13).
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Figure 4.13: Images and graph to show BOLD signal intensity change with ATII infusion for 
kidney ROI (same animal as in Figure 4.13).
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4.3.4  Intravital Microscopy results
The average time from window chamber surgery to intravital microscopy was  13.5 (±0.5) 
days for HT29 tumours and 11.3 (±0.3) days for CaNT tumours.
4.3.4.1  Comparis o n of HT29 and CaNT vas culature
HT29 tumour vessels were clearly delineated with long straight sections between branches. 
On fluorescence  s-illumination,  fluorescent red cells  could be  seen clearly at each time 
point.  CaNT tumour vessels were less clearly delineated and more tortuous, moving in and 
out of the  imaging plane.  The  CaNT tumour vessels  had more variable  diameters  and, 
sometimes, what initially looked like a single vessel turned out to be several smaller vessels 
entangled together.  Consequently,  labelled-red  cells  could  not  be  seen  as  clearly as  in 
HT29  tumour vessels  on  fluorescence  s-iUumination.  In  some  experiments,  flux  and 
velocity measurements were very low at baseline (probably due to CBA low blood pressure 
under anaesthesia -  see Discussion) and then increased considerably during ATII infusion 
such that red cells were taking <0.04 seconds  (one video frame) to pass between the two 
measurement points.  As  a  result, they became  smeared and  could not be  seen clearly. 
Because  of these  difficulties,  it  was  decided  not to  use  the  CaNT tumour for the  gas 
breathing protocol.
4.3.4.2  ATII protocol
Baseline  parameters  results  are  given in Table  4.2  for HT29  and CaNT tumours.  The 
number of animals and vessels used for the analysis are given in Table 4.3.  There were no 
significant differences between treatment and control groups (ATII and saline) for baseline 
parameters for HT29 or CaNT, except that the CaNT tumours were significantly larger for 
the saline group than for the ATII group (p<0.05) (Table 4.2).
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Tumour 
surface area 
(mm2 )
Tumour vessel 
diameter (|tm)
Skin arteriole 
diameter (|tm)
Tumour vessel 
flux (s'1 )
Tumour vessel 
velocity 
((im.s1 )
HT29
ATII
Saline
6.3 (±0.6) 
7.6 (±0.1.3)
18.1 (±1.1) 
15.7 (±1.2)
80.3 (±8.2) 
84.0 (±20.9)
0.84 (±0.14) 
0.67 (±0.11)
655 (±106) 
557 (±59)
CaNT
ATII
Saline
6.2 (±0.5)* 
8.1 (±0.5)*
23.7 (±1.5)
22.8 (±1.6)
101.6 (±16.1) 
101.7 (±10.4)
0.70 (±0.12) 
1.22 (±0.21)
541 (±65) 
489 (±59)
Table 4.2:  Intravital microscopy: baseline values for ATII protocol (±one standard error of the 
mean), ^significant difference between treatment groups.  Mean parameter values are for the 
vessels chosen for measurement, not the whole tumour.
Tumour vessel Skin arteriole Tumour vessel
diameter diameter flux & velocity
HT29
ATII 8(32) 6 7(20)
Saline 7(24) 4 7(20)
CaNT
ATII 12 (29) 8 7(17)
Saline 12 (35) 8 9(24)
Table 4.3:  Total animal and vessel numbers for ATII protocol  Vessel numbers are given in 
brackets.  Skin arteriole diameter measurements were made on 1 vessel per animal.
Figure 4.14 shows examples of the effect of ATII on vessel diameter for HT29, CaNT and 
a  normal  skin  arteriole.  HT29  tumour  vessels  vasoconstrict,  become  paler and  some 
disappear in response to ATII.  In contrast, CaNT tumour vessels vasodilate and become 
hyperaemic  in  response  to  ATII.  For both  SQD  and CBA mice,  skin arterioles  were 
observed to vasoconstrict and become paler in response to ATII.
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Figure 4.14: Intravital M icroscopy im ages show ing the effects o f A TII infusion using x20 
m agnification objective.  A: H T 29 pre-A T II, B:  H T 29 during A TII  infusion, C: CaN T pre-A TII, 
D : C aN T  during A T II infusion, E: skin arteriole pre-A T II, F: skin arteriole during A TII (from  a
C aN T  tum our preparation).
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There  was  a  significant  decrease  (p<0.05,  MANOVA)  in  mean  diameter  during  ATII 
infusion  compared  to  saline  control  in  both  HT29  tumour  vessels  and  normal  skin 
arterioles in the same window chamber preparation (Figure 4.15).  Therefore, both HT29 
tumour vessels and normal skin arterioles were capable of vasoconstriction in response to 
ATII.
In contrast, CaNT tumour vessels did not respond to ATII.  While there was a significant 
decrease in normal skin arteriole diameter in response to ATII (p 0.0001, MANOVA), as 
above, the  CaNT tumour vessels  tended to  increase  in diameter, although this was  not 
significant with the numbers used (Figure 4.16).
There was no significant change in HT29 tumour vessel red cell velocity or flux in response 
to  ATII  compared  to  saline  controls  (Figure  4.15).  However,  there  was  a  significant 
decrease  in tumour blood flow rate  (pO.Ol,  MANOVA)  that persisted after the  ATII 
infusion had been terminated.
For CaNT tumour vessels, there was a tendency for red cell flux, velocity and blood flow 
rate to  increase  in response to ATII  compared with saline  controls  (Figure  4.16).  This 
reached significance for individual time points (0 vs 9 and 0 vs 13 minutes for velocity, flux 
and blood flow rates, all p <0.05, MANOVA) but not over the whole analysis period.
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Figure 4.15: Mean percentage change in HT29 parameters for ATII protocol.
Graphs show mean +SEM.
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Figure 4.16: Mean percentage change in CaNT parameters for ATII protocol.  Graphs show
mean +SEM
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43.4.3  Gas  breathing protocol (H T29 only)
There were  no  significant differences  between treatment groups  for baseline parameters 
(Table 4.4).  The total number of animals and vessels used are given in Table 4.5.
Tumour 
surface 
area (mm2 )
Tumour vessel 
diameter (pm)
Skin arteriole 
diameter (pm)
Tumour 
vessel flux
(s-1 )
Tumour 
vessel velocity 
(pm.s1 )
Treatment
Control
5.8 (±0.5) 
5.6 (±0.5)
16.3 (±0.9) 
16.1 (±1.2)
57.2 (±6.6) 
74.5 (±10.3)
0.63 (±0.13) 
0.67 (±0.15)
490 (±67) 
617 (±65)
Table 4.4 Baseline parameters for gas breathing protocol (HT29 onl)) (±one standard error of the 
mean).  Treatment: air-5% CO2/carbogen; Control: breathing air throughout.  Mean parameter 
values are for the vessels chosen for measurement, not the whole tumour.
Tumour vessel Skin arteriole diameter Tumour vessel flux &
diameter velocity
Treatment 9 (32) 5 9(28)
Control 8(24) 5 6(20)
Table 4.5 Mouse and vessel numbers used for gas breathing protocol (HT29 onl}).
Figure 4.17 shows the mean percentage change from baseline in diameter, red cell velocity 
and flux, and blood flow rate for HT29 tumour vessels in response to the mouse breathing 
air- 5% C02 /  carbogen or air throughout.
There  was  no  significant  change  in  HT29  tumour  vessel  diameter  or  in  normal  skin 
arteriole  diameter in  response  to  breathing air-5%  C02   or carbogen compared with air- 
breathing controls  (MANOVA)  (Figure 4.17).  There was a significant decrease in HT29 
red cell flux in response to breathing air-5% C02  (p<0.05, MANOVA) but not in response 
to carbogen, compared to air-breathing controls  (Figure  4.17).  There was no significant 
change  in  red  cell velocity or blood  flow rate  in  HT29  tumour vessels  in  response  to 
breathing air-5% C 02  or carbogen compared with air-breathing controls (Figure 4.17).
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HT29: m ean percentage change
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Figure 4.17: Mean percentage change in HT29 parameters on gas breathing protocol.  Graphs
show mean +SEM.
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4.3.4.4  Intra vital Microscopy: Histology
Vessels  from  HT29  tumours  grown  in  window  chambers  showed  strong  staining  for 
(XSMA whereas vessels  from CaNT  tumour  did not, confirming the presence of mature 
vessels  in  the  HT29  window  chamber  preparation  (Figure  4.18),  as  found  for 
subcutaneous tumours (see Figure 4.7).
Figure 4.18: OCSMA staining of A: HT29 and B:  CaNT tumours taken from window chamber 
preparations.  Taken with x20 magnification objective.  Bar shows 100 pm.
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4A  Discussion
4.4.1  T138 tumours
The T138 tumours were included in the protocol as they arise spontaneously and so are 
more comparable to the clinical situation than xenografted tumours in this respect.  They 
have a variable degree of aSMA staining, but it was unfortunately not possible to compare 
BOLD responses and vascular maturation index for individual tumours as the amount of 
haemorrhage  and  necrosis  led  to  doubts  concerning  the  accuracy  of  the  vascular 
maturation index measurement.  There would have to be confidence in measurements in 
individual tumours  (rather than averaged as  a group)  for further work to continue using 
T138 mice.  Since data from individual tumours were not considered to be reliable, these 
mice were not used for intravital microscopy.
4.4.2  Mouse MABP measurements in response to ATII, air-5% C02/carbogen 
and anaesthesia
Mouse MABP increased rapidly in response to ATII and decreased rapidly following the 
end of the infusion.  The time course and magnitude of the change in MABP in response 
to ATII infusion is similar to that reported previously (Trotter et al., 1991).
Breathing air-5%  C 02  or carbogen had no effect on mouse MABP.  Other authors have 
reported  either  no  response  or  small  increases  in  blood  pressure  in  anaesthetised  rats 
breathing carbogen (Brizel et al.,  1995; Dewhirst et al.,  1996; Dunn et al,  1999; Iadecola, 
1992; Lanzen et al., 1998).
The values for MABP obtained from un-anaesthetised, restrained T138 and SQD mice are 
similar to those quoted by other authors for other mouse strains (Cullen & Walker, 1985; 
Mattson, 1998; Menke & Vaupel, 1988).  However, the average MABP in un-anaesthetised 
CBA mice was  — 20%  lower.  MABP decreased with anaesthesia for all three strains but 
was pronounced in the CBA mice, such that their average MABP when anaesthetised was 
only 63.5  mmHg.  The  inherent  low blood  pressure  of  CBA mice  and their particular 
sensitivity to anaesthesia might have affected the ability of BOLD-MRI to detect a CaNT 
tumour response to the vasoactive agents tested (see below).
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4.4.3  Tumour vessel response to angiotensin II as measured by BOLD-MRI and 
intmvital microscopy
A differential response to ATII between HT29 and CaNT tumours could not be detected 
using  BOLD-MRI  despite  their  very different  vascular  maturation  indices.  However, 
BOLD-MRI could detect a response to ATII in kidney as a significant decrease in BOLD 
signal  intensity was  seen  (and  in  \   and  T2*  for the  single  kidney section  imaged)  -  
consistent with a decrease in blood flow.  Other studies, using laser Doppler flowmetry or 
IAP, have also found that ATII infusion reduces kidney blood flow (Badzynska et al., 2002; 
Huang et al., 1991; Tozer & Shaffi, 1993). (See also Section 1.3).
However, the  intravital microscopy experiments  do show that HT29  and CaNT tumour 
vessels  have  a  differential  response  to  ATII,  as  HT29  tumour  vessels  are  capable  of 
vasoconstriction whereas  CaNT vessels  are  not.  (The  reason for an increase in tumour 
vessel  diameter  seen  with  CaNT  is  consistent  with  passive  expansion  in  response  to 
increased perfusion pressure.)  Therefore, the  two tumour types  responded as would be 
predicted from histological assessment of their vessel maturation status.  Also, there must 
be  active  ATII  receptors  and  intact downstream signalling machinery on HT29  tumour 
vessels.
Other explanations for the lack of a differential BOLD-MRI response must therefore be 
sought.  These  can  be  divided  into  issues  concerning  the  BOLD-MRI  protocol,  the 
particular tumour types used and the influence of anaesthesia on mouse blood pressure.
Limitations of the BOLD-MRI technique:
While a positive BOLD response  (increase  in signal intensity or T2*)  must be associated 
with an increase in tumour p 0 2  (with the size of change modulated by any blood volume 
change),  no  response  or a  negative  response  cannot be  interpreted easily (Howe  et  al., 
2001).  An increase in tumour blood flow may not produce a decrease in deoxyHb if the 
oxygen  extraction  fraction  increases.  Conversely,  a  change  in  blood  volume  due  to 
vasodilation  or  vasoconstriction  may  mask  any  changes  in  haemoglobin  oxygenation 
(Howe et al., 2001).
The aim of the BOLD-MRI study was to develop a technique that could be translated into 
the  clinic.  Therefore  a body coil  (imaging the  whole  mouse)  rather than a surface  coil 
(imaging the tumour only), was used to reflect clinical practice.  In addition, a surface coil
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would not have been practical for imaging T138 tumours due to their location, nor would it 
have allowed the acquisition of normal tissue data.  However, a surface coil probably would 
have produced a better signal to noise ratio, better spatial resolution and less movement 
artefact, as the tumour is fixed into the coil.
The  single-echo  multi-slice  protocol was  designed to  be  selective  for changes  in blood 
oxygenation and to minimise in-flow effects, which would have reduced the sensitivity to a 
change  in  tumour  blood  flow.  Neeman  et  al.  found  that,  when  their MRI  data were 
analysed  so  as  to  be  sensitive  to  in-flow  effects,  there  was  a  10-fold  increase  in  the 
magnitude  of response  to  air-5%  C 02   compared to when the  analysis  method was  not 
designed to be sensitive to in-flow effects (Neeman et al., 2001).  However, the multi-echo 
single-slice protocol used for the work presented here was sensitive to in-flow effects but 
still did not detect a significant response to ATII in HT29 tumour vessels.
Individual pixel by pixel analysis  was  done  to  see  if a possible  heterogeneous  response 
could be detected.  No response was seen, although small changes may have been obscured 
by movement artefact.  The spatial resolution was 0.16 x 0.35 mm and 0.1 x 0.4 mm for the 
multi-echo and single-echo protocols respectively, so even very slight movement may have 
affected results.
In  conclusion,  the  BOLD-MRI  technique  used was  not  sensitive  enough to  detect the 
response of tumour blood vessels to ATII, as detected by intravital microscopy.  However, 
it is possible that small changes in response to ATII infusion could have been detected if 
the BOLD-MRI protocol had been optimised: e.g. using a surface coil in order to improve 
spatial resolution and minimise movement.  These issues remain to be resolved.
Problems related to the particular tumour types used:
Another possible  explanation for lack of BOLD  response  in the HT29  is tumour vessel 
size.  It has been observed that vessel density and vessel size are important for BOLD-MRI 
response (Howe et al., 2002; Robinson et al., 2003).  Robinson et al. (Robinson et al., 2003) 
compared the  GH3  prolactinoma  (strong BOLD  response)  and the RIF-1  fibrosarcoma 
(poor BOLD  response)  and found that the RIF-1  functional vascular density and vessel 
size were much smaller than for GFD.  They estimated vessel size to be 14-21  jim  for the 
GH3  prolactinoma and 5-11  fim for RIF-1.  They concluded that there was  insufficient 
deoxyHb in the RIF-1 tumour for a BOLD response to be detected.  HT29 tumour vessels
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have been reported as having an average diameter of 18 /xm (measured using multi-photon 
fluorescence microscopy (Tozer et al., 2005), which is similar to the diameters measured in 
the intravital microscopy experiments (see Tables 4.2 & 4.4).  Robinson et al’s (Robinson 
et al., 2003)  diameter estimates  were  taken from MR measurements,  so  are  not directly 
comparable with the HT29  measurements, but based on the above, HT29 tumour vessel 
size should not have been a significant issue.
Influence of anaesthesia on results:
Anaesthesia was required for restraint for these experiments.  Hypnorm is known to affect 
rodent MABP, reducing it by — 25-30%, whereas Hypnovel has no effect (Cullen & Walker, 
1985; Menke  & Vaupel,  1988).  Anaesthesia had a severe  effect on  CBA mouse blood 
pressure (Figure  4.8).  The MABP of CBA mice did increase significantly in response to 
ATII but the consequent increase in tumour perfusion pressure may have been insufficient 
to produce a detectable BOLD-MRI response.  A recent study has also shown that general 
anaesthesia  in  rats  had  no  effect  on  the  vascular  response  to  the  vasodilator,  sodium 
nitroprusside, in tumour and a range of normal tissues, despite its effect on MABP (GM 
Tozer,  personal  communication).  Without  repeating  the  experiments  using 
unanaesthetised animals, it is difficult to judge how anaesthesia has influenced the results.
4.4.4  Tumour vessel response to air-5% C 02/carbogen as measured by BOLD- 
MRI and intravital microscopy
A differential response to air-5% C02 /carbogen between HT29 and CaNT tumours could 
not be detected using BOLD-MRI despite their very different vascular maturation indices. 
The intravital microscopy experiments have shown that HT29 tumour vessels, at least, do 
not vasodilate in response to the mouse breathing air-5% C02  or carbogen gas mixtures, 
despite  the  presence  of aSMA,  so  it is  not surprising that the  BOLD-MRI  results were 
negative.
C 02  does act as a vasodilator in some tumour types: air-5% C02  induced a positive BOLD 
response  (increase  of  — 10-30%)  in the  GH3  prolactinoma model with a further 40-50% 
increase in response to carbogen (Robinson et al., 1999) -  in keeping with Neeman et al.’s 
findings, though of a greater magnitude (see Section 1.3.1.1).
However, as discussed in Section 1.3.1.1, the action of C02  on both tumour and normal 
vasculature is not consistent.  In Neeman et al’s most recent paper (Gilead et al., 2004), any
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change (rather than an increase)  in BOLD-MRI signal intensity in response to breathing 
air-5% C02  was taken as being indicative of the presence of mature vessels and quantitative 
measurements were done on squared values to take into account both significant positive 
and negative changes.  Serial BOLD-MRI measurements were performed on MLS ovarian 
carcinoma spheroids implanted in nude mice.  A MRI vascular maturation index, defined as 
the fraction of mature vessels  (showing response to air-5% OOj) of the total functioning 
vessels  (showing  response  to  carbogen)  normalised to  normal control tissue  (skin)  was 
obtained which correlated with histological maturation index using aSMA (Gilead et al., 
2004).  Presumably their argument is  that any change  in BOLD-MRI signal intensity in 
response  to  air-5%  C 02   is  indicative  of  vasoreactivity  and  whether  C02   is  inducing 
vasodilation or vasoconstriction in individual vessels does not actually matter.  However, 
one could argue that no change  might be seen if both vasodilation and vasoconstriction 
were occurring within the same pixel and that using significant change rather than increase 
in BOLD signal intensity as the measurement parameter is just a convenient way of getting 
around that fact that C 02  may not act consistently as a vasodilator.
4.5  Conclusions
BOLD-MRI failed to discriminate between HT29 and CaNT tumours based on response 
to  ATII.  However,  the  intravital  microscopy  experiments  showed  that  ATII  could 
distinguish between HT29 and CaNT tumours and a positive BOLD response was seen in 
kidney.  This  suggests that the BOLD technique used lacked sufficient sensitivity.  How 
this work could be developed further is discussed in Chapter 5.
Neeman et al.’s hypothesis that mature and immature vasculature can be distinguished by 
differential BOLD-MRI  response to breathing air-5% C02  and carbogen gas (Neeman et 
al., 2001)) could not be reproduced - with the particular tumours and protocol used.  The 
explanation  for this  is  that,  for  HT29  tumour vessels  at  least,  C02   does  not  act  as  a 
vasodilator.  Based on the intravital microscopy data, C02  does not appear to be a suitable 
agent for the further investigation of tumour vessel maturity.
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Chapter 5  Concluding Discus sion
The results presented in this thesis demonstrate that
•  The platinum and taxane-based chemotherapy regimens tested do not cause acute 
anti-vascular changes,  as  detected by DCE-MRI.  Therefore, anti-vascular agents 
such as CA-4-P have a specific action and this gives further confidence to the use 
of DCE-MRI kinetic endpoints as biomarkers for response to this group of agents. 
(Tofts et al., 1999; Tofts & Kermode, 1991).
•  There is a dose-response relationship for the SW1222 tumour for CA-4-P with a 
clinically relevant dose  (30 mg.kg1 )  producing a reversible decrease in DCE-MRI 
kinetic parameters.  This dose level significantly increased antibody retention in the 
tumour,  which  is  promising  for  the  clinical  combination  of  CA-4-P  and 
radioimmunotherapy.
•  An  arterial  input  function  was  obtained  for  the  nude  mice  used  for  the 
SW1222/CA-4-P  study.  A simultaneous  fit  of  data  from the  in-mn and blood 
experiments proved to be the most robust as it incorporated both very early data 
{inrriw  experiment)  with  quantitative  time-points  (blood  sampling  experiment). 
Calculation of the arterial input function has allowed data to be fitted to the Tofts’ 
model (for calculation of quantitative parameters Ktrans and ve ).
•  BOLD-MRI  could  not  demonstrate  a  difference  between the  HT29  and  CaNT 
tumours  based  on  their response  to  air-5%  C02/carbogen or to  angiotensin II. 
The  intravital microscopy experiments  demonstrated that the explanation for the 
lack of response to air-5% C02/carbogen maybe because HT29 tumour vessels do 
not  vasodilate  in  response  to  5%  C 02.  However,  the  intravital  microscopy 
experiments  showed that  HT29  tumour vessels  do  vasoconstrict  in  response  to 
angiotensin II and the lack of a BOLD-MRI response in this instance must be due 
to a lack of sensitivity.
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5.1  Future Work
5.1.1  Clinical Study: DCE-MRI measurement of acute anti-vascular effects of 
cytotoxic agents
The experience gained from the clinical study reported here gives us greater confidence in 
using DCE-MRI as a surrogate marker in clinical trials  of vascular disruptive agents.  In 
retrospect,  patient  selection  could  have  been  better  as  several  patients  had very cystic 
tumours,  in  which  only a  small  percentage  of  pixels  within  the  tumour ROI  took up 
contrast and so  could be  analysed.  It is  important to take  time  to  position the  patient 
carefully to ensure that the same section of tumour is imaged each time.  Pelvic tumours 
are ideal as they do not move with respiration.
In  this  study,  only  median  parameter  values  have  been  quoted.  While  this  is  a 
straightforward method of summarising data, it does not take into account inherent tumour 
heterogeneity  and  heterogeneity  of  response  to  treatment.  Spatial  heterogeneity  of 
response was evaluated relatively simply for the CA-4-P/SW1222 study by identifying three 
regions: tumour rim, an intermediate area and tumour centre (Chapter 3).  An alternative 
strategy would be to perform a histogram analysis to determine whether the percentage of 
pixels with a particular parameter value has increased/decreased in response to treatment 
(Hayes et al., 2002).  How best to evaluate heterogeneity in the clinical setting and how to 
summarise it statistically needs to be determined.
An  individualised  arterial  input  function  is  the  obvious  next  step  in  order to  improve 
reproducibility.  An  artery within  the  same  image  slice  as  tumour could  be  used  as  a 
substitute for tumour-feeding arterioles, but it would have to be at least  ~5mm in diameter 
to avoid partial volume effects as the in-plane resolution for the Tr weighted sequence was
1.4  x 2.2  mm (pixel size).  Computer algorithms  can be  developed that identify suitable 
pixels  within  an artery,  e.g.  by setting a threshold of the  maximum average  Gd-DTPA 
concentration plus two standard deviations (Rijpkema et al., 2001).
An alternative strategy is to normalise to another tissue, such as muscle or spleen, but this 
is not a simple option.  As discussed in Chapter 2, muscle parameters were found to have 
a much worse  reproducibility than tumour parameters.  Also,  normalising to  muscle  or 
spleen  might  confound  analysis  of  tumour  response  to  a  vascular disruptive  agent,  as 
CA-4-P induces a small but significant acute reduction in blood flow in these tissues (~7
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fold  and  — 2.5  fold  at  6  hours  following  100  mg.kg'1   CA-4-P  in  spleen  and  muscle 
respectively as well as in tumour (Tozer et al.,  1999).  Reductions in splenic and muscle 
blood flow are also seen with lower, ‘clinically relevant’ doses of CA-4-P (10 and 30 mg.kg 
!) (Prise et al., 2002).
A reproducibility analysis was obtained for the T2* parameters, rBV and rBF, for visceral 
tumours.  rBV and rBF may be useful for the evaluation of vascular disruptive agents in 
visceral tumours but they need to be validated first, by ensuring that changes in rBV and 
rBF are positively correlated with changes in blood volume and blood flow obtained from 
‘gold standard’ techniques.
For blood flow measurements, radiolabelled iodoantipyrine (IAP) could be used to obtain 
absolute measurements of blood flow in an animal model (Maxwell et al., 2002; Tozer et 
al.,  1999).  Alternatively,  the  development  of the  new PET facility at the  Gray Cancer 
Institute  means  that  a  comparison between MRI  and PET measurements  of  change  in 
tumour rBF in response to a vascular disruptive agent such as CA-4-P could be made in an 
animal model.  PET has been used in clinical trials to assess changes in tumour blood flow 
measurements  in response to CA-4-P and razoxane, an anti-angiogenic agent, using lsO- 
labelled water (Anderson et al., 2003a; Anderson et al., 2003b).  However, lsO has a half- 
life  of 2  minutes  so  is  more  difficult to  use  if the  cyclotron and the  PET scanner are 
separately housed, which is the case at the Mount Vemon site.  An alternative would be to 
use  the  tracer  copper(II)  pyruvaldehyde  bis(N-4- methylthiosemicarbazone)  (Cu-PTSM) 
labelled with 62Cu, which has a half-life of 9.7 minutes so is short enough to allow repeated 
measurements after about 40 minutes.  Cu-PTSM has been used to measure tumour blood 
flow  in  patients  using  the  first-pass  extraction  technique  (Burke  et  al.,  2001). 
Fluoromethane gas, labelled with 1 8 F, has also been used for blood flow measurements in 
PET (Celesia et al., 1984; Holden et al.,  1981).  The advantage of using fluoromethane is 
that the arterial input function can be inferred from radioactivity in expired air, so arterial 
puncture  is  not required (Holden et al.,  1981).  The  advantage of using PET is that the 
experiments could be translated into the clinic, if so desired.
PET can also be used to measure blood volume using carbon monoxide gas (labelled with 
either lsO or nQ  (Anderson et al., 2003a; Anderson et al., 2003b; Kurdziel et al., 2003).  nC 
has a half-life  of 20  minutes, so  is a more practical choice than lsO.  Carbon monoxide 
binds to haemoglobin to form deoxyhaemoglobin, which remains in the vascular space and
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therefore  provides  a  measure  of  intravascular  volume.  Alternatively,  5 1Cr-labelled  red 
blood cells could be used (Tozer & Morris, 1990).
5.1.2  CA-4-P/SW1222 study
The pre-clinical study investigating the acute effects of different dose levels of CA-4-P on 
the SW1222 tumour has provided data that can be extrapolated to the clinical trial.  That is, 
it has provided an estimate of the magnitude of anti-vascular effect occurring at clinically 
achievable  doses.  However,  the  effect  of the  combination  of  a  lower,  more  clinically 
relevant, dose of CA-4-P (such as  30 mg.kg1 ) and 1 3 1 I-A5B7 on SW1222 tumour growth 
still needs to be investigated.
How  the  addition  of  CA-4-P  influences  tumour  response  to  1 3 1 I-A5B7  could  be 
investigated further.  A comparison of the pattern of antibody distribution within tumour 
with  the  pattern  of  anti-vascular effect  of  CA-4-P  (as  measured  by functional vascular 
volume, percentage necrosis, or DCE-MRI kinetic parameters) would help determine how 
much improvement is due to spatial cooperation.
5.1.3  Investigation of tumour vessel maturity
The ultimate aim of the BOLD-MRI experiments was to develop a non-invasive functional 
index  of tumour vessel  maturity that  could be  potentially translated into the  clinic  and 
which might help predict which patients are likely to respond to treatment with agents such 
as CA-4-P.
The  BOLD-MRI  and  intravital  microscopy experiments  have  been  helpful in that they 
have  shown  that  response  to  ATII  is  a  potential  discriminator between  tumours  with 
different levels of vessel maturity.  However, BOLD-MRI lacks the sensitivity to detect this 
effect (at least with the particular protocols and tumours used) and so another method of 
detecting response would be required.  As deoxyHb is an endogenous contrast agent, there 
is no control over the amount present within a tissue and sufficient amounts to be detected 
may not be present.  In addition, from Neeman et al.’s data (Neeman et al., 2001) changes 
in blood flow are  more  important than changes  in oxygenation.  An alternative  strategy 
would  be  to  use  an  exogenous  contrast  agent  instead  to  obtain  T2*-susceptibility 
measurements before and during administration of a vasoactive agent.  A blood-pool agent 
such as  Sinerem®  (Guerbet, France) would be a suitable candidate.  Sinerem is an ultra­
small  superparamagnetic  iron  oxide  particle  (USPIO)  that has  substantial T2*  relaxation
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properties  and a prolonged plasma circulation time  (36  hours  in humans).  Sinerem has 
already  been  tested  in  clinical  trials  (to  image  lymph  nodes,  as  it  is  taken  up  by 
macrophages)  (Anzai,  2004),  so  is  safe  for  clinical  use.  Sinerem  would  be  injected 
intravenously and baseline T2* measurements made, then a vasoactive agent administered 
and  T2*  measurements  repeated.  The  hypothesis  would  be  that  administration  of the 
vasoactive  agent  would  induce  vasoconstriction/  vasodilation  in  vessels  capable  of 
response and a consequent change in tumour blood volume and hence in signal intensity 
and T2*, as the amount of Sinerem present would be reduced/increased.  If a change in 
blood volume in response to a vasoactive agent could be reliably be detected using Sinerem 
(or a similar compound) then it could be used to develop a non-invasive index of tumour 
vessel maturity.  Then, of course, it would have to be  compared to tumour response to 
CA-4-P to  see  whether there  was  any correlation between the  degree  of tumour vessel 
maturity and response to CA-4-P.  Dmg company approval for the use of Sinerem for this 
particular indication would be required for translation into clinical trials.
Alternatively, it may be more profitable to investigate whether tumour vessel permeability 
predicts CA-4-P response better.  In this case, DCE-MRI could be used to investigate the 
relationship  between  vascular  permeability  to  macromolecules  and  CA-4-P  response. 
Beauregard et  al.  have  shown that  sensitivity to  CA-4-P,  as  measured by DCE-MRI,  is 
proportional to the permeability of the vascular wall to  Gd-DTPA bound with albumin, 
across a range of different rodent tumour types (Beauregard et al., 2001).  However, bovine 
albumin was used, so this compound could not be taken into clinical trials, but permeability 
to a USPIO might be an alternative option.
The above discussion highlights the need for further work to improve the reproducibility 
of DCE-MRI  and the  evaluation of response  to vascular disruptive agents using various 
MR parameters.  Whether it will be possible to develop a non-invasive  index of tumour 
vessel maturity and the  relevance  of this to the  assessment of vascular disruptive agents 
remains to be determined.
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Appendix
1.1  Conversion of signal intensity into Gd-DTPA concentration
Signal intensity on spoiled gradient echo images (the Tr  weighted sequence used) is given by.
s =  s_ x  ' - exP- (--r a /^   xexp  (- r e / r 2*)  (i)
1  -  coso' x exp(-TR /T})
where S^. is the maximal signal intensity (for T R » T X  and TE « T ^ ) and a is the flip angle 
(Hittmair et al., 1994).
If TE  « T 2*, the term exp(-TE/T2*) can be ignored and equation (1) simplified to:
S = ^m ax x t1  ~ exP(“K *TR/T;)]  (2)
where K is a flip angle correction factor (Hittmair et al., 1994) and is equal to  1.40 for our 
acquisition conditions (obtained by simulation).  The ratio of signal intensity at time t, St to 
baseline (pre-contrast) signal intensity, S0, is then:
S,/  1-expj-KxTR/T^t)]  ^
So  1  -  exp[-A^ xTR/T{  (0)]
where  Tj(t)  is  the  post-contrast  signal  intensity at  time  t,  and  Tj(0)  is  the  pre-contrast 
relaxation time  respectively.
Tj(0) is calculated from an inversion recovery sequence (see below) and Tj(t) calculated by 
rearranging equation (3):
V r(t\ = -------~ -----xln KxTR
1  -   (1 -  exp[-A: xTR/T, (0)] (4)
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The concentration of Gd-DTPA present at time t, Q, can then be calculated from equation 5 
(Donahue et al, 1994):
J T A i )   A ( 0 T
Ct  =  K/  lW  7  1   -   (5)
where q is the longitudinal relaxivity of protons in  mo due to Gd-DTPA (mMAs1 ).
1.2  Calculation of TJO)
In an inversion recovery sequence, a 180° pulse is applied which flips the net magnetisation 
vector down to the -Z axis.  When the pulse is removed, longitudinal magnetisation (MQ will 
begin to relax back to alignment with B0 (along the  +Z axis).  This is described by equation 
(6):
Mz =M0 [\-2 exp(-  )]  (6)
where Mq  is the equilibrium magnetisation.
If a 90° pulse is applied after a time known as  ‘inversion time’, TI  (time from the original 
inverting  180° pulse) then Mz will be  converted into Mxy (magnetisation in the transverse 
(XY) plane) and it will induce a signal.  The resultant signal intensity is a measure of Mz.  If a 
series of 180° and 90° pulses are applied with varying inversion times, then a graph of signal 
intensity versus inversion time can be plotted and fitted to the equation below:
S(TI) = Mz (TI) =  M0[   1-2 exp(-77 / T ,)]  (7)
where S(TI) is the signal intensity at inversion time, TI.  As TI — >oo, full relaxation will have 
occurred so signal intensity will ->Mq.  Values for the two unknown parameters Tj and Mq 
maybe obtained from curve-fitting (see Figure 1.1).
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TIME (s) H H
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Figure 1.1: Calculation of Ti(0)
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